2016 NORTHWEST RESIDENTS CONFERENCE
Pacific University College of Optometry – Jefferson 224
Friday, June 10 & Saturday, June 11, 2016

PROGRAM AGENDA

Faculty: Carole Timpone, OD, FAAO, FNAP, Associate Dean of Clinical Programs and Director of Residencies, will oversee the event. Each resident will deliver a 30 minute presentation that includes responding to questions and comments from attendees.

FRIDAY, JUNE 10, 2016	PAGES	
Shreya Malli, OD VA Portland Health Care System	**1-35**	Ocular Nevus vs Melanoma: Using OCT technology to differentiate
John Creger, OD Spokane VA Medical Center	**36-53**	To Doppler or Not to Doppler: OIS vs DR
Artika Naidu, OD VA Puget Sound Health Care System	**54-77**	Multimodal Imaging Findings in a Case of Hydroxycholoroquine Retinopathy
Sheila Morrison, OD Pacific University and Associated Clinics	**78-93**	Scleral Shape and Specialty Contact Lens Fitting: Research to Clinical Practice
	BREAK	
Trish Duffield, OD Eye Care Associates of Nevada	**94-108**	From CF to 20|Happy: The Post-Operative Journey of a Pellucid Patient
Maggie Wong, OD VA Portland Health Care System	**109-122**	Ocular Prosthesis – An Eye for An Eye
Megan Szarkowski, OD Spokane VA Medical Center	**123-137**	Cataract Surgery: Potential Complications Despite Advancements in Surgical Procedures
Inna TImshina, OD Bright Eyes Vision Clinic	**138-153**	Neuro-optometry Exam A to Z
Krista Letzring, OD Lebanon VA Medical Center	**154-197**	Bilateral Consecutive Non-Arteritic Anterior Ischemic Optic Neuropathy Secondary to Small Vessel Disease, Bradycardia and Hypotension
Karen Ma, OD Roseburg VA Medical Center	**198-218**	Funky Visual Fields
SATURDAY, JUNE 11, 2016		
Valerie Kitamori, OD Spokane VA Medical Center	219-230	Micro-invasive Glaucoma Surgery
Robert Cook, OD Jonathan Wainwright Memorial VAMC	**231-250**	When Good Corneas Go Bad
Emily Karben, OD VA Portland Health Care System	**251-269**	Diagnosis and Management of Periocular Malignant Lesions
Heather French, OD VA Southern Oregon	**270-291**	Shedding Light on Night Blindness
Shelby Gross, OD VA Portland Health Care System	**292-306**	In-office Removal of Benign Eyelid Lesions
	BREAK	
Alexandra Bavasi, OD Pacific University and Associated Clinics	**307-329**	When Malingering Reveals True Visual Distress: an Unforeseen Vision Therapy Case
Jacob Dufour, OD Vision Northwest	**330-339**	Motion Processing Asymmetry in Essential Infantile Esotropia: A Case Series
Charlotte Forgie, OD Northwest Eye Care Professionals	**340-364**	Vision Rehabilitation with Cortically Blind Patient
Karisa J. Etter, OD VA Portland Health Care System	**365-379**	Retinoschisis vs RD; Clinical Pearls
Rachel Kurohara, OD Jonathan Wainwright Memorial VAMC	**380-396**	Injecting Knowledge into your Optometric Practice: Several Case Reviews with IVFA
Victoria Kung, OD VA Puget Sound Health Care System	**397-419**	Choroidal Complications following Glaucoma Surgery

Choroidal Nevus vs. Melanoma: Using OCT Technology to Differentiate

Primary Eye Care Optometry Resident
VA Portland Health Care System

Shreya Malli, OD
June 10, 2016

Course Outline

- The Importance of Early Detection of Uveal Melanoma: Survival & Prognosis
- Potential Causes for Uveal Melanoma
- Choroidal Nevus
  - Typical Features
  - Risk Factors to Malignant Transformation
  - Preferred Practice Patterns for monitoring
- Choroidal Melanoma
  - Diagnostic Imaging: B-scan vs. OCT
- Clinical Cases: Assessment & Plan

"You go apple picking and among that group of fruit, there's going to be one that goes **bad**.

And, you, as eye care specialists need to know which nevus is going to turn into melanoma."

Carol Shields, MD

Plenary Session at AAO 2015

Importance of Early Detection: Prognosis & Survival

- Uveal melanoma **size** is the most important clinical factor related to prognosis.
- Risk of ocular melanoma metastasis at 10 yrs
  - Small melanoma (1-3mm thickness): 10%
  - Medium melanoma(3.1-8mm thickness): 23%
  - Large melanoma (>8mm thickness): 52%
- Each 1 mm increase in thickness caused 5% increased risk for metastatic disease at 10 years.

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.
Diener-West. Development of metastatic disease after enrollment in the COMS trial for treatment of choroidal melanoma: COMS No 26. Arch of Opthal: 2005

Importance of Early Detection: Prognosis & Survival

- Common sites of metastasis
  - Hepatic location:
    poor survival rate (6 months)
    - Liver (90%)
  - Extrahepatic locations:
    longer survival rate (19-28 months)
    - Lung (24%)
    - Bone (16%)
    - Skin (11%)
    - Lymph nodes (10%)

COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in COMS. Arch Opthalmol: COMS No. 15: 2001

Potential Causes for Uveal Melanoma

- Host factors
  - Nevus: 1 in 8845 risk
  - Melanocytosis: 1 in 400 risk
  - Light eye color
  - Fair skin color
  - Inability to tan
- Environmental factors
  - Arc welding
  - Chronic sunlight exposure



Shields. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanoma. Current Opinion Ophthalmology: 2014.

Choroidal Nevus

- 7% of white population
- Pigmented (90%)
- Thickness <2mm
- Drusen
- RPE atrophy



Shields. Choroidal nevus tranformation into melanoma: Analysis of 2514 consecutive cases. Arch. Ophthal: 2009

Choroidal nevus can change over time.

- Can enlarge slightly.
- Can thicken slightly.
- Can cause visual loss



Sheilds. Choroidal nevus transformation into melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmol: 2009
Shields. Visual Acuity in 3422 Consecutive Eyes with Choroidal Nevus. Arch Opthal: 2007
Mashayekhi. Slow enlargement of choroidal nevi: a long-term follow-up study. Ophthalmology 2011

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms

Decreased vision
Visual field defect
Flashes of light
Floaters

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms
- **O**range pigment



Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms
- **O**range pigment
- Within 3mm of optic disc **m**argin



Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms
- **O**range pigment
- Within 3mm of optic disc **m**argin
- **U**ltrasound **H**ollowness



Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms
- **O**range pigment
- Within 3mm of optic disc **m**argin
- **U**ltrasound **H**ollowness
- **H**alo Absence



Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

Choroidal Nevus: Risk Factors to Malignant Transformation

To Find Small Ocular Melanomas Using Helpful Hints Daily

- **T**hickness >2mm
- Subretinal **F**luid
- **S**ymptoms
- **O**range pigment
- Within 3mm of optic disc **m**argin
- **U**ltrasound **H**ollowness
- **H**alo Absence
- **D**rusen Absence

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.

AMERICAN ACADEMY™ OF OPHTHALMOLOGY
Protecting Sight. Empowering Lives.

Preferred Practice Patterns

- No Risk Factors:
  - Monitor q6mo in the 1st year.
  - Then annually if stable.
- 1-2 Risk Factors:
  - Monitor q4-6mo.
- 3+ Risk Factors:
  - Refer to experienced center for management/ treatment.

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.
Cheung. Distinguishing a choroidal nevus from a choroidal melanoma: EyeNet AAO: 2012.

Differentiating Intraocular Tumors with Technology:
Documentation of Growth &
Identification of Clinical Risk Factors

- **Fundus photo documentation**
  - Orange pigment, location to disc, drusen, halo
- **B-scan ultrasonography**
  - Thickness, subretinal fluid, ultrasound hollowness
- **Optical Coherence Tomography: EDI**
  - Thickness, subretinal fluid
- **Fundus Autofluorescence**
  - Orange pigment
- **Fluorescein Angiography**
  - "double circulation" sign

Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.
Gargoudas. Focal Points: Choroidal Melanoma Update: COMS Results. American Academy of Ophthalmology: 2005





Mrejen. Potential Pifalls in Measuring the Thickness of Small Choroidal Melanocytic Tumors with Ultrasonography. Retina: 2013
Kiernan. Spectral-domain optical coherence tomography: a comparison of modern high-resolution retinal imaging systems. AMJO: 2010

Ultrasound vs. EDI-OCT: Thickness

B-Scan



EDI-OCT (Raster C)

EDI-OCT (Raster D)



Mrejen. Potential Pifalls in Measuring the Thickness of Small Choroidal Melanocytic Tumors with Ultrasonography. Retina: 2013

Pitfalls in Measuring Thickness with B-Scan

- Ultrasonography over-estimates choroidal tumor thickness, compared to EDI-OCT, by 55% in analysis of both nevus & melanoma:
  - Difficulty in pinpointing choroidal-scleral interface
  - Poor resolution of overlying retina on ultrasound leads to inclusion of retinal thickness
  - Gross estimation using ultrasonographic calipers

Shields. Enhanced depth imaging optical coherence tomography of intraocular tumors: 2013 Francesco Orzalesi Lecutre. Retina: 2014
Mrejen. Potential Pifalls in Measuring the Thickness of Small Choroidal Melanocytic Tumors with Ultrasonography. Retina: 2013
Shah. Enhanced depth imaging of choroidal nevus: AAO: 2012
Shields. Enhanced Depth Imaging Optical Coherence Tomography of Small choroidal melanoma: Arch Ophtalmoogy 2012.

Ultrasound vs. EDI-OCT: Subretinal Fluid

"Apical double echo" sign



Double contour on B-scan



Double spike on A-scan



Krema. Role of optical coherence tomography in verifying the specificity of ultrasonography in detecting subtle subretinal fluid associated with small choroidal melanocytic tumors. Retina: 2014

Pitfalls in Measuring SRF with B-Scan

- The **Double echo sign** on B-scan has poor sensitivity
- OCT imaging can allow detection of **subclinical** subretinal fluid, not evident on B-scan.
- Also, OCT is more specific than B-scan, in differentiating between subretinal fluid vs. chronic retinal degeneration.

Krema. Role of optical coherence tomography in verifying the specificity of ultrasonography in detecting subtle subretinal fluid associated with small choroidal melanocytic tumors. Retina: 2014

Choroidal Nevus on EDI-OCT

- Common features
  - Deep optical shadowing (94%)
  - Choriocapillaris compression (94%)
  - Drusen (45%)
  - RPE atrophy (43%)
  - Subretinal Fluid (16%)
    - With retracted or absent photoreceptors (43%)



Shields. Enhanced depth imaging optical coherence tomography of intraocular tumors: 2013 Francesco Orzalesi Lecutre. Retina: 2014
Shields. EDI-OCT of Intraocular Tuimors. Retina Today: 2013.

Choroidal Nevus on EDI-OCT

- Common features
  - Deep optical shadowing (90%)
  - Choriocapillaris compression (94%)
  - Drusen (45%)
  - RPE atrophy (43%)
  - Subretinal Fluid (16%)
    - With retracted or absent photoreceptors (43%)



Shields. Enhanced depth imaging optical coherence tomography of intraocular tumors: 2013 Francesco Orzalesi Lecutre. Retina: 2014
Shields. EDI-OCT of Intraocular Tuimors. Retina Today: 2013.

Choroidal Melanoma on EDI-OCT

- Common features
  - Deep optical shadowing (97%)
  - Choriocapillaris compression (100%)
  - Subretinal fluid (92%)
    - Shaggy photoreceptors (49%)



Shields. Enhanced depth imaging optical coherence tomography of intraocular tumors: 2013 Francesco Orzalesi Lecutre. Retina: 2014
Shields. EDI-OCT of Intraocular Tuimors. Retina Today: 2013.

Case 1:



Case 1:



Case 1:



Case 1:



Case 1:



Case 1: Recap



Thickness: 0.5mm
(-) Subretinal **f**luid
(-) **S**ymptoms
(-) **O**range pigment
>3mm from disc **m**argin
(-) **U**ltrasound **H**ollowness
(-) Halo
(+)Drusen

1 Risk Factor: **Monitor q 6mo, then annually if stable**

Case 2:



07/2009

02/2016

Case 2:



Case 2:



Case 2:



Case 2:



Case 2: Recap

Thickness: 0.5mm
(+) Subretinal fluid
(-) **S**ymptoms
(+) Orange pigment
>3mm from disc **m**argin
(-) **U**ltrasound **H**ollowness
(-) Halo
(+)Drusen

3 Risk Factors: **Refer to experienced center for management/ treatment.**

Case 3:

06/2013

Case 3:

12/2015

Case 3:



12/2014

Case 3:



06/2015

Case 3:



11/2014

Case 3:



03/2016

Choroidal Nevus on EDI OCT:

Choroidal nevus with overlying RPE atrophy, demonstrating intraretinal fluid without subretinal fluid



Small choroidal melanoma, demonstrating intraretinal fluid with subretinal fluid



Shields. EDI-OCT of intraocular tumors. Retina today: 2013
Krema. Role of OCT in verifying the specificity of ultraosnography in detecting subtle subretial fluid associated with small choroidal melanocytic tumors. Retina 2014.

Case 3: Recap



Thickness: 0.80mm
(-) Subretinal fluid
(-) Symptoms
(-) Orange pigment
3mm from disc margin
(-) Ultrasound Hollowness
(-) Halo
(+)Drusen

1 Risk Factors: Monitor q6mo, then annually if stable.

Case 4:



04/2007

Case 4:

04/2007

Case 4: Recap



Thickness: 3.25mm
(+) Subretinal fluid
(+) Symptoms
(+) Orange pigment
> 3mm from disc margin
(-) Ultrasound Hollowness
(-) Halo
(-)Drusen

3+ Risk Factors: **Refer to experienced center for management/ treatment.**

Local Management of Choroidal Melanoma

- Small choroidal melanoma (1-3mm thickness)
  - Eye-sparing Treatments
    - Laser photocoagulation
    - Photodynamic therapy
    - **Plaque brachytherapy**
    - External beam charged particle radiation therapy
    - Transpupillary thermotherapy
    - Location tumor resection
  - Enucleation

Singh. Choroidal melanoma. Oman J Ophthalmol: 2012

Case 4:
I-125 plaque brachytherapy



Plaque inserted 05/17/2007
Plaque removed 05/22/2007

Kahn. I-125 Plaque Brachytherapy for Choroidal Melanoma. CEI Mature Signle Institution Outcome Analysis from OHSU 2012.

Systemic Monitoring of Choroidal Melanoma

- Careful screening for metastasis to liver, lung, bone & skin:
  - Every 6 months:
    - Physical Exam
    - Liver Function Tests
  - Every 1 year:
    - Chest radiograph
    - Liver imaging (ultrasound or MRI)

Case 4:



09/2007

4 mo s/p
I-125 plaque
radiotherapy

Case 4:



10/2007

5 mo s/p
I-125 plaque
radiotherapy

Case 4:



04/2008

11 mo s/p Plaque radiotherapy

Case 4:



04/2011

4 years s/p I-125 plaque brachytherapy

Case 4:



03/2012

5 years s/p I-125 plaque brachytherapy

Case 4:



11/2014

7 years s/p 1-125 plaque brachytherapy

Case 4:



11/2014 **7 years s/p 1-125 plaque brachytherapy**

Case 4:



04/2007 **prior to treatment: 3.25mm**

Case 4:



03/2010 **3 years s/p I-125 plaque brachytherapy: 2.82 mm**

Case 4:



10/2011 **4 years s/p I-125 plaque brachytherapy: 2.52mm**

Case 4:



12/2012 **5 years s/p I-125 plaque brachytherapy: 1.48mm**

Case 4:



12/2014 **7 years s/p I-125 plaque brachytherapy: 1.57mm**

Case 4: Liver Metastasis

Report:
Right upper quadrant quadrant abdominal ultrasound, 2/1/2016.

HISTORY: Choroid melanoma of right eye; monitor for metastases.

COMPARISON: Right upper quadrant abdominal ultrasound, 6/26/2015.

TECHNIQUE: Transverse and longitudinal grayscale sonographic images of right upper abdominal quadrant obtained.

FINDINGS:

No hepatomegaly. Liver contour appears smooth. Multiple new, heterogeneously hypoechoic liver masses, measuring up to 3.5 cm in craniocaudal dimension within the anterior, subcapsular right liver lobe. Additional, 1.1 cm heterogeneously hyperechoic mass at gallbladder fossa; and heterogeneously hypoechoic, complex-appearing mass measuring up to 1.4 cm in diameter within liver segment V.

Gallbladder mildly distended, without wall thickening or pericholecystic fluid. No sonographic Murphy's sign elicited. No evident cholelithiasis.

No biliary ductal dilatation; common bile that measures 3 mm diameter (within normal limits). Visualized pancreas unremarkable.

Right kidney measures 8.0 cm length, and is without hydronephrosis.

No ascites within visualized right upper abdominal quadrant

Addendum: Findings & impression discussed with Dr. Edward L. Rambousek at 0945 hours on 2/1/2016 by Dr. Jeffrey J. Hom of imaging.

Impression:

Multiple new liver masses, concerning for metastases; recommend dedicated abdominal CT scan for further assessment.



Found on routine surveillance 02/2016
9 years after diagnosis of choroidal melanoma

Summary

- To Find Small Ocular Melanomas Using Helpful Hints Daily
- Encourage use of EDI-OCT for increased sensitivity in identifying clinical risk factors for melanoma:
  - Choroidal thickness
  - Subretinal fluid vs. Retinal Degeneration
- Early detection of small choroidal melanoma is key to reducing risk of metastasis & subsequently mortality.

References

- Kahn. I-125 Plaque Brachytherapy for Choroidal Melanoma. CEI Mature Signle Institution Outcome Analysis from OHSU 2012.
- Krema. Role of OCT in verifying the specificity of ultrasonography in detecting subtle subretinal fluid associated with small choroidal melanocytic tumors. Retina 2014.
- Diener-West. Development of metastatic disease after enrollment in the COMS trial for treatment of choroidal melanoma: COMS No 26. Arch of Opthal: 2005
- COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in COMS. Arch Opthalmol: COMS No. 15: 2001
- Mrejen. Potential Pitfalls in Measuring the Thickness of Small Choroidal Melanocytic Tumors with Ultrasonography. Retina: 2013
- Shah. Enhanced depth imaging of choroidal nevus: AAO: 2012
- Font. The Nature of orange pigment over a choroidal melanoma: 1974
- Coleman. Ultrasonic diagnosis of tumors of the choroid: 1974
- Fuller. Ultrasonographic features of choroidal malignant melanomas: 1979
- COMS: The COMS Randomized Trial of I-125 Brachytherapy for choroidal melanoma
- Shields. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanoma. Current Opinion Ophthalmology: 2014.
- Shields. EDI-OCT of intraocular tumors. Retina today: 2013
- Shields. Enhanced depth imaging optical coherence tomography of intraocular tumors: 2013 Francesco Orzalesi Lecture. Retina: 2014
- Shields. Choroidal Nevus Transformation Into Melanoma: Analysis of 2514 Consecutive Cases. Arch Ophthalmology: 2009.
- Shields. Enhanced Depth Imaging Optical Coherence Tomography of Small choroidal melanoma: Arch Ophtalmoogy 2012.
- Shields. Clnical features of small choroidal melanoma: 2002
- Singh. Estimating the risk of malignant transformation of a choroidal nevus. AAO: 200
- Shields. Visual acuity in 3422 consecutive eyes with choroidal nevus
- Shields. Risk factors for growth & metastasis of small choroidal melanocytic lesions: 1990
- Shields. Diffuse choroidal melanoma: clinical features predictive of metastasis: 1996
- Sumich. Choroidal nevi in the white population: Blue Mountain Eye Study

To Doppler Or Not To Doppler: OIS vs DR

John Creger, OD

Objectives

- Review signs and symptoms of diabetic retinopathy with an emphasis on peripheral retinal changes.
- Review of Ocular Ischemic Syndrome
- Comparison of diabetic retinopathy to ocular ischemic syndrome findings and indications/review of a carotid Doppler.

Case #1

- 68 WM New Patient
- CC: Blurry Vision OU
- LEE: 6 months ago, health check only
- Systemic Hx: Diabetes type 2, Hypertension, Hyperlipidemia, Coronary Arteriosclerosis.
  - A1c 8.9
- Ocular Hx:
  - H/o Non-proliferative diabetic retinopathy OU

Case #1

Exam Results

- VA w/Habitual Rx
  - OD: 20/30+1
  - OS: 20/50
- Manifest Refraction
  - OD: -0.75 -0.50 x 095 20/25
  - OS: -1.00 -0.75 x 028 20/25
- Anterior Segment
  - Mild MGD
  - 2+NS, 2+ ACC Cataracts
- Posterior Segment
  - OD: few scattered 360 mid-peripheral intraretinal hemorrhages worse inf/temp
  - OS: 360 mid-peripheral intraretinal hemorrhage worse inf/temp


OD


OS

Case #1

- Differential Diagnosis
  - Diabetic Retinopathy
  - Ocular Ischemic Syndrome
- Further Testing
  - Carotid Doppler
    - Right Class D 50-79% Occluded
    - Left Class E Occluded/Closed

Peripheral Diabetic Retinopathy

- Pathophysiology:

  Micro-angiopathy due to hyperglycemia in patients with diabetes mellitus results in vascular leakage, which causes diabetic macular edema on one hand, and capillary occlusion on the other hand. Capillary occlusion then again causes retinal ischemia and increased levels of vascular endothelial growth factor (VEGF) which are responsible for the development of neovascularization and the proliferative stage of diabetic retinopathy.

  (Nentwich)

Peripheral Diabetic Retinopathy

- Indication Of Progression
  - Peripheral retinal vessels are more prone to undergo capillary nonperfusion than the posterior retina.

(Shimizu)

Peripheral Diabetic Retinopathy



- Indication Of Progression
  - The presence of predominantly peripheral lesions (PPLs) increased the risk of DR progression and onset of PDR over 4 years by 3.2-fold and 4.7-fold, respectively. In eyes that had PPLs at baseline, a greater extent of PPLs was associated highly with a greater risk of DR progression (P <0.004) and onset of PDR (P < 0.009)

*predominantly peripheral lesion defined as a lesion being graded that is more than 50% in the retinal peripheral field compared with the modified ETDRS field

(Silva)

Peripheral Diabetic Retinopathy

- Indication Of Progression
  - "These analyses demonstrate that there is considerable extra risk for eyes with lesions more prevalent in the peripheral retina. However, one cannot conclude that the lesions in the periphery are more important than posterior lesions, only that they add significantly to the risk assessment."

    - Frederick L. Ferris III

Peripheral Diabetic Retinopathy

- Treatment
  - Prevention
  - Laser photocoagulation
  - Anti-VEGF Injections for CSME

Ocular Ischemic Syndrome

- Pathophysiology
  - Most Common Cause is carotid stenosis leading to thromboembolism causing retinal ischemia
  - Other Causes include: dissecting aneurysm of the carotid artery, giant cell arteritis, fibrovascular dysplasia, Takayasu arteritis, aortic arch syndrome, Behcet's disease, trauma or inflammation causing stenosis of the carotid arteries, complications after intravitreal anti-VEGF injections, and after radiotherapy for nasopharyngeal carcinoma

(Terelak-Borys)

Ocular Ischemic Syndrome

- Hypertension is found in 73%
- Diabetes mellitus is found in 56%
- Myocardial infarction occurs in approximately 4% of patients with OIS
- The mortality rate is as high as 40% within 5 years of onset
- Cardiovascular disease is the main cause of death (approximately 66%), followed by stroke as the second leading cause of death

(Terelak-Borys)

Ocular Ischemic Syndrome

- Signs and Symptoms

Table 1. Clinical manifestations of the ocular ischemic syndrome [3,4,18].

Anterior segment
Rubeosis iridis and neovascular glaucoma
Uveitis
Anterior and posterior synechia
Spontaneous hyphema
Asymmetric cataract
Atrophy of sphincter pupillae and semi-dilated pupil
Sluggish reaction to light
Conjunctival and episcleral injection
Corneal edema with Descemet`s folds (sometimes with bullous keratopathy)
Scleral melting
Posterior segment
Narrowed retinal arteries
Spontaneous retinal arteries pulsations
Dilated retinal veins
Retinal hemorrhages
Microaneurysms
Retinal teleangiectasia
Cherry-red spot
Cholesterol emboli
Glaucoma (neovascular glaucoma, normal tension glaucoma)
Neovascularization (optic disc, retina)
Vitreous hemorrhage
Anterior and posterior ischemic optic neuropathy
Cotton-wool spots
Choroidal neovascular membrane
Areas of chorio-retinal atrophy
Orbital infarction syndrome
Anterior and posterior segment ischemia
Ophthalmoplegia
Orbital pain
Hypotony
Ptosis

(Terelak-Borys)

Ocular Ischemic Syndrome

- Signs and Symptoms
  - Visual Loss in affected eye
    - Gradual or Sudden
  - Periorbital pain in the affected eye
    - Usually described by a dull ache
  - Neovascularization of iris and angle
  - Mid-peripheral intraretinal hemorrhages and microaneurysms.
  - Branch or central retinal artery occlusions.
  - Visible emboli

(Terelak-Borys)


Ocular Ischemic Syndrome
Treatment
Treat underlying condition
Ocular Treatment:
PRP to reduce oxygen demand in retina
Treatment of neovascular glaucoma
(Terelak-Borys)

Case #2

- 71 WM
- Annual Diabetic Eye Exam
- Ocular History:
  - Hyper-mature traumatic cataract OD
  - History of complete retinal detachment OD
- Systemic History: Diabetes Type 2, Hypertension, Coronary Artery Disease.
  - A1C 6.2

Case #2

- Exam Results
- VA w/Habitual Rx
  - NLP
  - OS: 20/25
- Manifest Refraction
  - OD: Balance
  - OS: -3.50 -0.50 x 086 20/20
- Anterior Segment
  - OD:
    - Conjunctiva: 2+ limbal inj w/1+ diffuse inj elsewhere. 2+ chemosis nasal
    - Cornea: 2+ diffuse PEE with 1+ edema/haze
    - A/C: Small 0.5-1 mm hyphema – staining cornea inf
    - Iris: Neovascularization 360. Appears bleeding comes from 9 o'clock.
  - OS: All Unremarkable
- IOP:
  - OD: 36 mmHg
  - OS: 22 mmHg

OD



Case #2

- Neovascular Glaucoma
- Differential Diagnosis for cause
  - Diabetic Retinopathy
  - Ocular Ischemic Syndrome
  - Vein Occlusion
  - Ocular Mass

OS



Case #2

- Further Testing
  - B-Scan:
    - OD: Complete retinal detachment. No apparent Ocular Mass
  - Carotid Doppler
    - Right Class D+ 80-99% Occluded
    - Left Class C 16-49% Occluded

DR vs OIS

Table 2. The differential diagnosis of ocular ischemic syndrome, diabetic retinopathy and central retinal vein occlusion [3,4].

	Ocular ischemic syndrome	Diabetic retinopathy	Central retinal vein occlusion
Age	50s to 80s	Variable	50s to 80s
Laterality	80% unilateral	Bilateral	Usually unilateral
Posterior segment signs			
Retinal veins	Dilated but not tortuous	Dilated and beaded	Dilated and tortuous
Hemorrhages	Dot and blot, mid-periphery, in deeper retina layers	Dot, blot in deeper retina layers and flamme-shaped in in nerve fiber layer	Flamme-shaped in in nerve fiber layer
Microaneurysms	In midperiphery	In posterior pole	Variable
Hard exudates	Absent	Common	Rare
Optic disk	Normal	Diabetic papillopathy (rarely)	Swollen
Retinal arteria perfussion pressure	Decreased	Normal	Normal
Fluorescein angiography			
Arterio-venous transie time	Prolonged	Usually normal	Prolonged
Choroidal filling	Delayed, patchy	Normal	Normal
Retinal vessel staining	Arteries > veins	Usually absent	Veins > arteries

(Terelak-Borys)

DR vs OIS

- Neovascularization
  - 66% of OIS patients have Iris and/or angle neovascularization
  - IOP may not be elevated in the presence of neovascularization in OIS due to decreased perfusion of the ciliary body resulting in reduced aqueous production.
  - Consider OIS if iris or angle neovascularization is present in the following
    - the presence of markedly asymmetric diabetic retinopathy,
    - the presence of persistent NVI after PRP, or
    - a still-unidentified etiology for NVG after full ocular examination

Carotid Doppler

- Non-invasive
- Easy to administer
- Quick results
- Cost effective

Carotid Doppler

- About 30 Minutes
- Doppler ultrasound measures the change in frequency of the echoes to calculate how fast an object is moving



Carotid Doppler



https://www.youtube.com/watch?v=olmmH1lLsFk

Carotid Doppler

Table 1 – University of Washington (Strandness) carotid duplex interpretation criteria.

Stenosis (DR)	PSV_{ICA} (cm/s)	Spectral broadening	EDV_{ICA} (cm/s)	Plaque imaging
Normal	<125	None	NA	None
0–19%	<125	None	NA	Minimal lumen reduction
20%–49%	<125	Mild	NA	Moderate lumen reduction
50%–79%	>125	Moderate	<140	Significant lumen reduction
80%–99%	>125	Severe	>140	High-grade stenosis
Occlusion	No flow	NA	No flow	Lumen filled with plaque and thrombus

DR, diameter reduction; EDV_{ICA}, end diastolic velocity of internal carotid artery; NA, not applicable; PSV_{ICA}, peak systolic velocity of internal carotid artery.

(Quirk)

Carotid Doppler

- Interpretation
  - Strandness Classification given at the VA
    - A 0%
    - B 1-15%
    - C 16-49%
    - D 50-79%
    - D+ 80-99%
    - E Occluded

Objective Review

- Peripheral Diabetic Retinopathy increases risk for progression
- Ocular Ischemic Syndrome, Very likely to cause anterior segment neovascularization.
- Rule out ocular ischemic syndrome in all those with peripheral vascular changes consistent with OIS

Conclusion

- To Doppler or not to Doppler?

Doppler!

References

- Barbara Terelak-Borys, Katarzyna Skonieczna, Iwona Grabska-Liberek. Ocular ischemic syndrome – a systematic review. August 1st 2012
- Martin M Nentwich, Michael W Ulbig. Diabetic retinopathy - ocular complications of diabetes mellitus. World Journal of Diabetes. April 15, 2015
- Shimizu K, Kobayashi Y, Muraoka K. Midperipheral fundus involvement in diabetic retinopathy. July 1981
- Yong Cheng, Jinfeng Qu, Yi Chen, Mingwei Zhao, Xiaoxin Li. Anterior Segment Neovascularization in Diabetic Retinopathy: A Masquerade. June 1, 2015
- Sarwat Salim, MD, FACS Ingrid U. Scott, MD, MPH, and Sharon Fekrat, MD. Diagnosis and Treatment of Neovascular Glaucoma. August 2006
- Diana Gaitini, MD, Michalle Soudack, MD. Diagnosing Carotid Stenosis by Doppler Sonography. May 2005
- Kirk W Beach, Robert O Bergelin, Daniel F Leotta, Jean F Primozich, P Max Sevareid, Edward T Stutzman, and R Eugene Zierler. Standardized ultrasound evaluation of carotid stenosis for clinical trials: University of Washington Ultrasound Reading Center. Sep 2010
- Karen Quirk, and Dennis F. Bandyk. Interpretation of carotid duplex testing. 2014
- Frederick L. Ferris III, MD. The Importance of Peripheral Diabetic Retinopathy. March 2015
- Paolo S. Silva, MD, Jerry D. Cavallerano, OD, PhD, Nour Maya N. Haddad, MD, Hanna Kwak, BS, Kelli H. Dyer, DO, Ahmed F. Omar, MD, Hasanain Shikari, MD, Lloyd M. Aiello, MD, Jennifer K. Sun, MD, MPH, Lloyd Paul Aiello, MD, PhD. Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. May 2015
- Craig C. Freudenrich, Ph.D. How Ultrasound Works.
- What To Expect During Carotid Ultrasound. National Heart, Lung, and Blood Instutute. https://www.nhlbi.nih.gov/health/health-topics/topics/cu/during


Thank You!

Multimodal Imaging Findings in a Case of Hydroxychloroquine Retinopathy

By: Artika Naidu, OD
Optometry Resident at American Lake VA
Puget Sound Healthcare System

Bullseye Maculopathy

- Photo credit: Indian J Ophthalmol. 2015 Jul; 63(7): 570-574.

Whorl keratopathy/Corneal Verticillata

- not direct marker for retinal damage
- not associated with vision loss
- usually reversible
- good marker to ask questions about systemic meds

Hydroxychloroquine

- DMARD: Disease Modifying Anti-Rheumatic Drug
  - Anti-malarial
- Systemic Lupus Erythematosus
  - Improve muscle and joint pain, skin rashes, pericarditis, pleuritis, fever and fatigue
- Rheumatoid Arthritis
  - Reduce joint pain and swelling, may prevent joint damage and reduce risk of long term disability
- Other inflammatory and dermatologic conditions
  - Sjogrens, etc.

Hydroxychloroquine Retinopathy

- **Pathophysiology:** Primary damage is to the photoreceptors, and as the outer nuclear layer degenerates, there is secondarily disruption of the RPE.
- **Who is at risk?** Retinal toxicity occurring in approximately 10-20% of patients who received CQ and in 2-3% of patients who received HCQ therapy.
- **Risk factors:** Daily dosage, duration of use, concurrent tamoxifen therapy, kidney disease, pre-existing retinal or macular disease and lower weight

Most Significant Risk Factors

- Dose
- Duration of use
- **Most critical risk factor was excessive daily dose by weight.**

Risk Factor: Dose

- Previous recommended dosing <6.5mg/kg of ideal body
- As of March 2016, AAO new guideline: Max recommended dosage of **<5.0 mg/kg real body weight**

Ideal vs Real weight



Melles RB, Marmor MF. The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy. *JAMA Ophthalmol.* 2014;132(12):1453-1460.

Dosage Calculation

- Ideal body weight calculation
  - Women: 100lbs for the first 5 ft of height
  - Men: 110lbs for the first 5ft of height
    - add 5lbs for every additional inch
- Overdose at typical dosage of 400mg/day
  - Any woman < 5'7"
  - Any man <5'5"

Let's calculate for patient MA

- 37 yo Caucasian Male
- Height: 5'7"
- Weight: 133lbs
- Dose: previously 400mg QD, currently 300mg QD
- Daily dose
  - Ideal weight 145lbs= 65.8 kg → 300mg/65.8=4.56mg/kg/day
  - Ideal weight 145lbs= 65.8 kg → 400mg/65.8=6.08mg/kg/day
  - Real weight 133lbs= 60.33 kg→ 300mg/60.3=4.98mg/kg/day
  - Real weight 133lbs= 60.33 kg→ 400mg/60.3=**6.63mg/kg/day**
- Lifetime/cumulative dose
  - 300mg/day X 11 years= ~1200grams

Risk Factor: Duration

- Risk of toxicity
  - Mean daily dose of >5.0mg/kg of real body weight
    - 10% risk of retinal toxicity within first 10 years of treatment
    - 40% risk after 20 years
  - Intermediate amount of 4.0 to 5.0mg/kg of real body weight
    - < 2% risk of retinal toxicity within the first 10 years of treatment
    - 20% risk after 20 years
  - Even patients using a recommended dose have significant risk after decades of use

Risk Factor: Others

- **Kidney Function**
  - Kidneys are the main mechanism for clearance of hydroxychloroquine.
  - Decreased renal function leads to higher serum concentration of the drug, thus increased risk of retinal toxicity
  - Drop in kidney function by 50% leads to an approximate doubling of the risk of retinopathy.

Risk Factor: Others

- **Tamoxifen**
  - Tamoxifen increased risk by **~ 5X**
  - NONE showed crystalline deposits or macular edema that is characteristic of tamoxifen retinopathy



Tamoxifen Retinopathy
Photo credit: American Society of Retina Specialists

37 yo Caucasian Male

- Comprehensive Eye exam
  - CC: Doing well w current spec Rx. No visual complaints
- POH: none
- Fam Ocular Hx: (+)ARMD-maternal grandmother
- Pertinent PMHx: Lupus
- Allergies: None
- Current Meds:
  - Hydroxychloroquine 200mg tab – alternate daily- take two tablets by mouth one day and alternate with one tablet daily the next.
    - Reports taking Hydroxychloroquine since 2004
    - Current dose 300mg/day (previously 400mg/day)
  - Vitamin D3- 1000unit tab- two tabs daily

37 yo Caucasian Male

- Visual Acuity (Distance)- BCVA
  - OD: 20/20
  - OS: 20/20
- CVF, Pupils, EOM's: normal
- FDT screener C 20-5: No defects R+L w good reliability
- SLE (R+L, unless otherwise indicated)
  - Lids/lashes: nml
  - Conj/Sclera: nml
  - Cornea: clear
  - AC deep and quiet, no cells or flare
  - Angle: 4x4
- IOP: (x)NCT 15/13 mmHg

37 yo Caucasian Male

- Post Segment (R+L unless otherwise indicated)
  - Lens: Clear
  - Vitreous: (-)PVD, clear
  - C/D ratio: distinct disc margins, (-)pallor
    - OD: 0.30
    - OS: 0.30
  - Macula: mild pigmentary changes
  - Blood vessels: normal course and caliber
  - Peripheral Retina: (-) holes, tears, elevations or detachments
- **Note: upon exam patient was highly photophobic



Fundus photo OD



Fundus photo OS

Use of New Diagnostic techniques

- A more recent study found that 7.5% of long term HCQ users **screened with modern techniques** showed evidence of retinal toxicity. This is **3x higher** than previously reported.

Melles RB, Marmor MF. The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy. *JAMA Ophthalmol.* 2014;132(12):1453-1460.

Use of New Diagnostic techniques

- **Visual Field (white 10-2 pattern)**
- SD-OCT
- FAF-Fundus Autofluorescence
- mfERG- Multifocal ERG

Visual Field White 10-2 Pattern



Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. *Clinical Ophthalmology (Auckland, NZ)*. 2015;9:943-952.

SD-OCT



SDOCT: macular cross sections

- **Early stages**: parafoveal loss of the inner segment-outer segment and cone outer segment tip lines



Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity.*Arch Ophthalmol.* 2012;130(4):461-469

SDOCT: macular cross sections

- **Moderate toxicity-** showed a distinct loss of outer retinal substance on both sides of the fovea, giving the ONL an appearance of "sombrero" or "flying saucer"



Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity.*Arch Ophthalmol.* 2012;130(4):461-469

SDOCT: macular cross sections

- **Severe Toxicity :** Disruption of RPE and debris above the RPE were seen in some moderate, but clearly evident in the severe toxicity group



Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity.*Arch Ophthalmol.* 2012;130(4):461-469

FAF-Fundus Autofluorescence



Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity.*Arch Ophthalmol.* 2012;130(4):461-469

mfERG

- **Most useful in early cases** of HCQ toxicity to pick up depression to demonstrate or confirm bulls eye maculopathy.
- Is similar in sensitivity to visual fields and can provide objective confirmation of suspected field loss
- mfERG takes careful inspection to recognize focal loss and requires ring ratio analysis

mfERG

Normal **HCQ Toxicity**



Browning DJ, Lee C. Scotoma analysis of 10–2 visual field testing with a red target in screening for hydroxychloroquine retinopathy. *Clinical Ophthalmology (Auckland, NZ)* 2015;9:1499-1509.

Sensitivity and Specificity of Ancillary tests

Table 3 Sensitivity and specificity of ancillary tests for hydroxychloroquine retinopathy

Ancillary test	Sensitivity (%)	Specificity (%)
SD-OCT	78.6	98.1
10-2 VF	85.7	92.5
mfERG	92.9	86.9
10-2 VF + mfERG	100	82.2
10-2 VF + SD-OCT	85.7	92.5
mfERG + SD-OCT	100	86.0

Abbreviations: VF, visual field; mfERG, multifocal electroretinogram; SD-OCT, spectral domain optical coherence tomography.

Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.*Clinical Ophthalmology (Auckland,*

Other: M-color

- Multicolor technology- 3 lasers of different wavelengths
  - RED (815nm)- : Deepest: Choroid, RPE, PR
  - GREEN (518nm)- middle: strongly absorbed by Hemoglobin thereby imaging BV's, hemes, exudates
  - BLUE(486nm)- RNFL, Ganglion cells, retinal surface path: ie ERM



Sergott RC. Retinal segmentation using multicolor laser imaging. J Neuroophthalmol.2014;34(Suppl):S24–8

Other: M-color



https://www.heidelbergengineering.com

- M-Color imaging will supplement traditional FP and SD-OCT.

37 yo Caucasian Male -SDOCT



37 yo Caucasian Male -SDOCT



37 yo Caucasian Male- FAF



37 yo Caucasian Male- FAF



37 yo Caucasian Male- VF OD

10-2 FDT THRESHOLD



37 yo Caucasian Male- VF OS

10-2 FDT THRESHOLD



37 yo Caucasian Male- M color



37 yo Caucasian Male- M color Infrared



37yo Caucasian Male

- Impression
  - Suspect Early Hydroxychloroquine Retinopathy OU
    - Hydroxychloroquine- Duration of >10 years; current dose 300mg/day
    - (+)macular pigmentary changes R>L on fundus exam
    - Abnormal FAF and M-color photos suggestive of HCQ toxicity
    - (+)scattered paracentral defects on FDT VF matrix 10-2 R+L
    - Mac OCT: intact IS/OS, normal foveal and parafoveal thickness, no notable loss of ONL R+L
- Plan
  - DWP findings and possibility of discontinuing medication in future. Monitor for now. Inform rheumatology of findings. RTC in 6 months for repeat testing VF 10-2 and SD-OCT.

Tx: Cessation

- No treatment other than stopping med
- The amount of progression and risk to vision is dependent upon the severity of the retinopathy when detected.
- Clearance from the body can take many months.
- Mechanism of progressive HCQ Retinopathy after the drug is discontinued is unclear

Did you know?

- Classic bull's-eye infrequent in patients of Asian heritage.
  - Look beyond the central macula in Asian patients.
  - More peripheral pattern of change- extramacular distribution near the arcades.
- VF
  - Perform 24-2 or 30-2 along with 10-2
- SD-OCT
  - Wider angle scans across the vascular arcades

Screening

- Screening schedule:
  - Baseline Examination at start of medication use
    - Establish baseline fundus photos
    - r/o pre-existing maculopathy
  - Annual screening after 5 years on acceptable dose and no other major risk factors
    - Daily use, duration of use, concurrent tamoxifen therapy, kidney disease, and lower weight
    - Pre-existing maculopathy

AAO Recommended standard of care for a patient taking HCQ

- Recommended screening tests:
  - **Automated 10-2 white pattern VF**
  - **SD-OCT**
  - MfERG
  - FAF
- Tests not recommended for screening
  - Fundus exam and photo
  - Time domain OCT, resolution is not sufficient to detect early toxic changes
  - FA- only recognizes late RPE changes
  - Full field ERG
  - AG
  - Color vision

Summary/Closing:



Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of Ophthalmology .Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.Ophthalmology (2011) 118(2):415. 22.10.1016/j.ophtha.2010.11.017

Summary/Closing:

- Even the smallest defects on VF should be taken seriously
- Keep in mind media opacity can reduce quality of scans and subtle findings
- Examine the cornea carefully
- Take note of the daily dose relative to weight and duration of use of HCQ
- Discuss screening schedule and shorten follow-up intervals in suspicious cases

References

- 1. Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.*Clinical Ophthalmology (Auckland, NZ)*. 2014;8:1389-1399. doi:10.2147/OPTH.S66527.
- 2. Marmor MF. Comparison of Screening Procedures in Hydroxychloroquine Toxicity.*Arch Ophthalmol.* 2012;130(4):461-469. doi:10.1001/archophthalmol.2011.371.
- 3. Sergott RC. Retinal segmentation using multicolor laser imaging. J Neuroophthalmol.2014;34(Suppl):S24–8. doi: 10.1097/WNO.0000000000000164
- 4. Marmor MF, Hu J. Effect of Disease Stage on Progression of Hydroxychloroquine Retinopathy. *JAMA Ophthalmol.*2014;132(9):1105-1112. doi:10.1001/jamaophthalmol.2014.1099.
- 5. Melles RB, Marmor MF. The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy. *JAMA Ophthalmol.* 2014;132(12):1453-1460. doi:10.1001/jamaophthalmol.2014.3459
- 6. Browning DJ, Lee C. Scotoma analysis of 10–2 visual field testing with a red target in screening for hydroxychloroquine retinopathy. *Clinical Ophthalmology (Auckland, NZ)*. 2015;9:1499-1509. doi:10.2147/OPTH.S87850.
- 7. Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. *Clinical Ophthalmology (Auckland, NZ)*. 2015;9:943-952. doi:10.2147/OPTH.S82398.
- Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of Ophthalmology .Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.Ophthalmology (2011) 118(2):415–22.10.1016/j.ophtha.2010.11.017

THANKS FOR YOUR ATTENTION

Scleral Shape and Specialty Contact Lens Fitting: Research to Clinical Practice

Presented June 11, 2016
Northwest Resident Conference

Sheila D. Morrison OD, MS
Cornea & Contact Lens Resident
Pacific University College of Optometry

Acknowledgements & Disclosures

Many Thanks…

Dr. Matt Lampa
Proff Pat Caroline
Proff Mark Andre
Dr. Beth Kinoshita
Randy Kojima
Dr. Eef VanDerworp
Markus Ritzmann
Dr. Weon Jun
Dr. Molly Cardenal
Dr. Shannon Lutz
Dr. Mark Williams
Dr. Derek Louie
PUCO VPI team
PUCO MS Students

Disclosures: None

Introduction

- Performance of *modern therapeutic lenses* has been improved by:
  - Innovations in contact lens lathing technology
  - Availability of better soft and rigid-gas-permeable materials
- Understanding scleral shape is imperative to successful fitting of specialty contact lenses



Historic Beginnings

- Scleral Lenses
  - 1800's, 1st invented contact lens modality from glass blown shells
- Keratometry
  - Late 1800's, evaluate the shape of central cornea
  - Earliest method for gaining some form of topographical data of the eye



Beyond the Keratometer: Corneal Topography (videokeratography)

- **Reflection-based**
  - **Placido-ring**
- **Projection Based**
  - **Rotating slit-scan**
  - **Scheimpflug imaging**

*New software attributes may be able to predict starting sagittal height of a **scleral lens** by extrapolating 10mm chord corneal topography data*



Beyond the Limbus: Scleral Mapping Tools

- ***Anterior Segment OCT*** **(Carl Zeiss)**
- ***Scheimpflug Imaging*** **(Oculus Pentacam)**
- ***Profilometry*** **(Visionary sMap3D & Eaglet)**

Anterior Segment OCT

- **Images:**
  - cross-sections of anterior segment
- **Calipers Measure:**
  - distances, depths, and angles
- **Visualization of:**
  - junctions between central cornea, peripheral cornea, limbus, and sclera



Scheimpflug Imaging

- **Projection-based:**
  - anterior cornea
  - posterior cornea
  - anterior lens
- **Visualization of:**
  - 3-dimensional reconstruction of the anterior chamber



Profilometry

- Reflection-based:
  - scleral surface
  - corneal surface
- Fluorescein
- Lid retraction:
  - Can image beyond a 20mm scleral chord

sMap3D Scleral Topography: Data Acquisition



sMap3D Scleral Topography: Data Output



Process of empirical scleral fitting with the sMap 3D: scleral mapping with lens design software display (top), to empirically placing a digital scleral lens with fluorescein beneath it (bottom left), to the predicted lens on the in vivo eye (right).

Eaglet ESP Scleral Topography



- **Elevation Maps:**
  - **Blue = least elevated**
  - **Red = most elevated**
- **Lens will land on area of greatest elevation first**



Profilometry: Tips for Successful Aquisition

- Fluorescein works better than NaFl strips
- Lid retraction by patient and practitioner
- Speak to the patient throughout
- Can occlude fellow eye for better fixation
- Crosshair alignment



Performance: Comparison of Technology



Performance: Sagittal Height Comparison



Results:

- *Consistency of data at all chords*
- *Differences between right and left eyes*
- *Average scleral asymmetry measured by OCT and sMap3D was slightly greater in right eyes (210um) then left eyes (163um)*

Nomenclature

- **Shift in nomenclature: corneal astigmatism can be described by**
  - **Dioptric Power**
  - **Micron height differential between steep and flat meridians**
- **Globally accepted: 25um differential in corneal height (between the flat and steep meridians) is equal to approximately 1.00 D of toricity**

Nomenclature

- The description of sagittal depth in microns is also utilized in scleral mapping
  - There is no globally accepted standard to covert a micron height differential to diopters in the sclera
- Debatable Terminology:

'toricity'	'asymmetry'
the difference in height between the two principle meridians	the difference in height between the eight different meridians

- Presently, the trend appears to be the predominant use of the word 'asymmetry'

Normative & Demographical Data

- Normative and demographical data related to corneal topography exist in the literature
- Databases are currently in progress to begin to characterize scleral shape of 'normal eyes'
- In addition to race, gender, and age norms, there is a need to understand the relationship between corneal and scleral shape

Does the amount and orientation of corneal toricity extend across the limbus onto the sclera?



Corneal Toricity and Scleral Asymmetry…. Are They Related?

Beth Kinoshita OD, Sheila Morrison OD, MS, Patrick Caroline, Randy Kojima and Matthew Lampa OD

Pacific University College of Optometry, Forest Grove, Oregon

Introduction

Historically we have most often described astigmatism in terms of the dioptric power from the keratometer or axial display topography map. The axial display map does an excellent job of describing the dioptric power of the cornea and illustrating the shape and location of the corneal astigmatism (Figure 1). But, this map provides only limited information that can be used in the fitting of corneal contact lenses. Today, there has been a paradigm shift within our industry to describe corneal astigmatism not as a dioptric power but instead as a difference in height (i.e. sagittal depth) between the two principle meridians (flat and steep) of the cornea.

Using sagittal height data, the corneal topographer creates an elevation map by selecting a "theoretical" spherical surface that runs through the cornea (Figure 2). It is the elevation display map that best describes the ultimate fluorescein pattern seen clinically (Figure 3).

Previous studies at Pacific University have shown that a:

25 µm differential in corneal height (between the flat and steep meridians) is equal to approximately 1.00 D of toricity.

Purpose

The purpose of this study is to determine if there a relationship between the corneal toricity and the scleral shape (toricity) using sagittal height measurements.

Materials and Methods

- Twenty subjects, 10 left eyes with <0.75 D of with-the-rule corneal toricity and 10 left eyes with >1.75 D with-the-rule corneal toricity, participated in this pilot study.
- The Placido ring based Medmont E300 Corneal Topographer was used to determine the corneal toricity and elevation along the flat and steep meridians.
- The sMap3D by Precision Ocular Metrology was used to determine the scleral shape along four meridians (0-180°, 45°-225°, 90°-270°, 135°-315°) of the sclera at chords of 15.0 mm and 17.0 mm. The system uses Nafl and projected pattern sequences to map the corneal and scleral surface out to a chord of 22 mm (three fields of gaze are stitched together to form a single composite map).

Results

Low Corneal Astigmatism < 0.75 D

High Corneal Astigmatism > 1.75 D

Results Continued

- Of the 10 low WTR corneal astigmatism subjects, only 1 maintained a WTR orientation of the sclera at a 15.0mm chord and none of the subjects at a 17.0 mm chord.
- Of the 10 high WTR corneal astigmatism subjects, 3 maintained a WTR orientation of the sclera at chords of 15.0mm and 17.0 mm.
- The average amount of height differential between the principle meridians increased from the cornea to the sclera
- The orientation of the steep and flat meridians was variable at 15.0 & 17.0mm for both low and high astigmatism corneas.
- These results confirm that a 25 µm height differential of the principle corneal meridians is equal to ~1.00 D of corneal toricity.

Average Height Differential

Chord	Low Astigmatism	High Astigmatism
8 mm	8.5 µm	28.2 µm
15 mm	153.3 µm	235.0 µm
17 mm	208 µm	338 µm

Conclusions

- This pilot study appears to indicate that the scleral shape is highly asymmetric and confirms the presence of toricity that is often not in the same orientation and magnitude as the corneal toricity.
- The implications of these data may influence future contact lens designs to improve lens position and optics (i.e. Toric, MF, KCN)
- As future lens designs increase in diameter, it may be necessary for eye care professionals to image both the cornea and sclera and utilize lens designs that take into account the highly asymmetric shape of the human sclera.

Results: No Correlation

- **10% of subjects with low (<0.75D cyl) with-the-rule (WTR) astigmatism maintained a WTR orientation of the scleral at a 15mm chord and 0% of the subjects at a 17mm chord**
- **30% of subjects with high (>0.75D cyl) with-the-rule (WTR) astigmatism maintained a WTR orientation of the scleral at both 15mm and 17mm chords.**

Results: No Correlation

- Scleral asymmetry starts at the more symmetrical limbus and increases in asymmetry further into the periphery
  - ➢ average height differential increased from cornea to sclera
- The orientation of the steep and flat meridians was variable for both high and low astigmatism corneas.

Conclusion: scleral shape is highly asymmetric and this study confirms the presence of asymmetry that is not often in the same magnitude as the corneal toricity.

As practitioners could we achieve more efficient and appropriate scleral lens fits?



Asymmetrical sclera

- Asymmetry in the 8 meridians
- Scleral shape: 110um difference between the steep and flat meridians
- Nasal meridian higher; temporal meridian lower
- Right and left eyes are usually different



Ritzman et al, 2015

Clinical Application: Successful versus Non-successful Lens Wear



What Makes a Successful Scleral Lens Wearer?

Beth Kinoshita OD, Sheila Morrison OD, MS, Patrick Caroline, Matthew Lampa OD, Randy Kojima and Mark André

Pacific University College of Optometry, Forest Grove, Oregon

Introduction

Materials, Methods and Results

Discussion

Conclusion

Decoded with Scleral Mapping



Patient	OD Height Differential	OS Height Differential
1	498.5um	43.5um



Patient	OD Height Differential	OS Height Differential
2	536.0um	155.0um

Successful Versus Non-Successful

- ***'Accepted Knowledge':***
  - ***scleral elevation impacts successful contact lens fitting.***
- **Visser et al (2006) reported that with back surface toric scleral lenses:**
  - **lens stabilization was achieved**
  - **improved comfort and wearing time**
- **In some reports changing patients from a spherical to a toric back surface may decrease fogging**
- **Possible etiology for discomfort**
  - **unequal lens bearing on the asymmetrical sclera**

Should all scleral lenses be designed with a back toric?

- On average yes, but not always
  - The limbus is generally more symmetrical relative to the cornea and sclera,
  - mini-sclerals are usually more successful with spherical designs
- Though the majority of patients do have some degree of scleral asymmetry, there are exceptions:
  - binocular spherical scleral shape
  - one eye with a high degree of asymmetry while the fellow eye has a spherical shape
- Comprehensive scleral mapping is useful to most efficiently determine best lens design

Can we use scleral shape to our advantage to manage bumps, lesions, shunts, and difficult-to-correct refractive error?



Notching made possible by achieving rotational stability, using a toric back haptic to act as a 'lock-and-key' on the asymmetrical sclera of a patient with advanced keratoconus and raised pinguecula.

Can knowledge of scleral shape be applied to lens designs other than scleral lenses?



Anterior segment photography (top) showing typical temporal decentration of a soft conventional lens due to scleral anatomy (bottom).

Summary

- **Forefront of interest in research:**
  - **Scleral lens design**
  - **Myopia control**
  - **Placement of multifocal optics**
- **Developing and utilizing knowledge about scleral shape will facilitate better design of specialty contact lenses**

References

- American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Corneal Ectasia. San Francisco, CA: American Academy of Ophthalmology; 2013. Available at: www.aao.org/ppp.
- Gomes JA, Tan D, Rapuano CJ, et al. Global consensus on keratoconus and ectatic diseases. Cornea. 2015;34(4):359-69.
- Romero-Jimenez M, Santodomingo-Rubido J, Wolffsohn JS. Keratoconus: A review. Contact Lens & Anterior Eye. 2010;33:157-66.
- Van der Worp E. A guide to scleral lens fitting [monograph online]. Forest Grove, OR: Pacific University; 2010. Available from: http://commons.pacificu.edu/mono/4/.
- Wagner H, Barr JT, Zadnik K. Collaborative longitudinal evaluation of keratoconus (CLEK) study: methods and findings to date. Contact Lens & Anterior Eye. 2007;30:223-32
- Morrison S., Caroline P., Kojima P., Kinoshita B., Lampa M., Citek K. Empirically Determining the Physical Fit and Optimal Power of Scleral Contact Lenses – *Poster, Global Specialty Lens Symposium (GSLS) 2016*

Thank-you

Trish Duffield, O.D.
Ocular Disease Resident
Eye Care Associates of Nevada

FROM CF TO 20/HAPPY: THE POST-OPERATIVE JOURNEY OF A PELLUCID PATIENT

Cataract Evaluation

- 71YO WF
- Chief concern: bothered by glare, problems driving at night
- Ocular Hx: SCL wear x 40 yrs, (-) sx
- Medical Hx: seasonal allergies, peridontal disease
- Medications: Motrin prn, Alavert
- NKDA
- Family Hx: unremarkable

Cataract Evaluation

- DVA sc:
  - OD: CF 2', PH 20/150
  - OS: CF 2', PH 20/50
- Pupils, Pressures, EOMs, CVF normal
- OD dominant
- Glare testing (BAT) 20/400 OD, OS

Cataract Evaluation

- SCL Rx
  - OD: -8.75 +5.75 x 010
  - OS: -5.25 +2.25 x 160
- iTrace Autorefraction
  - OD: -13.87 +7.00 x 004
  - OS: -6.25 +3.37 x 180
- Manifest Refraction
  - OD: -13.00 +6.00 x 003 20/25-2
  - OS: -6.00 +2.25 x 180 20/20-2

Cataract Evaluation



Cataract Evaluation



Cataract Evaluation



Out of CL's x 24 hrs

Last name: [redacted]
ID:
Date of birth: 11/04/1943
Examination date: 09/29/2015
Surgeon: Paul W. Hiss, M.D.

Formula: Holladay 1
Target ref.: plano
n: 1.3375

The measurements should be checked for plausibility, as there may be pathological changes!

11/30 # MARK Corneas Pre-op for 90°

OD right

AL: 26.28 mm (SNR = 269.1)
K1: 42.83 D / 7.88 mm @ 109°
K2: 49.85 D / 6.77 mm @ 19°
R / SE: 7.32 mm / 46.34 D
Cyl.: 7.02 D @ 19° Axis 175°
ACD: 3.70 mm
Status: Phakic
OZA/TRIZ
May not be useful

OS left

AL: 26.15 mm (SNR = 166.9)
K1: 40.66 D / 8.30 mm @ 80°
K2: 43.89 D / 7.69 mm @ 170°
R / SE: 8.00 mm / 42.27 D
Cyl.: 3.23 D @ 170°
ACD: 3.47 mm
Status: Phakic
OZA/TRIZ

LensTec Softec HDO		B & L Softport AO LI61AO	
SF:	1.22	SF:	1.62
IOL (D)	REF (D)	IOL (D)	REF (D)
9.0	-0.48	10.0	-0.88
8.75	-0.32	9.5	-0.57
8.5	-0.16	9.0	-0.27
8.25	**-0.01**	**8.5**	**0.03**
8.0	0.14	8.0	0.33
7.75	0.30	7.5	0.62
7.5	0.45	7.0	0.91
Emme. IOL:	8.23	Emme. IOL:	8.55

LensTec Softec HDO		B & L Softport AO LI61AO	
SF:	1.22	SF:	1.62
IOL (D)	REF (D)	IOL (D)	REF (D)
14.5	-0.53	15.5	-0.87
14.25	-0.36	15.0	-0.53
14.0	-0.18	14.5	-0.19
13.75	**-0.01**	**14.0**	**0.14**
13.5	0.16	13.5	0.47
13.25	0.33	13.0	0.80
13.0	0.50	12.5	1.12
Emme. IOL:	13.73	Emme. IOL:	14.22

Cataract Evaluation

- Ocular Health Exam: Anterior Segment
  - Cornea:
    - OD: inferior endothelial scar
    - OS: clear
  - Lens:
    - OD: 1+NS/C/tr PSC
    - OS: 1-2+NS/C

Cataract Evaluation

- Ocular Health Exam: Posterior Segment
  - Optic nerve:
    - OU: C/D 0.1
  - Vitreous:
    - OU: PVD
  - Periphery:
    - OU: scattered lattice peripherally
    - OU: flat, (-) HRT

Cataract Evaluation

- Assessment:
  - Combined form cataract OU
  - Pellucid Marginal Degeneration OD>OS

Cataract Evaluation

- Plan:
  - Plan for cataract surgery OD 1st, then OS
- Discussed:
  - Cataract progression
  - Need for Toric IOL OU
  - Need for lower-level correction after surgery

Pellucid Marginal Degeneration

- Clinical Signs
  - Bilateral corneal ectasia
    - Inferior thinning
  - Against the rule astigmatism
    - Our patient: +7.00 x 004 (plus cyl)
  - I-S ratio: 13.61 (normal under 1.4)

Pellucid Marginal Degeneration

- Clinical signs
  - Topography
    - Classic crab claw appearance



Pellucid Marginal Degeneration

- Treatment Options
  - Refractive error correction
    - RGP, Hybrid, Sclerals
    - Less benefit from SCL
  - Corneal crosslinking
    - may postpone or eliminate the need of corneal transplantation
  - Intacs
    - BCVA 20/50 to 20/25
  - Corneal transplant

Cataract Surgery

- Candidacy requirements
  - ADL (activities of daily life)
  - BCVA worse than 20/40
  - Glare worse than 20/50-
  - Ocular health
- Intraocular lens calculations
  - Non-dominant eye 1st
  - Mild myopia 1st eye
  - MR at 1 week PO

Cataract Surgery

- Intraocular lens options
  - Monofocal distance
  - Monofocal monovision
  - Toric
  - Multifocal
  - Accommodating IOL



Cataract Surgery

- Surgical procedure
  - Conscious sedation
  - Clear corneal incision
  - Phaco
  - Implantation

Lens Choice

- Special order:

PO 1 Day OD

- CC: mild pain, photophobia
- Gtts: Maxitrol QID OD
- DVA sc: 20/60, PH 20/40-1
- IOP: 16mmHg

PO 1 Day OD

- Anterior Segment:
  - Conj: trace injection, 1+ chemosis
  - Cornea: 1+ edema
  - D/2+cell
  - PCIOL, centered



PO 1 Day OD

- Assessment:
  - Pseudophakia OD
- Plan:
  - CPM, RTC 1 week PO

PO 1 Week OD

- CC: good VA, mild FBS
- Gtts: Maxitrol QID OD
- DVA sc: 20/40, PH 20/40
- MR: -1.50 +2.00 x 180
- IOP: 14mmHg

PO 1 Week OD

- Anterior Segment:
  - Conj: trace injection
  - Cornea: 1-2+ scattered PEK
  - D/Q
  - PCIOL, centered

PO 1 Week OD

- Assessment:
  - Pseudophakia OD
- Plan:
  - Decrease gtts BID OD
  - RTC 1 month PO

PO 1 Month OD

- CC: good VA, no problems
- Gtts: Maxitrol BID OD
- DVA sc: 20/40, PH 20/40+2
- IOP: 16mmHg

PO 1 Month OD

- Anterior Segment:
  - Conj: quiet
  - Cornea: clear
  - D/Q
  - PCIOL, centered

PO 1 Month OD

- Assessment:
  - Pseudophakia OD
- Plan:
  - D/C gtts
  - Follow up with O.D. for SCL fit
  - RTC PRN surgery OS

Summary

- Every patient case is different
- Manage patient expectations
- Technology is our friend
- Surgery only when ready

20/Happy

References

1. Collagen cross-linking in the treatment of pellucid marginal degeneration
Ziad Hassan[1], Gabor Nemeth[2], Laszlo Modis[2], Eszter Szalai[2], Andras Berta[2]
1. http://www.pfmmedical.com/en/productcatalogue/featherR_micro_scalpels/clear_cornea_scalpel/index.html
2. http://vermontlaservision.com/cataract-surgery/selecting-an-intraocular-lens/
3. Mini-incision cataract surgery and toric lens implantation for the reduction of high myopic astigmatism in patients with pellucid marginal degeneration.
Balestrazzi A, Baiocchi S, Balestrazzi A, Cartocci G, Tosi GM, Martone G, Michieletto
1. Toric intraocular lens implantation for correction of astigmatism in cataract patients with corneal ectasia.
Parikakis EA, Chatziralli IP, Peponis VG, David G, Chalkiadakis S, Mitropoulos PG.
1. **Intacs for early pellucid marginal degeneration**
George D Kymionis, MD,PhD, Ioannis M Aslanides, MD,PhD, Charalambos S Siganos, MD, PhD
1. Surgical treatment of advanced pellucid marginal degeneration.
Rasheed K, Rabinowitz YS.



OCULAR PROSTHESIS: AN EYE FOR AN EYE

PRESENTED BY: MAGGIE WONG, O.D.
VA PORTLAND HEALTH CARE SYSTEM

ANOPHTHALMIC PROCEDURES

- Evisceration: contents in globe removed
- Enucleation: globe and optic nerve removed

- Exenteration: all ocular tissues + lids + bony orbit removed
  - Facial prosthesis or spectacle mounted prosthesis

FACIAL PROSTHESIS

- Orbital prosthesis



FACIAL PROSTHESIS

- Spectacle mounted prosthesis

EVISCERATION

- Primary indications:
  - Blind painful eye
  - Endophthalmitis
  - Penetrating ocular trauma
- Advantages:
  - **Less complex surgery**
  - **Decreased risk of infection to CNS**
- Disadvantages:
  - (?) Risk of **sympathetic ophthalmia**
  - Risk of **tumor dissemination**





ENUCLEATION



- Primary indications:
  - Intraocular malignancy
  - Sympathetic ophthalmia
- Advantages:
  - **Histologic exam** of globe and optic nerve
- Disadvantages:
  - **Reduced implant motility**

SURGICAL PROCEDURE

Evisceration

1. Cornea excised
2. Intraorbital contents are removed
   - Spoon, spatula, suction
3. Sclera is cauterized
4. Orbital implant w/o EOM reattachment

Enucleation

1. Conjunctiva is dissected, all EOMs are cut at insertion
2. Intact globe and partial ON removed
3. Orbital implant WITH EOM reattachment

OVERVIEW OF THE PROCESS

Orbital contents removed → Orbital implant → Conjunctiva sutured → Conformer → Prosthetic fitting





ORBITAL IMPLANTS



- Conjunctiva sutured over it
- Purpose of implants:
  - Maintains orbital structure
  - Helps w/ closure of conjunctiva
  - Imparts movement to prosthesis
- 80% porous implants
- 20% non-porous implants

POROUS ORBITAL IMPLANTS

- Better stability w/ decreased rejection risk
  - EOMs anchored to implant → better prosthetic motility
  - Fibrovascular ingrowth
- Examples:
  - Hydroxyapatite (27%)
  - Porous polyethylene (43%)
  - Other (10%)
    - Aluminum oxide
- Allows for pegged implants

PEGGED IMPLANTS





- Attaches to prosthesis
- Increased motility
  - More life-like movement
  - 87% of fellow eye motility
- Very selective patients
  - Well-vascularized socket
  - 6-12mo post-operatively

NON-POROUS ORBITAL IMPLANTS

- H/o infection with porous implants
  - Increased implant migration
  - Less expensive than porous implants
- Examples:
  - PMMA
  - Silicone
- Implant exposure risk
  - Not statistically significant from porous
  - Needs surgical removal if exposed

CONFORMER

- Maintains shape of socket
- Stabilizes the implant
  - Lids can blink w/o rubbing on sutures
  - Decreased risk of tissue contracture
- Made of acrylic or silicone
- Stays in fornix for 4-6 weeks



TYPES OF OCULAR PROSTHETICS



STOCK VS. CUSTOMIZED EYES

Stock

- Pre-fabricated with generic shapes/color
- Cheaper cost
  - Not provided to individuals

Custom

- Customized to orbit
- $1500-$5000 per eye
- Impression fitting
  - Takes 1 week to make

IMPRESSION FITTING

1. Direct impression: inject paste into orbit
   - Takes 4-6min to harden
   - Wax mold is created from anterior part of orbital impression
   - Iris is painted at this visit
2. Wax fitting: wax mold is shaped, iris is positioned
3. Scleral color matching
   - Iris is embedded
   - Red cotton is used to create veins

IMPRESSION FITTING, CONT.

- Modified impression fitting
  - Use alginate (1min to harden)
  - Takes 2 days
- Materials: glass or PMMA resin
  - Glass deteriorates faster (18-24mo)
  - PMMA is more compatible (5 years)



PATIENT HISTORY

- How old is the current device?
  - 5 years for replacement
- How often is the prosthetic cleaned?
  - 1-3 months to clean off protein
- How do you clean the prosthetic?
  - Mild soap/water, RGP cleaner
  - NEVER clean with rubbing alcohol!
- How often do you see the ocularist?
  - 6-12 months for polishing
  - 1 year for possible enlargement/reduction

INSERTION/REMOVAL

- Can use RGP suction cup for insertion/removal

Removal:

- Pull down the lower lid and tuck behind prosthesis.
- Prosthesis will gently slide out.

Insertion:

- Lift upper lid and slide **thicker side up** under the lid.
- Pull down lower lid and tuck.

INSPECTING THE PROSTHESIS

- Smoothness of surface
  - Wash with soap/water or RGP cleaning solution
  - If deposits remain or large scratches, needs polishing
- Sharpness of edges
  - Contouring with ocularist



COMMON COMPLICATIONS



- Discharge
  - Green or yellow = infection
  - White = mechanical irritation
- Giant papillary conjunctivitis
  - Increase cleaning/polishing
  - Can use antihistamine/MCS gtts, but topical steroids not very useful
- Dry eye syndrome
  - Silicone lubricants (Sil-Ophtho)

OCULAR DISCOMFORT

- Malignancy
  - Tumor growth
  - Metastasis posterior to implant
- Thyroid eye disease
  - EOM swelling = shallow orbit
- Contracted socket syndrome
  - Tightening from fibrosis
  - Punctal or lid adhesions
- Implant exposure





IMPLANT EXPOSURE



- More likely in HA porous implants
- Usually occur in first 3-12 months
  - Occurs in 1.6% to 22% of cases
- Sx: epiphora, discharge, pain
- Measure size of defect
  - <4mm: close spontaneously or have conjunctiva pulled/sutured over
  - >4mm: need grafting or new implant

IMPLANT INFECTION

- Risk factors:
  - Implant exposure
  - First 6-12 months of porous implant
- Characteristic Sx:
  - Recurrent discharge
  - Implant discomfort to touch
  - Recurrent pyogenic granuloma
- Treatment:
  - Doesn't respond well to antibiotics
  - Need a new implant (non-porous)



PEG COMPLICATIONS

- High complication rate (48-71%)
  - Implant infection
  - Conjunctival overgrowth
  - Conjunctival regression
- Can occur from 15 days to 10yrs







SUMMARY

- **Ensure proper follow-up with ocularist**
  - Replacement every 5 years
  - Cleaning regimen/frequency
- **Always remove the prosthetic eye!**
  - Inspect for smoothness/sharpness of device
- **Pay attention to recurrent symptoms**
  - Discharge and pyogenic granulomas
  - Ocular pain could be serious

RESOURCES

1. Anderson, Richard L. "Pegged implants vs. unpegged implants." Ocular Surgery News: Mar 1 2006.
2. Cafiero-Chin et al. "Ocular Prosthesis: Indications to Management." Canadian Journal of Optometry. Vol. 77, Issue 2. pp 24-32
3. Christmas et al. "Evaluation of Efficacy and Complications of Primary Pediatric Orbital Implants After Enucleation." Arch Ophthalmology. Vol 118, Apr 2000 pp 503-506.
4. Christmas et al. "Intraorbital Implants After Enucleation and Their Complications." Arch Ophthalmology. Vol. 116, Sep 1998 pp 1199-1202.
5. Himanshi et al. "A Multidisciplinary Approach for Management of Post-enucleation Socket Syndrome with Dermis-Fat Graft and Ocular Prosthesis: A Clinical Report." Journal of Prosthodontics (2013) pp 657-660.
6. Himanshi et al. "Different Intraorbital Implant Situations and Ocular Prosthetic Rehabilitation." Journal of Prosthodontics (2015) pp 01-09.
7. Kim, Yoon-Duck. "Porous orbital implants." Ocular Surgery News: Mar 1 2006.
8. Sanjayagouda et al. "Ocular Prosthesis: a brief review and fabrication of an ocular prosthesis for a geriatric patient." Gerodontology 2008; 25: 57-62.

Cataract Surgery: Potential Complications Despite Advancements in Surgical Procedures

Megan Szarkowski, O.D.
Optometry Resident
Mann-Grandstaff VA Medical Center
Spokane, WA
meganszarkowski@gmail.com

Cataract Surgery in America

- Affects over 24 million Americans age 40 and older
- 3.6 million cataract procedures performed in the United States in 2015
- 50 million Americans projected to have cataracts by the year 2050
- More individuals having cataract surgery at a younger age

Aging Changes to the Crystalline Lens

- Changes in structure of plasma membrane and degradation of cytoskeletal components contribute to nuclear sclerosis
- Change in permeability ratio of Na+:K+ correlates with increase in optical density of the lens
- Absorption of both UV and visible light by the lens increases with age



http://d1vn86fw4xmcz1.cloudfront.net/content/royptb/366/1568/1278/F3.large.jpg

Cataract Surgery Advancements

- Phacoemulsification
- ICCE ==> ECCE
- Large incision ==> small incision
- Clear corneal incision (CCI)
- Femtosecond laser assisted cataract surgery (FLACS)
  - Less ultrasound (phaco) energy
  - More reproducible capsulorrhexis diameter and centration
  - Possible decrease in endothelial cell loss?
  - Better sealing incisions → decreased risk for endophthalmitis

Cataract Surgery Advancements

- Premium/"advanced technology" IOLs
  - Pupil size is an important consideration
  - Accommodating (ex: Crystalens)
  - Multifocal (ex: TECNIS, ReSTOR)
    - Focal zones/rings
  - Toric (ex: AcrySof)
  - Toric accommodating (ex: TRULIGN Toric)

Cataract Surgery Advancements

- Limbal or corneal relaxing incisions (LRI/CRI)
  - LRI = weaker corrective procedure
  - LRI used for 0.5-4.0D of astigmatism (up to 8D)
  - Less post-op glare than CRI
  - 1-2 clock hour incision



Cataract Surgery Advancements

- Optiwave Refractive Analysis (ORA)
- TrueVision

Cataract Surgery Advancements

- Dropless cataract surgery
  - Intravitreal transzonular injection
    - Triamcinolone/moxifloxacin (Tri-Moxi)
    - Triamcinolone/moxifloxacin/vancomycin (Tri-Moxi-Vanc)
- Most common side effect is peripheral floaters

Potential Complications

- Striate keratopathy
- Subconjunctival hemorrhage
- Hyphema
- Posterior capsular opacification (PCO)
  - Fibrous
  - Pearl
  - Combination

Potential Complications

- Anterior capsular opacification
  - Important with premium/"advanced technology" IOLs
- Cystoid macular edema (CME/Irvine-Gass)
  - Occurs in outer plexiform layer of the retina
  - Peak incidence ~6-10 weeks post-op
  - Treatment: topical corticosteroid and topical NSAID
  - Other treatment options: sub-Tenon's or subconjunctival periocular corticosteroids, anti-VEGF
    - Newer NSAIDs preferred due to enhanced penetration into posterior chamber (nepafenac, bromfenac)



Potential Complications

- Endophthalmitis (rare)
  - Acute: 2-5 days post-op
    - Gram (+) bacteria, patient's normal flora
  - Chronic: several weeks or more
  - Signs:
    - Ciliary injection, conjunctival chemosis, hypopyon, decreased visual acuity, ocular pain
  - Treatment:
    - Culture aqueous and vitreous
    - Intravitreal, topical and sub-conjunctival antibiotics
  - Immune suppressive diseases (such as Diabetes Mellitus increases risk
  - Vitreous loss at time of surgery increases risk

Potential Complications

- Pseudophakic retinal detachment (RD)
  - Predisposing factors: axial length >24.5mm, myopic refractive error, lattice degeneration, h/o RD in fellow eye
- Lens subluxation
  - Asymmetric haptic placement
  - Loss of zonular support
  - Pupillary capture of IOL optic



Potential Complications

- Wound leak
  - (+) Seidel sign
- Toxic Anterior Segment Syndrome (TASS)
  - Non-infectious, acute, post-operative inflammation
  - 12-24 hours post-op
  - Limited to anterior segment
  - Improves with steroid use
  - Primary differential diagnosis is infectious endophthalmitis
  - Symptoms: blurred vision, mild ocular pain
  - Signs: hypopyon, diffuse corneal edema

Potential Complications

- Retained lens fragments
  - Cortex
    - Easier to manage
    - Small amounts may resolve with increase in topical steroid
  - Nucleus
    - More dense

Potential Complications

- Elevated IOP
  - Day 1: most likely retained viscoelastic
    - Symptoms: nausea, vomiting, ocular pain
    - Treatment: burp wound, paracentesis, oral diamox, topical medications (avoid prostaglandin analogs)
  - 1 week: most likely TM inflammation
    - Treatment: increase steroids
  - 3-4 weeks: most likely steroid response
    - Discontinue steroid use, add topical IOP lowering drop (avoid prostaglandin analogs) and/or switch to Lotemax

Burping Corneal Wounds

- Thorough examination
- Instill proparacaine, topical antibiotic and sodium fluorescein
- Select instrument
- Burp wound
- Re-check IOP
- Monitor closely



Additional Considerations

- Residual refractive error
- Pseudoexfoliation (PXF) → zonular dialysis
  - Post-op IOP spikes
  - Prolonged inflammation
  - Poor pupillary dilation increases risk



http://www.medscape.com/viewarticle/831485

Additional Considerations

- Intraoperative Floppy Iris Syndrome (IFIS)
  - Patients taking alpha-1 antagonists such as Flomax (tamsulosin)
  - Progressive pupillary constriction during surgery
  - Iris hooks, pupil dilators may need to be used





- History of acute or chronic uveitis
- Severe blepharitis or dry eye syndrome

Additional Considerations

- Fuch's endothelial dystrophy
  - Possible corneal decompensation after surgery
- Blood thinners
- Diabetes Mellitus
  - Disruption of blood-aqueous barrier
  - No substantial increase in retinopathy progression in uncomplicated surgery
    - Natural course of disease over time?
- Glaucoma

Topical Anesthesia vs. Retrobulbar Block

Topical Anesthesia	Retrobulbar Block

• Safer procedure
• Speed and ease of administration
• Increased surgical difficulty
• More pain during procedure
• Faster visual recovery
• Higher blood pressure during procedure
	• Anesthesia more difficult to administer
	• Less pain during procedure
	• Lower blood pressure during procedure
	• Potential sight threatening complications
	  • Brain stem anesthesia
	  • Ocular perforation
	  • Retrobulbar hemorrhage

Topical Anesthesia

- Benoxinate (oxybuprocaine) 0.4% frequently used
- Proparacaine (proxymetacaine) 0.5% less toxic to corneal epithelium, but shorter duration of action
- Other topical anesthetics:
  - Tetracaine (amethocaine) 0.5-1.0%
  - Longer duration, but increased likelihood for corneal toxicity

Retrobulbar Block

- 2 mL Lidocaine 2% and hyaluronidase 1/15000 with a 23-gauge needle
- Needle entered eye at junction of lower and outer edges of the eye
- Needle placed between extraocular muscles and 2mL of anesthetic solution injected



Pre-operative Testing Considerations

- IOL master
- Corneal topography
- Macula OCT
- Pachymetry
- B-scan ultrasound

Pre-operative Testing Considerations

- Gonioscopy
- Anterior segment OCT





Pre-operative Testing Considerations

- Specular microscopy



Pre-operative Testing Considerations

- Ocular surface preparation

Thank you!

Megan Szarkowski, O.D.
Optometry Resident
Mann-Grandstaff VA Medical Center
Spokane, WA
meganszarkowski@gmail.com

REFERENCES

- Abouzeid, H., Ferrini, W. (2014). Femtosecond-laser assisted cataract surgery: a review. Acta Ophthalmol. Volume 92: 597–603. doi: 10.1111/aos.12416
- Ascaso, F. J., Huerva, V., & Grzybowski, A. (2015). Epidemiology, Etiology, and Prevention of Late IOL-Capsular Bag Complex Dislocation: Review of the Literature. Journal of Ophthalmology, 2015, 1-7. doi:10.1155/2015/805706
- Boezaart, A., Berry, R., Nell, M. (2000, February). Topical anesthesia versus retrobulbar block for cataract surgery: the patient's perspective. Journal of Clinical Anesthesia, 12(1), 58-60. doi:10.1016/S0952-8180(00)00117-3
- Dewey, S., Beiko, G., Braga-Mele, R., Nixon, D. R., Raviv, T., & Rosenthal, K. (2014). Microincisions in cataract surgery. Journal of Cataract & Refractive Surgery, 40(9), 1549-1557. doi:10.1016/j.jcrs.2014.07.006
- Ellis, B., OD, & Lighthizer, N., OD. (2016, February 15). Learn to Burp Corneal Wounds Without a Hiccup. Retrieved March 1, 2016, from https://www.reviewofoptometry.com/article/learn-to-burp-corneal-wounds-without-a-hiccup
- Findley, H., OD, & Ajamian, P. C., OD. (2013, May 15). When the Lens Won't Leave. Retrieved March 1, 2016, from http://www.reviewofoptometry.com/article/when-the-lens-wont-leave
- Gerstenblith, A. T., & Rabinowitz, M. P. (2012). The Wills eye manual: Office and emergency room diagnosis and treatment of eye disease. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.
- Ho JW, Afshari NA. Advances in cataract surgery: preserving the corneal endothelium. Current opinion in ophthalmology. 2015;26(1):22–7. doi: 10.1097/ICU.0000000000000121 .

REFERENCES

- Jabbarvand, Mahmoud et al. Endophthalmitis Occurring after Cataract Surgery Ophthalmology, Volume 123, Issue 2, 295-301
- Patel, A. S., M.D., Feldman, B. H., M.D., Alejandro de Alba, M., M.D., & Eke, T., M.D. (2015, January 20). Retrobulbar anesthesia. Retrieved May 31, 2016, from http://eyewiki.aao.org/Retrobulbar_anesthesia
- Rally, D. R., MD, & Shah, C. P., MD. (2014, March 5). Pseudophakic Cystoid Macular Edema. Retrieved March 1, 2016, from http://www.reviewofophthalmology.com/content/d/retinal_insider/c/46967/
- Sáles, C. S., & Manche, E. E. (2015). Managing residual refractive error after cataract surgery. Journal of Cataract & Refractive Surgery, 41(6), 1289-1299. doi:10.1016/j.jcrs.2015.05.001
- Turalba, A., Payal, A. R., Gonzalez-Gonzalez, L. A., Cakiner-Egilmez, T., Chomsky, A. S., Vollman, D. E., Daly, M. K. (2015). Cataract Surgery Outcomes in Glaucomatous Eyes: Results From the Veterans Affairs Ophthalmic Surgery Outcomes Data Project. American Journal of Ophthalmology, 160(4). doi:10.1016/j.ajo.2015.07.020
- Vasavada, A., Raj, S., Johar, S. K., Vasavada, V., & Vasavada, V. (2010). Post-operative capsular opacification. Nepalese Journal of Ophthalmology Nep J Oph, 1(1). doi:10.3126/nepjoph.v1i1.3673
- Yanoff, M., Duker, J. S., & Augsburger, J. J. (2004). Ophthalmology. St. Louis, MO: Mosby.
- Yonekawa, Y., MD, Eliott, D., MD, Kim, I., MD, Feldman, B. H., MD, & Shah, V. A., MD. (2014, December 21). Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome). Retrieved March 1, 2016, from http://eyewiki.aao.org/Pseudophakic_Cystoid_Macular_Edema_(Irvine-Gass_Syndrome)#Prophylaxis_and_Treatment

NEURO-OPTOMETRIC REHABILITATION EXAM - A TO Z

INNA TIMSHINA, OD

BRIGHT EYES VISION CLINIC – MINNEAPOLIS, MN

PEDS/VT/REHAB RESIDENCY

WHAT IS NEURO-OPTOMETRIC REHABILITATION (NOR)?

- Arguably EVERYTHING we do!
- More specifically – vision rehabilitation following any type of brain injury
- Includes using a variety of lenses and vision therapy procedures to improve visual function and eliminate symptoms

WHO NEEDS NOR?

- Patients who have/had – CVA, severe/penetrating TBI, mild TBI/concussion, degenerative neuro diseases (MS, etc.), brain injuries due to infectious/inflammatory causes
- Sometimes patients who have none of the above that can be identified but still present with similar symptoms
- Sometimes patients who have multiple causes of symptoms

POST TRAUMA VISION SYNDROME

- A typical constellation of symptoms/findings following a brain injury
- Patient complaints include – blurry, double, headaches/mental fog, difficulty concentrating, eye strain, “floor is slanted” or “walls are moving” (spatial disorientation), balance problems, dizziness/motion sensitivity, light sensitivity

- Findings of PTVS include – convergence insufficiency, various phorias or tropias – mostly exo, accommodative dysfunction, poor saccades and pursuits, ambient vision dysfunction
- Can be accompanied by visual midline shift/abnormal egocentric localization

MORE ON AMBIENT VISION

- Ambient = peripheral
  - Organize/process spatial information
  - Balance and movement
- Focal = central
  - Detail
- Dysfunction often happens with overemphasized focal vision and poor integration of the two

EYE EXAM COMPONENTS

- Detailed case history, including:
  - What kind of brain injury, when and how happened, loss of consciousness or altered mental status following injury
  - Head/neck imaging – MRI, CT scan
  - Any treatments/therapies already doing
  - Previous eye care, eye wear
  - Other concurrent injuries (i.e. hip/leg damage will affect gait/posture, etc.)
  - Symptoms checklist (COVD, etc.); impact to ADLs

HEALTH EXAM

- Evaluate integrity of eye structures, integrity of whole visual pathway
- Include – VA, CVF, EOM, pupils, color, IOP, SL and DFE
- Consider automated visual field and visual evoked potential testing
- OCT, ERG, photos, etc. as needed
- *Ocular health is the foundation for function, don't ever skip or minimize importance of this part of testing*

REFRACTION

- Aim for most plus to clearest vision
- Retinoscopy is your friend!
  - Do distance and near
- Be sure to recheck retinoscopy when dilated
- Keep in mind – what you measure is not necessarily what you will prescribe
- It is not unheard of for patient to have a shift in refractive error following brain injury

BINOCULAR VISION EFFICIENCY TESTING

- This is where it gets real!
  - Many of patient's symptoms will be explained with these findings
- Include – cover test, NPC, vergence ranges (horizontal and vertical), pursuits, saccades, maddox rod, W4D, stereo, NRA/PRA, etc.
- Be sure to ask how the patient feels throughout testing – will often find visual motion sensitivity during pursuits, dizziness and increased headaches

VISUOSPATIAL/AMBIENT VISION TESTING

- Another high yield area of testing to explain symptoms
- Include – posture and gait observations and egocentric localization with and without prism – low BI prism, yoked prism, even tiny amounts of vertical prism can make huge difference in balance and symptoms
- Prism correction tends to be temporary, goal is to use therapeutically now, eliminate in the future

TINTS

- These can be the difference between participating in life or sitting in a dark house
- Some photosensitivity will improve with prism alone
- Test a few different colors, aim for lightest version of color to make a difference, goal will be to function without tint eventually

- Further visual processing testing – usually if patient will be starting in-office vision therapy or want to dig deeper, can use variety of standardized tests
- Evaluate visual discrimination, visual memory, visual sequential memory, visual figure ground, visual directionality, visual motor integration, presence of primitive reflexes, finer assessment of eye movements, etc.
- Include – Visagraph, DEM, VMI, TVPS, Piaget, Gardner's Reversal Test, DTVP, Wold Sentence copy, TAAS, DESD, VO star, color fields (syntonics), etc.

WORKING AS PART OF A REHAB TEAM

- With any patients, but especially with brain injury patients – rehabilitating whole person!
- Coordinate care with other specialties – including physiatry, neurology, sports medicine, chiropractic care, physical therapy, occupational therapy, speech therapy, ophthalmology/neuro-ophthalmology, athletic trainers, primary care, psychology, (educators), etc.

CASE REPORT – 42YOBF

- Complains of: “eyes get tired and overwhelmed,” headaches constantly, difficult to work on computer but needs to for work, cannot read anymore – book looks like it’s shaking, fluorescent lights bothersome, “everything is too much to look at!”
- Injury: MVA 2mos ago, concussion, no other injuries
- Referred by OT
- Does not remember ever having eye exam before

HEALTH EXAM

- scVA: dist 20/50 OD, OS; near 20/40 OU
- CVF FTFC; +PERRL; EOMs FROM OU
- IOP – 28 OD, 17 OS (w/ 494/505 pachys)
- SLE – reveals traumatic cataract nasal half of lens w/i line of sight OD, large vanHerrick angles OU, MGD OU
- Gonioscopy – reveals 2 clock hours angle recession inf/nas OD
- DFE – reveals asymmetric C/Ds 0.85OD, 0.35OS; pinpoint drusen with trace RPE mottling in macula

AUTOMATED VF (1ST TRY)

OS



OD



OCT



VEP



Parameters	OD	OS	Difference	Remarks
Amplitude Low Contrast μV	4.9	8.9	4.0	Low
Amplitude High Contrast μV	15.3	19.0	3.7	
Latency Low Contrast ms	108.4	106.4	2.0	
Latency High Contrast ms	102.5	99.6	2.9	

- Abnormal LX – waveform OU and amplitude OD
- Other trials (TR):

  +Binocular dysfunction

  +Ambient dysfunction

  +Improvement w/ prism

REFRACTION

- Retinoscopy – opacity OD!, dim reflex OU
- Manifest – patient had a very hard time with this

  +0.25 20/40

  -0.75 20/40 //+1.50ADD to 20/30 OU
- Wet Ret/AR – still hard for patient, for acuity used trial frame on 2nd visit, did single letter acuities & only got OU

  +0.25-0.75x050

  -0.50-0.50x040 20/20OU
- On 2nd visit – preferred +1.00 ADD, computer distance

BINOCULAR VISION EFFICIENCY TESTING

- CT: ortho and 6XP'
- NPC: at 20cm backs away head, unable to look
- Horiz Bar Verg: BO 16/12, BI 10/6
- Pursuits/saccades: difficulty in upper gazes – "everything looks tilted", dizzy, difficulty fixating
- W4D: fusion all distances
- Stereo: 500sec (shapes), 80sec (wirt circles)
- NRA/PRA: +1.00/-1.00 (around +1.50ADD)

VISUOSPATIAL/AMBIENT VISION TESTING

- EL: shifted over left eye and down below nose – improved to near normal w/ prism
- Posture/gait – very careful walking forward and backward, holding wall and very unsteady on tandem walk – much improved, no holding wall w/ BI prism and felt comfortable/"grounded" w/ BU yoked prism
- Best lens combination – last retinoscopy w/ 0.5BI/2BU each eye

TINTS

- Best comfort with #1 (15%) FL41 tint – decided on this one for distance glasses
  - Amber/Rose combo



A&P

- Glaucoma secondary to eye trauma, right eye
  - Ended up with Combigan bid OD
- Traumatic cataract, right eye
  - Monitor, patient very anxious anytime surgery mentioned
- Macular drusen, bilateral (early AMD?)
  - Discussed healthy lifestyle, no smoking, daily multivitamin, UV protection; monitor
- Dry eye syndrome, bilateral (+MGD)
  - Begin warm compresses bid OU, ATs tid OU, Omega 3 supplements daily

A&P (CONTINUED)

- Post Trauma Vision Syndrome
  - Convergence Insufficiency
  - Poor saccades/pursuits
  - Headaches
  - Dizziness/visual motion sensitivity
  - Photophobia
  - Abnormal egocentric localization (visual midline shift)
  - Continue vision exercises w/ OT, consider in-office VT in the future, glasses w/ BI/BU prism and tint per findings

A&P (CONTINUED)

- Hyperopia, right eye
- Myopia, left eye
- Regular Astigmatism, bilateral
- Presbyopia
  - Separate distance and near (computer) glasses

FEW MONTHS LATER… REMEMBER THOSE VISUAL FIELDS?

OS



OD



NOW MUCH IMPROVED

OS



OD



TAKE AWAY POINTS

- Poor visual function affects other areas and overall rehabilitative success.
  - Vision is dominant sense for sighted people. Visual information makes up at least 70% of total sensory information and at least half the brain deals with it.
- If you can't help them – refer!

REFERENCES/RESOURCES

- Vision Rehabilitation – Multidisciplinary Care of the Patient Following Brain Injury edited by P. Suter and L. Harvey
- Neuro-optometric Rehabilitation Association - www.nora.cc
- AOA guidelines - Brain Injury Electronic Resource Manual (BIERM)
- Vision Related Literature on Acquired Brain Injury - List of 117 articles http://www.covd.org/?page=ABI

QUESTIONS?

- Email: **drt5815@gmail.com**

Bilateral consecutive non-arteritic anterior ischemic optic neuropathy in a patient with bradycardia, hypotension and small vessel disease

Krista Letzring, OD
Optometric Resident
Lebanon VA Medical Center

Bilateral Consecutive NAION

- No financial interests associated with this presentation

Learning Objectives

- By the end of the presentation attendees will be able to:
- *Identify* patients at risk for NAION and understand the potential for bilateral disease
- *Recognize* co-morbidities, medication effects and when to refer for further work-up
- *Recognize* the importance of co-management with primary care/systemic specialties
- *Understand* the importance of ancillary testing to assist in diagnosis

Review of NAION

- Most common acute optic neuropathy
- Typical age is usually 60-70
- Affects about 2-10 patients per 100,000
- Caucasians are more at risk: 95% of cases: smaller cup to disc ratios
- Ischemic damage to the anterior portion of the ONH
  - Supplied by short posterior ciliary arteries
  - Proposed theory: insufficient optic disc circulation, which is worsened by structural crowding and causes inadequate oxygen and produces ischemia and disc edema

Review of NAION

- Sudden, painless vision loss
- Acuity: wide variety
- Diffuse or sectoral disc edema
- Peri-papillary splinter hemorrhages
- Altitudinal VF defect

Review of NAION

- Natural History
  - Sudden vision loss that may progress over 2 weeks
  - Disc edema resolved and reveals ONH pallor by 6 weeks
  - Condition is generally stable at 6 months
- Important information to note
  - Almost 50% of NAION eyes present with 20/15 to 20/30 acuity
    - if papillomacular nerve fibers are spared, acuity remains normal
    - Can lead to mis-diagnosis
  - Unfortunately: more than 50% of patients will have vision worse than 20/200 with constricted visual fields
    - Low vision referral

Review of NAION

- Recurrence
  - Occurs in about 5%
  - Rare after 2 months after initial event
    - Consider other diagnosis
- Bilateral condition
  - ~15% within 5 years
  - From IONDT

Case Presentation

- Demographics:
  - 60 year old white male
- Ocular History
  - Cataract surgery OU 5+ years ago
  - Mild NPDR
- Social History
  - Former smoker

Case Presentation

- Medical History
  - DM II
  - CAD
  - Hypercholesterolemia
  - HTN
  - Ischemic cardiomyopathy
    - MI in 2000
    - Pacemaker 2003
    - MI 11-2014: on respirator for 1 month

Case Presentation

- Medications

Aspirin: 325mg QD	Clopidogrel: 75mg QD
Digoxin: 0.25mg QD	Ferrous Sulfate: 325mg QD
Folic Acid: 1mg QD	Furosemide: 40mg BID
Insulin Aspart protamine: 20 units TID	Insulin Glargine: 30 units BID
Lisinopril: 2.5mg QAM	Metformin: 1000 mg BID
Metoprolol Succinate: 100mgBID	Nitroglycerin: 0.4mg as needed
Simvastatin: 40mg QHS	Spironolactone: 25mg QD
Warfarin: 5mg QHS	Zolpidem: 10mg QHS

Case Presentation
Initial Visit: April 9, 2015

- Chief Complaint
  - "Lower part of vision is dark" OS x 6 wks
  - No report of pain, scalp tenderness, malaise, or jaw claudication.
  - Patient is still recovering from cardiac arrest in November 2014 (spent 1 month in hospital).

Case Presentation
Initial Visit: April 9, 2015

- Entrance Testing
  - BVA:
    - OD: 20/25
    - OS: 20/60 PHNI
  - EOMs: full, no restrictions OD, OS
  - CVF: full OD, difficult inferiorly OS
  - Pupils: PERRL (+) RAPD OS
  - Amsler: no metamorphopsia or scotoma OD, scotoma lower 2/3 OS

Case Presentation
Initial Visit: April 9, 2015

- Anterior Segment: unremarkable
- Goldmann Tonometry
  - OD: 15mmHg
  - OS: 14mmHg

Case Presentation
Initial Visit: April 9, 2015

- Posterior Segment
  - ONH: distinct margins OD; diffuse disc edema superiorly with heme inferior to disc OS
  - CD: 0.25/0.25 round OD; diffuse edema and no visible cup OS
  - AV ratio: ½ OD, venous caliber abnormalities
  - Posterior Pole: scattered dot/blot hemes OU, Venous caliber abnormalities OU
  - Periphery: mid-peripheral dot/blot hemes, (-) holes/tears
  - Vitreous: floaters

Case Presentation
Initial Visit: April 9, 2015

- Posterior Segment




Case Presentation
Initial Visit: April 9, 2015



Humphrey Visual Field 24-2

- Significant inferior altitudinal defect OS and mild inferior defects OD



OCT: Optic Nerve Head Analysis

- Significant elevation of optic nerve head OS



Blood Pressure Analysis



Pulse Analysis



Initial Visit: April 9, 2015

- Differentials
  - Optic neuritis
  - AAION
  - NAION
- Working Diagnosis
  - NAION OS
- Plan
  - Alerted PCP about systemic risk factors
  - Patient to discuss blood pressure with cardiologist at appointment coming up
- Return to clinic: 4 weeks

Vascular Risk Factors

- Diabetes mellitus: 2.7x more likely
- Hypertension
- Anemia
- High cholesterol: younger patients
- Coronary ischemia
- History of ischemic stroke
- Smoking: not an independent risk factor

Bradycardia

- Note:
  - Normal pulse ranges from 60-100bpm

Hypotension

- Hypotension generally considered as systolic <90 and diastolic <60
- Nocturnal hypotension
  - Blood pressure is on average about 10-20% lower during the night
  - Patients with hypertension can have more than 20% decrease at night

Anti-hypertensive Medications

- Multiple arterial hypotensive drugs are often prescribed and can cause arterial hypotension (specifically nocturnal hypotension)
  - Beta blockers, diuretics, ACE inhibitors
- Alpha blockers for benign prostate hyperplasia medications especially when taken at night
  - Causes blood vessels to relax which decreases blood pressure
- Time of day that patients take these medications should be considered
  - This patient was on many medications to reduce blood pressure
    - lisinopril, furosemide, metoprolol, spironolactone

Follow-up Visit: June 15, 2015

- BVA:
  - OD: 20/20
  - OS: 20/40
- Pupils: (+) RAPD OS
- Visual Field: stable
- Posterior Pole
  - Optic nerve head pallor OS
- Plan
  - Return in 3 months

Follow-up Visit: July 22, 2015

- Chief Complaint
  - Progressive decrease in vision OD x 2 weeks
  - Left eye is improving,
  - Vision is equally bad between the two eyes.
  - Patient reports photophobia

Follow-up Visit: July 22, 2015

- Pertinent Changes
  - Cardiology appointment 3 weeks prior
  - Decreased water pill to 1x per day (furosemide)
  - Reports stable blood pressure readings at home
    - BP: 110/70
    - Pulse: 60 bpm

Follow-up Visit: July 22, 2015

- Entrance Testing
  - Visual Acuity: cc
    - OD: 20/60 PHNI
    - OS: 20/50+1 PHNI
  - EOMs: full, no restrictions OD, OS
  - CVF: FTFC OU
  - PUPILS: PERRL (-)RAPD; 3 dim/2 bright OU

Follow-up Visit: July 22, 2015

- Anterior Segment: unremarkable
- Goldmann Tonometry
  - OD: 15mmHg
  - OS: 15mmHg

Follow-up Visit: July 22, 2015

- Posterior Segment
  - ONH: OD disc edema 360 OD with hemes; OS pallor
  - C/D: OD no visible cup; OS .3/.3 round OS
  - Vessels: dilated veins with flame heme superior/nasal off disc OD
  - Posterior Pole: scattered dot hemes inferior>superior OU; OD>OS; (-)irma/cws/nve OU; exudates temporal to macula OD
  - Periphery: flat and intact 360 ou (-)holes/tears/RD
  - Vitreous: floaters OU

Follow-up Visit: July 22, 2015

- Optic Nerve Head Photos




Follow-up Visit: July 22, 2015

- Optic Nerve Head Photos



Humphrey 24-2 Visual Field

- Dense I/N defect OD; stable inf. defect OS



OCT: ONH and RNFL Analysis

- Significant optic nerve head edema OD



Bilateral Involvement

- Consider other potential causes

Follow-up Visit: July 22, 2015

- Differential Diagnoses
  - Bilateral NAION
  - Giant Cell Arteritis
  - Compressive Lesion
- Plan: due to bilaterality of the condition, need to rule out the differentials
  - Further testing ordered
    - Carotid Doppler
    - CT
    - Lab work: ESR, CRP and CBC

Further Testing and Analysis

- Lab Studies
  - ESR
    - 10mm/hr
    - normal reference range: 0-20mm/hr
  - CRP
    - 0.366mg/dL
    - normal reference range: 0.00-0.747mg/dL

Further Testing and Analysis

- Radiology Studies
  - Carotid Duplex
    - No evidence of flow-limiting stenosis
  - CT scan
    - Patient unable to do MRI due to pacemaker
    - Mild atrophy and small vessel changes without acute intracranial abnormality

Further Testing and Analysis

- Blood Pressure and Pulse Analysis
  - Sub-optimal levels
    - Blood pressure as low as 100/50
    - Pulse as low as 59 bpm

Blood Pressure Analysis



Pulse Analysis



Differential Diagnosis

- Compressive optic neuropathy
  - Gradual, progressive onset
  - Evaluate with CT or MRI
- AAION secondary to GCA
  - Pallid disc edema
  - Pain, constitutional symptoms
  - Evaluate with blood work (ESR, CRP)
- Carotid Occlusive Disease
  - More likely present with CRAO/BRAO or GCA
  - Evaluate with Carotid Doppler
- Bilateral consecutive NAION
  - Most consistent with symptoms

Working Diagnosis

- Bilateral consecutive NAION secondary to bradycardia, hypotension and small vessel disease

Bilateral Consecutive NAION

- Bilateral presentation occurs in ~15% by 5 years
- Fellow eye is exposed to same risk factors
- Risk of second eye seems to be more likely with younger patients with 35% having second eye involvement within 7 months (IONDT)
- Fellow eye involvement related to poor baseline acuity in the first eye and diabetes
- If second eye presents with worse acuity, first eye may show improvement

Treatment and Management

- No definitive treatment

Previous Attempted Treatments for NAION

- Optic nerve decompression
  - Ischemic Optic Neuropathy Decompression Trial (IONDT)
    - Study showed that optic nerve decompression was ineffective and potentially harmful
- Systemic corticosteroids
  - Studies show improvement, however, trials were non-randomized and did not use diabetics
  - Remains a controversial topic

Previous Attempted Treatments for NAION

- Aspirin therapy
  - No overwhelming evidence; only looked at aspirin use retrospectively with no standard dose and not on acute presentation
- Anticoagulation
  - No evidence for or against
- Thrombolytics
  - Single case report showed acuity recovery with urokinase and stellate ganglion block

Previous Attempted Treatments for NAION

- Intravitreal triamcinolone
  - Faster improvement of disc edema; better visual acuity recovery; no improvement of visual field defects
- Anti-VEGF
  - To reduce vasogenic edema; single case report with improvement in acuity but no VF improvement
- Vasodilators
  - May cause systemic hypotension

Previous Attempted Treatments for NAION

- Levodopa
  - Enhance neuronal plasticity
  - Weak study with many flaws
- Brimonidine
  - No significant advantage

Previous Attempted Treatment: Take Home Point

- Any intervention after an NAION is not proven to be effective
- It's all about prevention and managing risk factors
- Involve entire healthcare team as appropriate

Consultation and Management

- Reviewed case with Neuro-ophthalmologist who suggested patient undergo sleep study
  - Underwent polysomnography
    - Diagnosed with Obstructive Sleep Apnea Syndrome: prescribed CPAP
- Modify the risk factors
  - Control systemic conditions
  - Important in order to consider same eye recurrence
    - Recurrence is usually only present in about 5 % of cases
- Plan
  - Return in 1 month

Obstructive Sleep Apnea Syndrome

- Sleep Apnea
  - Repeated episodes of complete or incomplete pharyngeal collapse
  - Affects 5% of general population and 18% older than 50 years
  - Causes adaptation of cardiovascular system: endothelial dysfunction, systemic inflammation, oxidative stress, coagulation abnormalities, sympathetic hyperactivity and metabolic dysfunction

Obstructive Sleep Apnea Syndrome

- Polysomnography Testing
  - Criterion standard for documenting abnormal events that occur during sleep
- Continuous positive airway pressure (CPAP)
  - Standard treatment for OSAS
  - Pressurized air at 5-15cm of water into the upper airways

Obstructive Sleep Apnea Syndrome

- Apnea Hypopnea Index (classifications) by American Academy of Sleep Medicine
  - Mild OSA: AHI of 5-15 Involuntary sleepiness during activities that require little attention, such as watching TV or reading
  - Moderate OSA: AHI of 15-30 Involuntary sleepiness during activities that require some attention, such as meetings or presentations
  - Severe OSA: AHI of more than 30 Involuntary sleepiness

Obstructive Sleep Apnea Syndrome

- Sleep Apnea and NAION
  - High association of sleep apnea with NAION
  - One study showed a 75% and another showed 71% prevalence of OSAS in patients with NAION (depending on AHI)
  - Patients non-adherent to CPAP with severe OSAS has increased risk of NAION in the second eye by 5.54x
- Sleep apnea and the eye
  - Floppy Eyelid
  - Glaucoma
  - Dry eyes secondary to CPAP usage
  - Keratoconus

Take Home Point

- Sleep apnea increases risk of all vascular risk factors!
- Referral for polysomnography in patients with NAION: will not only reduce the risk of second eye involvement, but also improve quality of life and potentially increase life expectancy

Follow-Up Visit: August 31, 2015

- Chief Complaint: patient notices it is difficult to see down below but it doesn't bother him much anymore

Follow-Up Visit: August 31, 2015

- Entrance Testing
  - BVA:
    - OD: 20/20
    - OS: 20/25
  - EOMs: full, no restrictions OD, OS
  - CVF: FTFC OU
  - PUPILS: PERRL (-)RAPD; 3 dim/2 bright OU

Follow-Up Visit: August 31, 2015

- Anterior Segment: unremarkable
- Goldmann Tonometry
  - OD: 14mmHg
  - OS: 12mmHg

Follow-Up Visit: August 31, 2015

- Posterior Segment
  - ONH: distinct margins OU, pallor OU; CD: 0.2 round OD, 0.3 round OS
  - AV ratio: ½ OU, Venous caliber abnormalities
  - Posterior Pole: scattered microaneurysms OU
  - Periphery: mid-peripheral dot/blot hemes, (-) holes/tears
  - Vitreous: floaters

Optic Nerve Head Photos



Humphrey Visual Field 24-2

- Dense inferior defects OU: stable



OCT: ONH and RNFL Analysis

- Thick rim but RNFL thinning OU



Follow-Up Visit: Aug 31, 2015

- Plan
  - Return to clinic in 6 months
  - Continue to maximally manage systemic conditions with healthcare team

Follow-up visit: 1 year after initial onset

- Chief Complaint
  - Patient notes glare sensitivity, especially in stores

Follow-up visit: 1 year after initial onset

- Pertinent changes
  - Patient spent 2-3 weeks in hospital ~1 month ago
  - Liver and kidney issues
  - Now has port to drain gall bladder
  - No longer taking digoxin
  - Patient is compliant with CPAP usage

Follow-up visit: 1 year after initial onset

- Entrance Testing
  - Visual Acuity: cc
    - OD: 20/25
    - OS: 20/25
  - EOMs: full, no restrictions OD, OS
  - CVF: FTFC OU
  - Pupils: PERRL (-) RAPD OS

Follow-up visit: 1 year after initial onset

- Anterior Segment: unremarkable
- Goldmann Tonometry
  - OD: 13mmHg
  - OS: 14mmHg

Follow-up visit: 1 year after initial onset

- Posterior Segment
  - Dilated with 1% Tropicamide
  - ONH: pallor OU
  - CD: 0.4 round OU
  - Vessels: venous caliber abnormalities
  - Posterior Pole: scattered dot/blot hemes OU
  - Periphery: peripheral dot/blot hemes, (-) holes/tears
  - Vitreous: floaters

Fundus Photography




Fundus Autofluorescence




B-Scan

- Did not reveal any buried drusen

Visual Field 24-2



OCT: ONH and RNFL

- Superior/inferior RNFL thinning OU
- 360 ganglion cell thinning



Assessment and Plan

- Persisting visual field defects secondary to history of bilateral consecutive NAION
- Mild NPDR
- Photophobia
  - Refer for tint evaluation with VISOR

Anatomical Predisposition

- Crowded optic nerve fibers: Disc at risk
  - Small disc <1.2mm
  - Small cup <0.2
- Disc drusen:
  - Found in ~2% of the population
  - Often bilateral: ~75% of cases
  - can use ancillary testing

Anatomical Predisposition

- Evaluation of optic disc drusen
  - B-scan
  - OCT
  - Autofluorescent photos

Optic Disc Drusen: B-scan



http://emedicine.medscape.com/article/1228865-overview

Optic Disc Drusen: OCT



Johnson LN, Diehl ML, Hamm CW, Sommerville DN, Petroski GF. Differentiating Optic Disc Edema From Optic Nerve Head Drusen on Optical Coherence Tomography.*Arch Ophthalmol.* 2009;127(1):45-49. doi:10.1001/archophthalmol.2008.524.

Optic Disc Drusen: Autofluorescent photos



In Summary…

Risk Factors for NAION

- Vascular Conditions
  - DM, HTN, hyperlipidemia, heart disease
- Obstructive Sleep Apnea
  - Highly associated with NAION
- Arterial hypotension (specifically nocturnal)
  - Generally medication induced
  - Causes hypo-perfusion or non-perfusion to the ONH
- Medication induced
  - Phosphodiesterase 5 inhibitors (sildenafil, vardenafil), amiodarone, Imitrex
- Anatomical
  - Disc drusen, disc at risk

Take Home Point

- Excellent teaching case
- Evolved over period of time
- Frustrating: can't improve vision loss, but can refer for low vision evaluation
- Where you can help is facilitation in risk factor modification (our role)
- Timing of medications is an important factor
- Sleep apnea is a big deal (respiratory arrest every night)

Conclusion: NAION

- Consider possibility of bilateral involvement
- Evaluate all risk factors and modify when possible
- Remember sleep apnea association

Conclusions

- It is very common to be concerned for fellow-eye involvement with AAION, however, considering bilateral potential and controlling risk factors in NAION can reduce risk of second eye involvement, as well as improve quality of life
- Must consider the bilateral potential for non-arteritic anterior ischemic optic neuropathy
- The cause of NAION is likely multifactorial and clinicians should consider all the risk factors
- Patients with NAION should be worked up for obstructive sleep apnea syndrome
- Consider work-up for patients who have not had NAION, but who have risk factors for the condition, as well as symptoms of sleep apnea as it may be life-saving to the patient

Special Thanks

- Daniel Petley, OD
- Kevin Wolford, OD
- Erin Heinly, OD
- William Cantore, MD

References

- Albert, D. M., & Jakobiec, F. A. (2008). *Principles and practice of ophthalmology*(3rd ed., Vol. 3). Philadelphia: W.B. Saunders.
- Aptel, F., MD, PhD, Khayi, H., MD, Pepin, J., MD, PhD, Tamisier, R., MD, PhD, Levy, P., MD,, PhD, Romanet, J., MD, & Chiquet, C., MD, PhD. (2015). Association of Nonarteritic Ischemic Optic Neuropathy With Obstructive Sleep Apnea Syndrome: Consequences for Obstructive Sleep Apnea Screening and Treatment. *JAMA Ophthalmology, 133*(7), 797-804. doi:10.1001/jamaophthalmol.2015.0893
- Atkins, E. J., MD, Bruce, B. B., MD, Newman, N. J., MD, & Biousse, V., MD. (2010). Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy. *Survey of Ophthalmology, 55*(1), 47-63.
- Behbehani, R., MD, FRCSC, Mathews, M. K., MD, Sergott, R. C., MD, & Savino, P. J., MD. (2005). Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Sleep Apnea While Being Treated With Continuous Positive Airway Pressure.*American Journal of Ophthalmology, 139*(3), 518-520. doi:10.1016/j.ajo.2004.11.004
- Bilgin, G., MD, FEBO, Koban, Y., MD, & Arnold, A. C., MD. (2013). Nonarteritic Anterior Ischemic Optic Neuropathy and Obstructive Sleep Apnea. *Journal of Neuro-Ophthalmology, 33*, 323-234.
- Cantor, L. B., MD, Rapuano, C. J., MD, & Cioffi, G. A., MD. (2015). *Basic and Clinical Science Course: Neuro-Ophthalmology* (3rd ed., Vol. 5).
- Hayreh, S. S., MD, MS, PhD, FRCS, FRCOphth, & Zimmerman, B., PhD. (2005). Visual Field Abnormalities in Nonarteritic Anterior Ischemic Optic Neuropathy: Their Pattern and Prevalence at Initial Examination. *Archives of Ophthalmology, 123*(11), 1554-1562. doi:10.1001/archopht.123.11.1554
- Hayreh, S. S., MD, PhD, & Zimmerman, M. B., PhD. (2008, February). Nonarteritic Anterior Ischemic Optic Neuropathy: Natural History of Visual Outcome. *Journal of Ophthalmology, 115*(2), 298-305. doi:10.1016/j.ophtha.2007.05.027
- Hayreh, S. S., MD, PhD, & Zimmerman, M. B., PhD. (2008). Non-arteritic anterior ischemic optic neuropathy: Role of systemic corticosteroid therapy. *Graefes Archive for Clinical and Experimental Ophthalmology, 246*(7), 1029-1046. doi:10.1007/s00417-008-0805-8
- Hayreh, S. S., MD, Phd, DSc, FRCS, FRCOphth, & Zimmerman, M. B., PhD. (2013). Bilateral Nonarteritic Anterior Ischemic Optic Neuropathy: Comparison of Visual Outcome in the Two Eyes. *Journal of Neuro-Ophthalmology, 33*, 338-343.
- Hayreh, S. S., MD, PhD, DSc, Podhajsky, P. A., BSN, & Zimmerman, B., PhD. (2001). Ipsilateral Recurrence of Nonarteritic Anterior Ischemic Optic Neuropathy.*American Journal of Ophthalmology, 132*(5), 734-741.
- Kerr, N. M., Chew, S. S., & Danesh-Meyer, H. V. (2009). Non-arteritic anterior ischaemic optic neuropathy: A review and update. *Journal of Clinical Neuroscience, 16*, 994-1000. doi:10.1016/j.jocn.2009.04.002
- Purvin, V., MD, King, R., MD, Kawasaki, A., MD, & Yee, R., MD. (2004). Anterior Ischemic Optic Neuropathy in Eyes With Optic Disc Drusen. *Archives of Ophthalmology, 122*, 48-53.

WTF: WHY THAT FIELD?

A SYSTEMATIC APPROACH TO UNUSUAL VISUAL FIELDS

Karen Ma, O.D.
Roseburg VA Medical Center
June 10, 2016

Objectives

Who… What… Where… When… Why…

By the end of this presentation, attendees will be able to…

- Review the normal visual pathway anatomy
- Localize the origin site of visual field defects
- Identify causes of damage to the visual pathway

Visual Pathway Anatomy

Retinal fiber layer

- Papillomacular bundle: contain ~65% of retinal nerve fibers
- Superior and inferior arcuate
  - Respect horizontal raphe
- Superior and inferior radiating bundle



Visual Pathway Anatomy

Optic nerve

- Fibers from peripheral retina enter peripherally
- Fibers from peripapillary and arcuates area enter central part of nerve

Visual Pathway Anatomy

Chiasm and optic tract



Visual Pathway Anatomy

Chiasm



Visual Pathway Anatomy

Lateral geniculate body (LGB)

- Retinal ganglion cells terminate at the LGB and synapse on cells that project to the cortex as optic radiations
- Consists of 6 lamina layers
  - Crossed fibers terminate in 1, 4, and 6
  - Uncrossed fibers terminate in 2, 3, and 5



Visual Pathway Anatomy

Optic radiations



Visual Pathway Anatomy

Visual cortex (occipital lobe, striate cortex)

- Highly organized and devoted to macular function



Visual Pathway Damage

Who

- Ocular and retinal disease
- Vascular disease



Visual Pathway Damage

What

- Hemianopsia: affects half of visual field
- Quadrantopsia: affects quarter of visual field
- Homonymous: affects same side
- Complete: affects entire section
- Incomplete: parts of visual field are spared
  - Congruous: appears symmetrical
  - Incongruous: appears asymmetrical

- Homonymous hemianopsias will always indicate a problem on the contralateral side

Localizing Visual Field Defects



Localizing Visual Field Defects

Monocular

- Retina
  - Vascular: arcuate scotomas with its apex pointing to the blind spot
  - VF defects correspond to shape and location of retinal lesion



Localizing Visual Field Defects

Monocular

- Optic nerve
  - Glaucoma: arcuate scotoma, nasal steps
  - Vascular: unilateral central scotomas, altitudinal hemianopsia



Localizing Visual Field Defects

Chiasm

- Classical bitemporal hemianopsia that respects vertical midline





Localizing Visual Field Defects

Optic tract

- Contralateral homonymous hemianopsia
- Can be congruous or incongruous
- APD may be present



Localizing Visual Field Defects

Lateral geniculate body

- Contralateral homonymous hemianopsia
- Can be congruous or incongruous
- Damage to multiple laminae will cause asymmetric defects on the corresponding homonymous visual field



Localizing Visual Field Defects

Temporal lobe

- Incongruous contralateral superior quadrantopsias or hemianopsia starting from the vertical midline



Localizing Visual Field Defects

Parietal lobe

- Contralateral homonymous hemianopsias
- Densest part of defect in lower field



Localizing Visual Field Defects

Occipital lobe

- Congruous homonymous hemianopsias
- Steep margins, macular sparing due to the large macular representation and dual blood supply
- Macular splitting can occur but is rare



Localizing Visual Field Defects

Visual cortex

- Tip of occiptal lobe: contralateral congruous homonymous hemianopsia to paracentral scotoma



Visual Pathway Damage

Causes of visual field defects

- Compression
- Hemorrhage
- Ischemia
- Inflammation
- Trauma

Visual Pathway Damage

Compression

- Tumors
  - Adenoma: epithelial cells of glands
    - Pituitary gland
      - VF defect: bitemporal
  - Glioma: glial cells of brain or spine
    - Optic nerve
      - VF defect: general depression, central scotoma
  - Meningioma: membranes surroundings CNS
    - Usually asymptomatic

Visual Pathway Damage

Compression

- Aneurysm: bulge of blood vessel wall
  - Usually located in the circle of Willis
  - Can involve optic nerve, chiasm, and optic tract
  - VF defects:
    - unilateral scotoma
    - asymmetric bitemporal, unilateral nasal or binasal
    - incongruous homonymous hemianopsia



Visual Pathway Damage

Hemorrhagic Compression

- Subdural hematoma
  - Hemorrhagic blood between the dura mater and brain
  - Directly or indirectly compress anterior tract
  - VF defect: contralateral incongruous homonymous hemianopsia with sloping margins

Visual Pathway Damage

Hemorrhage

- Retinal hemorrhage
  - VF defect: unilateral visual loss and scotoma depending on size and location
- Intracerebral hemorrhage
  - Small arterioles in temporal, parietal, and occipital lobe
  - VF defect: homonymous hemianopsia that are usually sudden and dense
  - Location plays major role in symmetry

Visual Pathway Damage



Visual Pathway Damage

Ischemia

- Stenosis or occlusion of carotid, vertebral, and basilar arteries
- Stroke accounts for 52-70% of hemianopsia in adults
- Location, location, location

Visual Pathway Damage

Ischemia

- Ophthalmic artery and its branches: CRAO
  - VF defect: sudden, permanent, monocular vision loss



Visual Pathway Damage

Ischemia

- Middle cerebral artery: cerebral infarct
  - VF defect: contralateral homonymous hemianopsia or quandrantopsia, may be incongruous



Visual Pathway Damage

Ischemia

- Vertebral and basilar artery: occipital lobe
  - VF defect: contralateral homonymous hemianopsia, congruous



Visual Pathway Damage

Inflammation

- Can occur at any location
- Vision loss can be sudden, total, and permanent in one eye or both
- Incomplete vision loss can range in central, paracentral, arcuate scotomas to altitudinal defect

Visual Pathway Damage

Trauma

- Usually post-chiasmal and can involve multiple sites
- Causes can widely vary: car accident, concussion, violence, fall
- VF defect: homonymous hemianopsias, general depression

WTF…… WTH?

Who, what, where, when, why…. HOW

Imaging Pathology

CT scan (computerized axial tomography)

- Uses x-rays in cross section
- Pros
  - Good for bony lesion
  - Fast (<5 mins)
  - Inexpensive
- Cons
  - Lower resolution
  - Radiation exposure
  - Potential for allergic reaction to iodized contrast



Imaging Pathology

MRI scan (magnetic resonance imaging)

- Uses radio waves and magnetic waves
- Pros
  - Higher resolution
  - Good for soft tissue lesions
  - No radiation exposure
  - Less likely for allergic reaction to gadolinium contrast
- Cons
  - Higher cost
  - Contraindicated in patients with metallic foreign bodies, most cochlear implants and cardiac pacemakers
  - Requires patient to lie very still for 30-60 mins



Management

Prognosis

- Activities of daily living affected
- 17-19% of stroke patients with homonymous hemianopsia have complete recovery within 1 month

Treatment options

- Prism
- Compensatory training
- Vision Restoration Therapy

Case Review

78 year old male presents for CEE
red-tipped white walking stick

- Medical history:
  - (+) HTN, hyperlipidemia, BPH, heart attack, strokes
- Ocular history:
  - (+) pseudophakia OU
- Entering VA sc: 20/20-2 OD/OS
- Entrance testing: unremarkable except constricted CVF
- Anterior seg: unremarkable
- IOP: 14/14 mmHg OU
- Posterior seg: C/D 0.4 OU, mild macular drusen OU

Case Review



Case Review



Conclusions

Vision loss is alarming but usually explainable

General patterns of visual field defects

- Monocular defects are pre-chiasmal
- Binocular defects are post-chiasmal
  - The side with the visual field defect will indicate a problem on the contralateral side

WTF: Who… What… Where… When… Why That Field

References

- Harrington, David O. Drake, Michael V. *The Visual Fields: Text and Atlas of Clinical Perimetry*. St. Louis: The C.V. Mosby Company, 1990. Print.
- Walsh, Thomas J. *Neuro-ophthalmology: Clinical Signs and Symptoms.* Philadelphia: Lea & Febiger, 1992. Print.
- Goodwin, Denise. "Homonymous Hemianopsia: Challenges and Solutions." *Clinical Ophthalmology*. 2014;8:1919-1927
- Lemke, Sonne et al. "Automated Perimetry and Visual Dysfunction in Blast-Related Traumatic Brain Injury." *American Academy of Ophthalmology*. 2016; 123:415-424.
- Draskovic, Kristie. McSoley, John J. "Automated Perimetry: Visual Field Deficits in Glaucoma and Beyond." *Review of Optometry*. Mar 2016:84-91
- Bruce, BB et al. :Traumatic homonymous hemianopia." *J Neurol Neurosurg Psychiatry.* 2006;77:986-988
- "CT Scan vs MRI." *Diffen.com.* Diffen LLC, n.d. Web. 7 May 2016.
- n.p. Peli Lens for Hemianopia. *Chadwick Optical*. Web. 31 May 2016

Microinvasive Glaucoma Surgery

Valerie Kitamori, OD
Spokane VA Medical Center, WA
kita4016@pacificu.edu

Learning Objectives

- Identify problems with traditional medical and surgical treatments for glaucoma
- Recognize the principles of Microinvasive Glaucoma Surgery
- Distinguish ideal candidates that may benefit from such procedures
- Describe current and future Microinvasive Glaucoma Surgery procedures

Problems with traditional glaucoma medical and surgical treatments

Suboptimal safety profile with high long term rate of failure

- Risk of hypotony, bleb leak, choroidal detachment, endophthalmitis
- Reoperation rate for complications at 5 years 18-22%

Long term exposure to antiglaucoma medications limit filtering procedure success rate

- Preservatives cause conjunctival inflammation and ocular surface damage
- Poor compliance with long term medication treatment

(Brandao *et al*, 2013)

(http://www.diseasepictures.com)

Anatomy Review of the Anterior Chamber



(http://www.bing.com/images/search?q=anterior+chamber+angle+anatomy&view=detailv2&&id=7619A13B689F2B01933C68746D94434E5E52E1D7&selectedIndex=4&ccid=%2bBRSSFBq&simid=608011866482674416&thid=OIP.Mf8145248506a3c289ef183095f938eb9Ho&ajaxhist=0)

Principles of Microinvasive Glaucoma Surgery

- Ab interno microincisional approach
- Minimally traumatic to the target tissue
- Extremely high safety profile
- Modest procedure efficacy
- Rapid recovery with minimal impact on patient's quality of life

(Saheb *et al*, 2012)

Ideal candidates for Microinvasive Glaucoma Surgery

- Mild to moderate glaucoma with modest targeted IOP reduction
  - Open angle glaucoma, pigmentary glaucoma, pseudoexfoliation glaucoma, steroid glaucoma, traumatic glaucoma, ocular hypertension
- Concomitant visually significant senile cataracts
- H/O poor compliance with medical treatments

(Brandao *et al*, 2013)

Microinvasive Glaucoma Surgery Procedures

Trabecular Meshwork	Suprachoroidal Space	Schlemm's Canal	Subconjunctival Space	Aqueous Production
iStent Trabectome ELT	Cypass Gold Microshunt	Hydrus Ab Externo Canaloplasty SCE GATT	Aquesys	ECP

Trabecular Microbypass Stent (iStent, Glaukos)

FDA approval: 2012

Device characteristics/Mechanism

- Heparin-coated nonferromagnetic titanium L-shaped device that bypasses the trabecular meshwork and inner wall of Schlemm's canal (enhances conventional outflow facility)
- Currently approved for the application of 1 iStent device in the US

Common complications

- Mild hyphema, transient IOP spike, corneal edema, stent obstruction/malposition

(Saheb *et al*, 2012)



(Brandao *et al*, 2013)

Trabecular Microbypass Stent (iStent, Glaukos)

Phacoemulsification vs. iStent w/ Phacoemulsification (Craven *et al*, 2015)

- **Phacoemulsification**
  - 61% IOP <21mmHg, 54% achieved +20% IOP reduction
  - ~0.5 mean medication use
- **iStent w/ Phacoemulsification**
  - 71% IOP <21mmHg, 61% achieved +20% IOP reduction
  - ~0.3 mean medication use

Effect of multiple iStent devices (Hays *et al*, 2014)

- Only 1-2 correctly placed stents needed to achieve the best IOP reduction
- 3-4 iStents not much more effective than 2 iStents (limitations from canal, collector system and episcleral venous pressure on aqueous outflow)

Next Generation iStent Devices

FDA approval: pending

Second generation iStent: iStent Inject (Glaukos)

- Heparin-coated titanium conical shaped iStent device facilitates multiple stent implantations (new design improves ease of device placement)
- Clinical studies underway



(Hunter *et al*, 2014)

Third generation iStent: iStent Supra (Glaukos)

- Heparin-coated polyethersulfone microstent implanted into the suprachoroidal space (enhances uveoscleral outflow facility)
- Clinical studies underway

(Saheb *et al*, 2012)

Ab Interno Trabeculotomy (Trabectome, NeoMedix)

Device characteristics/Mechanism

- Selective ablation and removal of a segment of trabecular meshwork tissue using high frequency electrocautery (enhances conventional outflow facility)
- Applied to 60-120 degrees of tissue in nasal angle, minimizes thermal injury to underlying structures and avoids cleft closure

Phaco/Trabectome vs Phaco/Trabeculectomy results after 1 year (Francis *et al* 2011)

- Phaco/Trabectome: IOP decrease from ~22.1 to ~15.4mmHg
- Phaco/Trabeculectomy: IOP decrease from ~23.0 to ~11.0mmHg
- No significant difference between success rates
- Greater postoperative surgical complications for trabeculectomy/phacoemulsification

Common complications

- Transient IOP elevation, hyphema, goniosynechiae

(Brandao *et al*, 2013)

FDA approval: 2004



(Brandao *et al*, 2013)

Ab Interno Excimer Laser Trabeculotomy (ELT, Glautec)

Device characteristics/Mechanism

- Multiple full-thickness microperforations created in the trabecular meshwork with a xenon chloride (XeCl) pulsed excimer laser (enhances conventional outflow facility)
- Similar to Selective Laser Trabeculoplasty (SLT), no thermal damage to underlying tissue

Effect of ELT with phacoemulsification (Toteberg-Harms *et al*, 2011)

- IOP reduction ~25.33 to ~16.54mmHg
- Glaucoma medication reduction ~2.25 to ~1.46

SLT vs ELT (Babighian *et al*, 2010)

- No statistically significant difference

Common complications

- Hyphema, transient IOP increase, fibrin reaction

(Babighian *et al*, 2016)

FDA approval: pending
Performed in Europe since 1998



(Saheb *et al*, 2012)

Suprachoroidal Microstent (Cypass, Transcend Medical)

Device characteristics/Mechanism

- Fenestrated biocompatible polyimide tube implanted into the supraciliary space creating a small cyclodialysis cleft (enhances uveoscleral outflow facility)

Efficacy of Cypass Microstent after 1 year (Hoen *et al*, 2016)

- High uncontrolled IOP- achieved 35% IOP reduction
  - Med reduction ~2.1 to ~1.1
- Controlled IOP w/ meds- achieved 65% free of meds

COMPASS Clinical Trial- in process

Common complications

- Transient hypotony, IOP fluctuation, postoperative hyphema, corneal edema, corneal endothelial contact, device obstruction

(Hoeh *et al*, 2015)

FDA approval: pending
CE mark ~2008 (European Union)

(Transcend Medical Inc)

Schlemm's Canal Scaffold (Hydrus Microstent, Ivantis)

Device characteristics/Mechanism

- Elastic biocompatible nickel-titanium alloy intracanalicular scaffold that dilates one quadrant of Schlemm's canal (enhances conventional outflow facility)

Efficacy of Hydrus vs iStent (Hays *et al*, 2014)

- Hydrus had a greater outflow facility increase (73%) compared to 2 iStent (34%)

Hydrus IV clinical trial- in progress

Common complications

- Subconjunctival hemorrhage, hyphema, peripheral anterior synechiae

(Mansouri *et al*, 2015)

FDA Approval: pending



(Brandao *et al*, 2013)

Ab Externo Canaloplasty

Mechanism

- Circumferential viscodilation of Schlemm's canal from an external incision, enhancing conventional outflow facility
- Technically challenging procedure, cause conjunctival scarring that limits effectivity of subsequent glaucoma surgery

Effect of canaloplasty vs phaco/canaloplasty after 3 years (Khaimi *et al*, 2015)

- Canaloplasty: 34% mean decrease in IOP
  - 53% mean reduction in postoperative meds
- Phaco/canaloplasty: 42% mean decrease in IOP
  - 80% mean reduction in postoperative meds

Common complications

- Transient microhyphema, iris prolapse, IOP spike, cataract, hypotony, peripheral anterior synechiae, Descemet's membrane detachment, suture cheese-wiring through inner wall of the canal

(Khaimi *et al*, 2015)

FDA approval: yes



(http://new-glaucoma-treatments.com/canaloplasty/introducing-ab-interno-canaloplasty/)

Advancements w/ Canaloplasty

Ab Interno Canaloplasty (ABiC)

- Circumferential viscodilation of Schlemm's canal through central corneal incision, evolved directly from ab externo approach
- Conjunctiva sparing procedure with no tensioning suture required to maintain the IOP reduction

Stegmann Canal Expander (SCE, Ophthalmos GmbH)

- Flexible polyimide stent device dilates a section of Schlemm's canal, removes complication of "cheese-wiring", able to thread the SCE into each side when it's not possible to use a tension suture
- Overcomes complications with canaloplasty
- CE mark 2013

(Khaimi *et al*, 2015)



(http://new-glaucoma-treatments.com/canaloplasty/introducing-ab-interno-canaloplasty/)



(Brandao *et al*, 2013)

Subconjunctival Implant (Xen Gel Stent, Aquesys)

Device Characteristics/Mechanism

- Collagen-derived gelatin stent that creates a bleb filtering process into the subconjunctival space through an internal approach

Allergan acquired Aquesys company in Sep 2015

- US Investigational Device Exemption (IDE) clinical trial In late-stage development expected by late 2016/early 2017

Common Complications

- Bleb-related problems are not solved with this procedure

(Ahmed *et al*, 2014/Nguyen *et al*, 2013)

FDA Approval: pending
CE mark 2011 (European Union)



(Nguyen *et al*, 2013)

Gonioscopy-assisted transluminal trabeculotomy (GATT)

Device characteristics/Mechanism

- Blunted suture or iTrack microcatheter cleaves the trabecular meshwork circumferentially, enhancing conventional outflow facility

Advantages

- Successful outcomes in juvenile and adult glaucoma
- Leaves other options available for future filtration surgery

Effect in PCG and JOAG (Grover *et al*, 2014)

- 12.5mmHg mean decrease in IOP
- 1.8 decrease in meds

Common complications

- Transient hyphema

(Barrett *et al*, 2015)

FDA approval: yes



Less Microinvasive Glaucoma Procedures

- **Gold Microshunt (SOLX) –**
  - Biocompatible 24-carat gold drainage device implanted in the suprachoroidal space through an external approach (enhances uveoscleral outflow facility)
  - Avoids severe postoperative hypotony and bleb-associated complications (Melamed *et al*, 2009)
- **Endoscopic Cyclophotocoagulation (ECP)**
  - Reduces aqueous production through targeted destruction of the ciliary processes with a diode laser and endoscope
  - Previously used for advanced end stage glaucoma with minimal visual potential and previously failed surgical treatments (Clement *et al*, 2013)



(review of ophthalmology allaboutvision.com)



(Francis *et al*, 2014)

Future Directions

- Universal protocols for surgical procedures and operative technique
- Determine optimal extent of Schlemm's canal surgery
  - Limit for number of inserted devices
  - Advantageous combinations of surgical/implantation procedures
- Comparison of effectivity of new procedures/devices
- Long term effectivity of new procedures/devices
- Optometrist's role

Conclusion

- Microinvasive glaucoma surgery procedures provide new alternative treatment options for mild to moderate glaucoma
  - Reduce intraocular pressure as effectively as established procedures while avoiding serious postoperative complications
- Numerous medical devices and surgical procedures available
  - More currently in development
- Further studies needed to establish universal protocols for procedures and optimal device/surgical procedures with long term effectivity

References

- Ahmed IK, Jampel HD, Saheb H. Clinical outcomes for a Schlemm's canal scaffold for IOP reduction after cataract surgery in mild to moderate open angle glaucoma submitted to AGS 2012, New York City.
- Arriola-Villalobos P, Morales-Fernandez L, Martinez-de-la-Casa JM, and J Garcia-Feijoo. Effects of Glaukos Trabecular Stent in the Treatment of Glaucoma. European Ophthalmic Review. 2013: 10-13.
- Babighian S, Rapizzi E, and A Galan. Efficacy and Safety of ab interno Excimer Laser Trabeculotomy in Primary Open-Angle Glaucoma: Two Years of Follow-up. Ophthalmologica. 2006;220:285-290.
- Babighian S, Caretti L, Tavolato M, Cian R, Galan A. Excimer laser trabeculotomy vs selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye, vol 24, no 4, pp 632-638, 2010.
- Bacharach J. One-year results of randomized controlled trial of cataract surgery with second-generation trabecular micro-bypass stents in mild to moderate open-angle glaucoma. 2011.
- Bahler CK, Fjield T, Hann CR. Second generation trabecular meshwork bypass stent increases outflow facility in cultured human anterior segments. 2010.
- Barrett A and C Chaya. Gonioscopy-Assisted Transluminal Trabeculotomy: Blending Tradition with Innovation. Glaucoma Today. Jan/Feb 2015.
- Brandao, LM and MC Grieshaber. Update on Minimally Invasive Glaucoma Surgery (MIGS) and New Implants. Journal of Ophthalmology. Vol 2013, p1-12.
- Brusini P. Canaloplasty in Open-Angle Glaucoma Surgery: a Four-Year Follow-Up. Scientific World Journal. 2014:1-7.
- Chin S, Nitta T, Shinmei Y. Reduction of intraocular pressure using a modified 360-degree suture trabeculotomy technique in primary and secondary open-angle glaucoma: a pilot study. J Glaucoma 2012;21:401-7.
- Clement CI, Kampougeris G, Ahmed F, Cordeiro MF, Bloom PA. Combining phacoemulsification with endoscopic cyclophotocoagulation to manage cataract and glaucoma. Clinical and Experimental Ophthalmology 2013;41:546-551.
- Craven, RE. Trabecular Micro-Bypass Shunt (iStent: Basic Science, Clinical, and Future). Middle East African Journal of Ophthalmology. 2015 Jan-Mar; 22(1):30-37.
- Fea AM, Consolandi G, Pignata G, Cannizzo PML, Lavia C, Billia F, Rolle T, and FM Grignolo. A Comparison of Endothelial Cell Loss in Combined Cataract and MIGS (Hydrus) Procedure to Phacoemulsification Alone: 6-month Results. Journal of Ophthalmology. 2015:1-5.
- Figus M, Lazzeri S, Fogagnolo P, Lester M, Martinelli P, and M Nardi. Supraciliary shunt in refractory glaucoma. The British Journal of Ophthalmology. August 2011: 1-5.
- Francis BA. Trabectome combined with phacoemulsification versus phacoemulsification alone: a prospective, nonrandomized controlled surgical trial. Clinical & Surgical Ophthalmol. 2010;28(10):1-7.
- Francis BA, Berke SJ, Dustin L, Noecker R. Endoscopic cyclophotocoagulation combined with phacoemulsification versus phacoemulsification alone in medically controlled glaucoma. J Cataract Refract Surg 2014;40:1313-1321.
- Francis BA, Winarko J. Combined Trabectome and cataract surgery versus combined trabeculectomy and cataract surgery in open-angle glaucoma. Clin Surg Ophthalmol 2011; 29:4-10.
- Gayton JL, Van Der Karr M, Sanders V. Combined cataract and glaucoma surgery: trabeculectomy versus endoscopic laser cycloablation. J Cataract Refract Surg 1999;25:1214-1219.

References

- Grover DS, Smith O, Fellman RL, Godfrey DG, Butler MR, Montes de Oca I, Feuer WJ. Gonioscopy assisted transluminal trabeculotomy: an ab interno circumferential trabeculotomy for the treatment of primary congenital glaucoma and juvenile open angle glaucoma. Br J Ophthalmol 2015;0:1-5.
- Grover DS, Godfrey DG, Smith O, Feuer WJ, Montes de Oca I, Fellman RL. Gonioscopy-Assisted Transluminal Trabeculotomy, a Novel Ab Interno Trabeculotomy. American Academy of Ophthalmology 2014;1-7.
- Hays CL, Gulati V, Fan S, Samuelson TW, Ahmed IIK and CB Toris. Improvement in Outflow Facility by Two Novel Microinvasive Glaucoma Surgery Implants. Investigative Ophthalmology & Visual Science. 2014;55:1893-1900.
- Hoeh H, Vold S, Ahmed IK, Anton A, Rau M, Signh K, Chang D, Shingleton B, Ianchulev T. Initial Clinical Experience With the CyPass Micro-Stent: Safety and Surgical Outcomes of a Novel Supraciliary Microstent. J Glaucoma 2016, 25:106-112.
- Hueber A, Roters S, Jordan JF, and W Konen. Retrospective analysis of the success and safety of Gold Micro Shunt Implantation in glaucoma. BMC Ophthalmology. 2013,13:35.
- Jea SY, Mosaed S, Vold SD, Rhee DJ. Effect of a failed Trabectome on subsequent trabeculectomy. J Glaucoma 2011.
- Kahook MY, Salim S, and LK Seibold. MIGS Advances in Glaucoma Surgery. Slack Incorporated, 2014.
- Khaimi, Mahmoud A. Canaloplasty: A Minimally Invasive and Maximally Effective Glaucoma Treatment. Journal of Ophthalmology. 2015:1-5.
- Klamann MKJ, Gonnermann J, Pahlitzsch M, Maier, A-KB, Joussen AM, Torun N, and E Bertelmann. iStent inject in phakic open angle glaucoma. Graefes Arch Clin Exp Ophthalmol (2015)253:941-946.
- Lima FE, Carvalho DM, Avila MP. Phacoemulsification and endoscopic cyclophotocoagulation as primary surgical procedure for coexisting cataract and glaucoma. Arq Bras Oftalmol 2010;73:419-22.
- Lindfield D, Ritchie RW, Griffiths MFP. 'Phaco-ECP': combined endoscopic cyclophotocoagulation and cataract surgery to augment medical control of glaucoma. BMJ Open 2012;2.
- Mansouri K and T Shaarawy. Update on Schlemm's Canal Based Procedures. Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):38-44.
- Melamed S, Simon GJB, Goldenfeld M, and G Simon. Efficacy and Safety of Gold Micro Shunt Implantation to the Supraciliary Space in Patients With Glaucoma. Arch Ophthalmol, 2009;127(3):264-269.
- Minckler D, Mosaed S, Dustin L, Francis B. Trabectome (Trabeculectomy – Internal Approach): Additional Experience and Extended Follow-Up. Transactions of the American Ophthalmological Society. 2008 Dec; 106: 149-160.
- Mosaed S, Rhee DJ, Filippopoulos T, et al. Trabectome outcomes in adult open-angle glaucoma patient: one-year follow-up. Clinical & Surgical Ophthalmol. 2010;28(8):5-9.
- Saheb, H and IIK Ahmed. Micro-invasive glaucoma surgery: current perspectives and future directions. Current Opinion Ophthalmology. 2012, 23: 96-104.
- Saheb H, Ianchulev T, and IK Ahmed. Optical coherence tomography of the suprachoroid after CyPass Micro-Stent implantation for the treatment of open-angle glaucoma. Br J Ophthalmol 2014 98:19-23.
- Seuthe A-M, Januschowski K, and P Szurman. Micro-invasive 360-degree suture trabeculotomy after successful canaloplasty – one year results. Graefes Arch Clin Exp Ophthalmol. 2015.
- Toteberg-Harms M, Ciechanowski PP, Hirn C, Funk J. One-year results after combined cataract surgery and excimer laser trabeculotomy for elevated intraocular pressure. Ophthalmologe 2011;108:733-738.

Thank you!

When Good Corneas Go Bad… the Non-responsive Infectious Keratitis

Robert Cook, O.D.
Optometric Resident Jonathan M Wainwright VAMC Walla Walla, WA
&
Pacific Cataract and Laser Institute, Kennewick, WA

Objectives

- Understand how to initiate care, manage, and coordinate care for difficult non-responsive infectious keratitis/ulcer
- Understand some of the new exploration and technology in the field of infectious keratitis/ulcer management

Case 1

- 63yo male for corneal evaluation
- CC: decreased vision OS for past 2 months
  - Eyelid swelling, redness, and irritation
- VA (cc): 20/80 ph: 20/50
- Medications: Pred-Acetate TID OS only
  - Topical steroid Rx'ed for dry eye treatment



Case 1

- Diagnosis: Herpes Viral Keratitis
- Treatment: Zirgan gel 5x OS only, Vigamox TID OS
  - Discontinue Pred Acetate TID OS

Case 1



- Over next few visits dendritic ulcer resolved and cornea left with large reverse-C shaped epithelial defect
  - No apparent active ulcerative process
  - Zirgan stopped and Acyclovir started 5x daily over last few visits
    - Homatropine BID for pain management
- New Diagnosis: Neurotrophic Keratoconjunctivitis
  - Progress plateau: non-healing epithelial defect
  - Discussed and placed Prokera Amniotic membrane in office
    - Promote wound healing

Amniotic Membrane Graft

- Amniotic membrane grafts derived from inner-most layer of the placenta
  - Removed/harvest during Cesarean section[9]
  - Clinical trials indicate membrane placement promotes epithelization and differentiation of epithelial cells (Seitz B; Sippel et al)
  - Grafts will last 7-14 days depending on graft thickness



Amniotic Membrane: Intrinsic healing properties

- Two main growth factors promoting wound healing[9]
  - Epidermal growth factor
  - Keratocyte growth factor
- Structural proteins AM basement membrane
  - Laminin and type VII collagen both with high affinity for epithelial cells[9]
- Intrinsic neurotropic components
  - Schroeder et al studied effects of AM on neuronal cell cultures[10]
    - Axonal regrowth stimulated by AM tissue
  - Promote epithelial regrowth in neurotrophic conditions[9,10]

Amniotic Membrane: Intrinsic healing properties continued

- Anti-scarring
  - Decreased scarring risk by inhibition of TGF-beta and fibroblasts[9]
- Anti-inflammatory
  - Inflammatory modulators
    - Interleuken-10 and interleukin-1 receptor antagonists[9]
    - Modulates inflammation in the epithelium and stroma

Case 1 Continued

- Over next two weeks amniotic membrane place twice
  - After first placement: small diamond shaped epithelial defect remained, NaFl stained
  - Second placement yielded little improvement



Case 1

- Progress plateau; persistent diamond shaped epithelial defect
  - Discontinue Vigamox and Homatropine
  - Start Doxycycline 100mg PO QD, E-mycin ung TID OS, and lid taping OS





The Doxycycline We know and Love

Anti-inflammatory	Anti-microbial
Recurrent corneal erosions	Ocular surface disease & eyelid disease

Doxycycline: Mechanism of action

- Anti-inflammatory action via matrix metalloproteinase inhibitors (MMP)
  - All MMPs degrade at least one component of the extracellular matrix
  - MMP-9 mediates wound healing and promotes inflammation
  - Tetracyclines reduce MMP activity:
    - Binding zinc and calcium cations needed for MMP activation[11]
    - Doxycycline highly specific for endothelial and epithelial cells[11]

Doxycycline For Corneal Ulcers

- MMP-9 present at low levels in healthy cornea[11]
  - Synthesis is induced by corneal injury
  - Destroys the adhesive structure of epithelial cell basement membrane[11]
  - Delays re-epithelialization[11]
- Remaining corneal and tear film MMPs → ulcerative processes proceed in absence of microbes

Doxycycline For Corneal Ulcers

- MMP inhibitors:
  - reduce progression of stromal ulceration,
  - speed epithelial healing,
  - minimize corneal scaring[11]
- Topical antibiotic therapy combined with MMP inhibitors speeds corneal healing
- Doxycycline highly specific for endothelial and epithelial cells[11]
  - In vitro Doxycycline 96.3% regulation of MMP activity

Case 1 Conclusion

- Treatment continued over the 7 weeks
  - Vision improved from 20/200 to 20/60
  - Complete re-epithelialization leaving persistent reverse C shaped stromal scaring
  - Most recent visit visual acuity was 20/60+ with pinhole improvement to 20/20
    - Continue Doxycycline QD and ATs Q4-6h
      - E-Mycin ung and lid taping discontinued
    - Patient scheduled for continued follow up

Case 2

- 59 yo male presenting as a referral for eye pain OS for past 2 days. Reported as severe. Current topical medications not helping. Hx of SCL wear.
  - Besivance q2H (started 2 days prior),
  - Visual acuity:
    - OD 20/25
    - OS: CF 3'

Case 2



Case 2



Case 2

- Assessment: Central corneal ulcer
- Plan:
  - Culture taken
  - Besivance q1/2h
  - Fortified Tobramycin q1/2h (q2h @ night)
  - In office loading dose 5 gtts q5mins

Case 2



- Small but notable clinical improvement
  - Culture results: no microbial growth
  - Dense but improved central ulcer
  - No hypopyon present
- Start Pred Acetate BID OS only

- SCUT study[3] (Steroid for Corneal Ulcer Treatment Trial)
  - Improved visual acuity at 12 months
  - Decreased scarring[2,3]
    - Sub-group analyses: notable decreased scarring[2]
  - Decreased corneal melt, neovascularization, scarring[2]
  - Showed no increased adverse side effects[3]
    - No delay in re-epithelialization or increased risk of perforation[3]

Topical Steroid Indications

- Addition of steroids
  - 48-72 hours after presentation[2,3]
    - Notable clinical response and/or organism isolated
    - Continued antibiotic or anti-viral coverage
- Contraindicated
  - fungus, Acanthoamoeba, or Norcardia[,2,3]
  - Trauma, poor contact lens wear strongly cautioned[2]
    - Nature of trauma is reason for caution

Case 2 Continued

- Plateau in progress 2 weeks later
  - Persistent central opacification
    - Non-healing central epithelial defect
  - Discussed Prokera vs. corneal cross-linking
  - Discontinue current treatment for re-culture during procedure

Corneal Cross-linking

- Originally researched & developed for corneal ectatic disorders
  - Became gold standard for treatment in several countries
  - April 2016 FDA approval in the US





Corneal Cross-linking

- UV-A and Vitamin B_2 or Riboflavin
  - Dresden Protocol[6]
    - Epithelium removed
    - Stroma saturated with Riboflavin
    - UV-A (365nm) used to irradiate the cornea
  - Riboflavin photo reactive → free radical production within stroma[6]
    - New covalent bonds between stromal collagen and proteoglycans

Corneal Cross-linking: Bacterial Keratitis

- Ultraviolet light long known for its antimicrobial abilities
- Mechanism of Action:
  - Oxidative destruction of pathogen
  - Riboflavin disrupts pathogen replication → increased resistance to proteolytic degradation



Corneal Cross-linking: Bacterial Keratitis

- Sieler et al 2000; a pilot study
  - Treated patients with advanced non-infectious corneal melt with greater than 75% success[5,7]
- Iseli et al 2008[5]
  - CXL treatment in patients therapy resistant infectious corneal melt
  - 5 patients unresponsive to full topical therapy
    - 4/5 corneal melt halted[5]
      - Immune reaction and not an active pathogen
- Both studies showed success in late stages

Corneal Cross-linking: Bacterial Keratitis

- Does it work in early/acute onset?
  - Makdoumi et all 2011[5,8]
    - 16 patients with infectious keratitis
    - 15/16 complete epithelial closure
    - All showed improvement and reduction in inflammation
  - Meta analysis showed: (with standard antimicrobial therapy)
    - Bacterial 88% healing[13]
    - Fungal 78% healing rate[13]
    - 10/11 acanthamoeba cases healed
      - 5 required retreatment but healed

PACK-CXL

- 2013 9th international Cross-linking Congress
  - Distinguished CXL for infections
  - Photo-Activated Chromophore for Keratitis – CXL[5]
    - PACK-CXL
    - Same procedure as Dresden CXL for ectasias
  - Current research and focus on making it more available and easier to perform in office

PACK-CXL







Case 2 Conclusion

- 7 day post op: 20 days from initial presentation
  - Prokera ring in place but membrane dissolved
  - Vision improved: 20/400
  - Medications continued; Besivance TID and Pred-Acetate QD OS only
- Culture Results:
  - No isolated organisms
- Most recent visit
  - Improved signs/symptoms
  - Visual acuity 20/50+ ph 20/30
  - Continue current treatment

Management strategies

- Culture guided
- Empirical approach
  - Broad spectrum antibiotic and wait for response
- Case guided approach

Make a plan and commit!

Corneal Ulceration

"One the most serious conditions faced by eye care providers and a true ocular emergency"

~Dr. James Guzek MD

Take Home Points

- Topical steroid 48-72 hours after initiation of antimicrobial therapy
  - If notable response and/or isolated organism
- Matrix metalloproteinase inhibitors beneficial for new onset and persistent corneal keratitis/ulcers
- PACL-CXL as adjunct to topical therapy and with possibility to become more common place
- Amniotic membrane graft placement shows significant benefit for management of infectious keratitis
- Appropriate empirical therapy is a must
  - 4th generation fluoroquinolone
  - Fortified for higher risk
- Communicate with your corneal specialist

Special thanks

- Pacific Cataract and Laser Institute Kennewick
  - Dr. Bruce Flint O.D.
  - Dr. Aaron Bronner O.D.
  - Dr. James Guzek M.D.
  - Dr. Loren Seery M.D.
- Darlene Fleming MLS
  - Walla Walla VAMC Medical Library

References

1. Amescua, G., Miller, D., & Alfonso, E. C. (2011). What is causing the corneal ulcer? Management strategies for unresponsive corneal ulceration. Eye, 26(2), 228-236. doi:10.1038/eye.2011.316
2. Palioura, S., Henry, C. R., Amescua, G., & Alfonso, E. C. (2016). Role of steroid in the treatment of bacterial keratitis. Clinical Ophthalmology, 179-186. Retrieved May 10, 2016.
3. Srinivasan, M., Mascarenhas, J., Rajaraman, R., Ravindran, M., Lalitha, P., O'brien, K. S., . . . Acharya, N. R. (2014). The Steroids for Corneal Ulcers Trial (SCUT): Secondary 12-Month Clinical Outcomes of a Randomized Controlled Trial. American Journal of Ophthalmology,157(2). doi:10.1016/j.ajo.2013.09.025
4. http://www.aao.org/eyenet/article/confronting-corneal-ulcers?july-2012
5. Tabibian, D., Mazzotta, C., & Hafezi, F. (2016). PACK-CXL: Corneal cross-linking in infectious keratitis. Eye and Vis Eye and Vision, 3(1). doi:10.1186/s40662-016-0042-x
6. Wollensak, G., Spoerl, E., & Seiler, T. (2003). Stress-strain measurements of human and porcine corneas after riboflavin–ultraviolet-A-induced cross-linking. Journal of Cataract & Refractive Surgery, 29(9), 1780-1785. doi:10.1016/s0886-3350(03)00407-3
7. Wollensak, G., Spoerl, E., & Seiler, T. Riboflavin/ultraviolet-a-induced collagen cross-linking for treatment of keratoconus. Am J Ophthalmol. 2003; 135(5):620-7
8. Makdoumi, K., Mortensen, J., Sorkhabi, O., Malmvall, B., & Crafoord, S. (2011). UVA-riboflavin photochemical therapy of bacterial keratitis: A pilot study. Graefes Arch Clin Exp Ophthalmol Graefe's Archive for Clinical and Experimental Ophthalmology, 250(1), 95-102. doi:10.1007/s00417-011-1754-1
9. Meller, D., Pauline, M., Thomasen, H., Westekemper, H., & Stuhl, K. (2011). Amniotic Membrane Transplantation in the Human Eye. Etsch Arztebl Int, 108(14), 243-248. Retrieved May 10, 2016.
10. Schroeder, A., Theiss, C., Steuhl, K., Meller, K., & Meller, D. (2007). Effects of the Human Amniotic Membrane on Axonal Outgrowth of Dorsal Root Ganglia Neurons in Culture. Current Eye Research, 32(9), 731-738. doi:10.1080/02713680701530605
11. Brooks, D. E., & Ollivier, F. J. (2004). Matrix metalloproteinase inhibition in corneal ulceration. Veterinary Clinics of North America: Small Animal Practice, 34(3), 611-622. doi:10.1016/j.cvsm.2003.12.005
12. Mcdonald, E. M., Ram, F. S., Patel, D. V., & Mcghee, C. N. (2014). Topical antibiotics for the management of bacterial keratitis: An evidence-based review of high quality randomised controlled trials. British Journal of Ophthalmology, 98(11), 1470-1477. doi:10.1136/bjophthalmol-2013-304660
13. Seitz, B. (2007). Amniotic Membrane Transplantation. An indispensable therapy option for persistent corneal epithelial defects. Ophthalmologe, 104, 1075-1079. Retrieved May 10, 2016.
14. Sippel KC, Ma JJ, Foster CS: Amniotic membrane surgery. Curr Opin Ophthalmol 2001; 12:269-81
15. Mattila, J. S., Korsbäck, A., Krootila, K., & Holopainen, J. M. (2013). Treatment of Pseudomonas aeruginosa keratitis with combined corneal cross-linking and human amniotic membrane transplantation. Acta Ophthalmologica, 91(5). doi:10.1111/aos.12115
16. Karsten, E. (2012). Diversity of Microbial Species Implicated in Keratitis: A Review. TOOPHTJ The Open Ophthalmology Journal, 6(1), 110-124. doi:10.2174/1874364101206010110
17. Noureddin, G., & Yeung, S. (2016). The use of dry amniotic membrane in pterygium surgery. OPTH Clinical Ophthalmology, 705. doi:10.2147/opth.s80102
18. Abdulhalim, B. H., Wagih, M. M., Gad, A. A., Boghdadi, G., & Nagy, R. R. (2014). Amniotic membrane graft to conjunctival flap in treatment of non-viral resistant infectious keratitis: A randomised clinical study. British Journal of Ophthalmology, 99(1), 59-63. doi:10.1136/bjophthalmol-2014-305224
19. Chan, T. C., Lau, T. W., Lee, J. W., Wong, I. Y., Jhanji, V., & Wong, R. L. (2015). Corneal collagen cross-linking for infectious keratitis: An update of clinical studies. Acta Ophthalmologica Acta Ophthalmol, 93(8), 689-696. doi:10.1111/aos.12754
20. Chan, T. C., Agarwal, T., Vajpayee, R. B., & Jhanji, V. (2016). Cross-linking for microbial keratitis. Current Opinion in Ophthalmology, 1. doi:10.1097/icu.0000000000000271
21. McClintic SM, Prajna NV, Srinivasan M, et al. Visual outcomes in treated bacterial keratitis: four years of prospective follow up. Invest Ophthalmol Vis Sci 2014;55:2935-2940 McClintic SM, Prajna NV, Srinivasan M, et al. Visual outcomes in treated bacterial keratitis: four years of prospective follow up. Invest Ophthalmol Vis Sci 2014;55:2935-2940
22. Marangon, F. B., Miller, D., & Alfonso, E. C. (2004). Impact of Prior Therapy on the Recovery and Frequency of Corneal Pathogens. Cornea, 23(2), 158-164. doi:10.1097/00003226-200403000-00009
23. Brooks, D. E., & Ollivier, F. J. (2004). Matrix metalloproteinase inhibition in corneal ulceration. Veterinary Clinics of North America: Small Animal Practice, 34(3), 611-622. doi:10.1016/j.cvsm.2003.12.005
24. Mcdonald, E. M., Ram, F. S., Patel, D. V., & Mcghee, C. N. (2014). Topical antibiotics for the management of bacterial keratitis: An evidence-based review of high quality randomised controlled trials. British Journal of Ophthalmology, 98(11), 1470-1477. doi:10.1136/bjophthalmol-2013-304660
25. Seitz, B. (2007). Amniotic Membrane Transplantation. An indispensable therapy option for persistent corneal epithelial defects. Ophthalmologe, 104, 1075-1079. Retrieved May 10, 2016.
26. Sippel KC, Ma JJ, Foster CS: Amniotic membrane surgery. Curr Opin Ophthalmol 2001; 12:269-81
27. Mattila, J. S., Korsbäck, A., Krootila, K., & Holopainen, J. M. (2013). Treatment of Pseudomonas aeruginosa keratitis with combined corneal cross-linking and human amniotic membrane transplantation. Acta Ophthalmologica, 91(5). doi:10.1111/aos.12115
28. Karsten, E. (2012). Diversity of Microbial Species Implicated in Keratitis: A Review. TOOPHTJ The Open Ophthalmology Journal, 6(1), 110-124. doi:10.2174/1874364101206010110
29. Noureddin, G., & Yeung, S. (2016). The use of dry amniotic membrane in pterygium surgery. OPTH Clinical Ophthalmology, 705. doi:10.2147/opth.s80102
30. Abdulhalim, B. H., Wagih, M. M., Gad, A. A., Boghdadi, G., & Nagy, R. R. (2014). Amniotic membrane graft to conjunctival flap in treatment of non-viral resistant infectious keratitis: A randomised clinical study. British Journal of Ophthalmology, 99(1), 59-63. doi:10.1136/bjophthalmol-2014-305224
31. Chan, T. C., Lau, T. W., Lee, J. W., Wong, I. Y., Jhanji, V., & Wong, R. L. (2015). Corneal collagen cross-linking for infectious keratitis: An update of clinical studies. Acta Ophthalmologica Acta Ophthalmol, 93(8), 689-696. doi:10.1111/aos.12754
32. Chan, T. C., Agarwal, T., Vajpayee, R. B., & Jhanji, V. (2016). Cross-linking for microbial keratitis. Current Opinion in Ophthalmology, 1. doi:10.1097/icu.0000000000000271
33. McClintic SM, Prajna NV, Srinivasan M, et al. Visual outcomes in treated bacterial keratitis: four years of prospective follow up. Invest Ophthalmol Vis Sci 2014;55:2935-2940

EYELID MALIGNANCIES

EMILY KARBEN, OD
VA PORTLAND HEALTH CARE SYSTEM



OBJECTIVES

- Identify the most common signs of eyelid malignancy
- Understand the most common risk factors of eyelid malignancy
- Identify the most common eyelid malignancies and features of these malignancies including:
  - Appearance
  - Diagnosis
  - Treatment
  - Recurrence, metastasis and mortality

2

MALIGNANT EYELID TUMORS

- Eyelid cancers account for 5-10% of all cutaneous malignancies
- Frequency:
  - Basal cell carcinoma (86-96%)
  - Squamous cell carcinoma (3.4-12.6%)
  - Sebaceous cell carcinoma (0.60-10.2%)
  - Malignant melanoma (<1%)
  - Merkel cell (<1%)
- The incidence of skin cancer has tripled since 1980. 1 in 5 Americans will be diagnosed with skin cancer (1:3 Caucasians) in their lifetime.

3

TABLE 4. Reported Frequency of Eyelid Tumors: for Comparison Purpose, Inflammatory and Cystic Lesions have been Removed from Series

Authors	Deprez and Uffer	McLean et al	Font et al	Tesluk[9]	Halon et al[6]	Ni[8]
Referral center	Hospital Jules Gonin, Lausanne, Switzerland	AFIP Registry, United States	Doheny Eye Institute, California	Wills Eye Hospital, Pennsylvania	Wroclaw Medical University, Poland*	Shanghai Medical University, China*
Period of data collection	1989–2007	1984–1989	1970–2000	1980–1982	1946–1999	1953–1992
Total number of cases	4981	846	1474	497	2031	3510
Benign tumors, n (%)	4087 (82)	456 (54)	880 (60)	372 (75)	1262 (62)	
Squamous cell papilloma	1063 (26)	18 (4)	237 (27)	71 (19)	659 (52)	658 (28)
Seborrheic keratosis	876 (21)	23 (5)	120 (14)	73 (20)		212 (9)
Melanocytic nevus NOS	816 (20)	74 (16)	161 (18)	28 (8)		578 (24)
Hidrocystoma	326 (8)	29 (6)	128 (15)			
Xanthoma and xanthelasma	246 (6)	20 (4)	5 (<1)			
Actinic/solar keratosis	198 (5)	19 (4)	31 (4)	6 (2)		
Inverted follicular keratosis	117 (3)	28 (6)	18 (2)	24 (6)		
Trichilemmoma	47 (1)	24 (5)	1 (<1)			
Syringoma	45 (1)	8 (2)	16 (2)			
Keratoacanthoma	35 (<1)	5 (1)	20 (2)			
Others	318 (8)	208 (46)	143 (16)	170 (NA)		Including 222 (10) angiomas
Malignant tumors, n (%)	894 (18)	390 (46)	594 (40)	125 (25)	433 (21)	
Basal cell carcinoma	772 (86)	107 (27)	410 (69)	103 (82)	314 (73)	430 (38)
Squamous cell carcinoma	67 (7)	50 (13)	28 (5)	3 (2)		216 (19)
Sebaceous carcinoma	29 (3)	102 (26)	82 (14)	8 (6)		363 (32)
Merkel cell carcinoma	4 (<1)	12 (3)	4 (<1)			
Metastasis	4 (<1)	10 (2)	7 (1)			
Lymphoma	0	26 (7)	18 (3)			21 (2)
Others	18 (2)	83 (21)	45 (8)	11 (NA)		Including 56 (5) melanomas

4

INCIDENCE OF MALIGNANT EYELID LESIONS

Immunosuppression and Cancer

- The greatest change in the nature and frequency of some orbital disorders has been in those that occur more frequently in the immunosuppressed patient.
  - Increase in those with organ transplants and those with certain infections (ie: HIV)
  - Within the first 5 years of immunosuppression, 40% of transplant recipients experience premalignant or malignant skin tumors.

5

ANATOMICAL CONSIDERATIONS

- Eyelid malignancies require different considerations from other cutaneous malignancies due to unique anatomical considerations.
  - Also, eyelid skin has unique texture, is the thinnest of the entire body at 700-800 um in thickness.
- Must consider the functional impact of surgical resection and reconstruction on ocular protection and visual function

6

PATIENT EVALUATION

- Patients who present with suspected eyelid malignancies should undergo:
  - A thorough medical history with specific inquiry about prior skin CA
  - Ask the right questions:
    - When did you first notice?
    - Signs?
    - Symptoms?
    - CHANGE in appearance?
  - Inquire about:
    - Sun and radiation exposure
    - Immune status
  - Complete ocular adnexa exam

Patients with eyelid cancers should also undergo a full body skin check by a dermatologist.

7

SIGNS OF MALIGNANCY

- Change/loss of lid architecture
- Irregular or pearly borders
- Ulceration/bleeding
- Poliosis
- Madarosis
- Telangiectasia
- Non-painful, non-tender
- Induration

Always photograph suspicious lesions and watch for change.

8

SIGNS OF ORBITAL INVASION

- No symptoms
- Strabismus/EOM abnormalities
- Involvement of the 7th and/or 5th cranial nerve
- Involvement of the canthal areas
- Hypoglobus
- Hyperglobus
- Proptosis

9

CASE #1: 85 Y/O WHITE MALE

- Pertinent medical history:
  - Prostate cancer
  - ? H/o skin cancer lesion removed from right temple. Mentioned on only 1 chart note from optometry 12/2005.
  - Outdoor work/ sun exposure
- Prior ocular history:
  - Dry eye disease
  - Allergic conjunctivitis
  - Choroidal nevi OD
- Ocular medications:
  - Artificial tears, ketotifen

10

First noted lesions on 8/19/15
Sent to oculoplastics, next available.





Photos courtesy of Dr. Omaya Youssef

11

OCULOPLASTICS

Questions asked by oculoplastics specialist:

1. Do lesions have a history of crusting/bleeding?
2. Family history of skin cancer?
3. Smoking/tobacco?
4. Outdoor work?



Pertinent ocular history questions:

1. Eyelid/facial skin cancer?
2. H/o sunburn?
3. Head/neck XRT?

Assessment: suspected BCC L medial canthus and LLL margin

12

OCULOPLASTICS PLAN

- Excisional biopsy with frozen section L medial canthus and LLL; reconstruction with FTSG
- D/c Plavix prior to surgery
  - With approval from PCP notified
- Obtain photos
- s/p medications: Maxitrol ung, AT, tylenol
- Dermatology consult for skin check

13

PATHOLOGY REPORT



Eyelid, left lower, excision
- Basal cell carcinoma, nodular type

Eyelid, left medial canthus, excision
- Basal cell carcinoma, nodular type

14

RISK FACTORS FOR BASAL CELL CARCINOMA

- Sun exposure
- Age
- Immunosuppression
- Fair skin, blond/red hair, blue eyes
- Radiation (head/neck)
- Prior h/o BCC
- Smoking in women
- Chronic infection by the mite demodex folliculorum may also be a triggering factor?
- Incidence increased in those with xeroderma pigmentosum and Gorlin-Goltz syndrome (especially in younger patients).

15

PRESENTATION OF BASAL CELL CARCINOMA

- Noduloulcerative (80%)
  - Shiny, translucent, firm, raised nodule with induration. (+) telangiectatic vessels
  - As it grows: edges raised and indurated
  - Spreads slowly, extending under the skin
  - Easily bleeds
- Sclerosing/morpheaform (2-15%)
  - Originates in the epithelium
    - may mimic chronic blepharitis
  - Flat indurated plaque, (-) telangiectatic vessels
  - Margins difficult to delineate
  - Most common to invade orbit



16

SITES OF PERIOCULAR INVOLVEMENT OF BASAL CELL CARCINOMA

- Lower lid (50-60%)
- Medial canthus (25%) → associated with a higher risk of orbital involvement
- Upper lid (15%)
- Lateral canthus (5%)

Median age: 61 years

17

NODULOULCERATIVE BCC



71 y/o female



Medial canthus in an 85 y/o man.



61 y/o female



Lateral canthus in an 87 y/o man

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook*

18

MORPHEAFORM BCC



71 y/o female



78 y/o male



Note the secondary conjunctival inflammation in a 76 y/o female

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook.*

19

CASE #2: 66 Y/O WHITE MALE

Pertinent medical history:

- Actinic keratosis
- History of BCC on nose (resected via Mohs)

Ocular history:

- Enlarged/inflamed caruncle
- Blepharitis

Ocular medications:

- None

20





Photos courtesy of Dr. Omaya Youssef

Presented in early 2015:

- Gradual growth reported over 14 months (per another VA notes)
- Prior MRI showed discrete mass with no invasion of local structures
- Prior anti-inflammatory (Tobradex) and lubricant drops have not helped

21

TREATMENT AND BIOPSY RESULTS

Treatment/Plan:

1. Frozen margin controlled excision
2. Topical MMC 0.4% gtt qid
    1. 3 cycles, 1 week on followed by 1 week off

Biopsy results:

- Right eye caruncular tissue: Squamous cell carcinoma, in situ
- Right conjunctiva, lower lid: squamous cell in situ
- Right inferior fornix: squamous cell in situ



22

SQUAMOUS CELL CARCINOMA

- Second most common form of skin cancer in the United States
  - 40x less common than BCC, but more aggressive
  - Accounts for about 3.4-12.6% of malignant eyelid tumors
- Australia has the highest incidence

http://www.sciencephoto.com/media/414574/view

23

RISK FACTORS FOR SQUAMOUS CELL CARCINOMA

- Male gender (men are 2-3x more affected)
- Fair skin
- UV exposure (especially in albino patients)
- Immunosuppression (AIDS in younger people)
- Radiation exposure
- High fat diet
- Chemical exposure
- Infection with HPV

24

PRESENTATION OF SQUAMOUS CELL CARCINOMA (SCC)

- Raised nodule or plaque with overlying scaling, induration, keratinization or ulceration
  - May masquerade as chronic anterior blepharitis
- May arise de novo or from preexisting actinic keratosis, Bowen's disease, Xeroderma pigmentosum
  - These generally behave less aggressively than lesions that arise de novo

Most common locations:

- Lower eyelid → medial canthus → upper eyelid → lateral canthus
- If on conjunctiva, termed ocular surface squamous neoplasia (OSSN)

25



88 y/o female with diffuse infiltrative tumor with ectropion of the eyelid



87 y/o man with h/o chronic sunlight exposure



Bilateral, crusty, ulcerated SCC of eyelids in a 41 y/o man who was immunosuppressed after renal transplantation



Orbital invasion in a 69 y/o man. Exenteration was necessary

26

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook.*

PROGNOSIS OF SQUAMOUS CELL CARCINOMA

- SCC is much more invasive
  - Regional lymph node metastasis (in as high as 24%)
    - most common in the parotid, preauricular, submandibular
  - Hematogenous spread is most deadly
- SCC that arises from AK has a more favorable prognosis (<2% metastatic rate)

27

TREATMENT FOR BCC AND SCC

- Surgery with histologic control of the margins
  - Either Mohs or frozen section technique
- In cases not amenable to surgical resection
  - Cryotherapy
  - Radiation therapy
  - Oral vismodegib (Erivedge)- prevents expression of tumor mediating genes in patients with BCC
- Suspected orbital invasion
  - CT/MRI
  - Orbital exenteration- necessary in ~1% of cases

28

SEBACEOUS GLAND CARCINOMA

- 3rd most common eyelid malignancy in the United States
- Average age 68 years (>50 years)
- Due to abundance of sebaceous glands, the face is the most common site.

Risk Factors:
- Asian race (6.21x more likely)
- Elderly females
- Prior ocular irradiation
- Relationship with Muir-Torre syndrome



29

SEBACEOUS CELL CARCINOMA IS ONE OF THE MOST DANGEROUS EYELID TUMORS

- 50% misdiagnosed on clinical appearance

Why?

1. Varied clinical presentation according to site of origin
2. Masquerades as an inflammatory condition
   - Many SebCa's contain a lipid-laden cytoplasm which attracts inflammation. Therefore, misdiagnosed as:
     - blepharoconjunctivitis
     - recurrent chalazia
   - Should be considered in any unilateral chronic inflammatory condition of the eyelids

Orbital Invasion
- 36% of cases

30

CLINICAL FEATURES OF SEBACEOUS CELL CARCINOMA

- Nodular type
  - Easy to mistake for a chalazion
  - Later, grows and destroys meibomian gland orifice
- Diffuse/Pagetoid type
  - Grows along lid margin and causes diffuse lid swelling
  - May invade the conjunctiva and mimic chronic conjunctivitis
    - May also cause eyelash misdirection and madarosis
  - Multicentric is common, separate upper and lower tumors occur in 6-8%

31

LOCATION OF SEBACEOUS CELL CARCINOMAS

- Can arise from any sebaceous glands, however most classically arises from Meibomian glands of upper and lower lids
- Less commonly found in Glands of Zeis
- Even less common in caruncle, eyebrow or lacrimal gland



32

NODULAR



65 y/o man



44 y/o woman



78 y/o female

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook.* 33

DIFFUSE/ PAGETOID



75 y/o woman.



78 y/o man

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook* 34

RECURRENCE, METASTASIS, MORTALITY

Basal cell carcinoma:

- Rate of recurrence of BCC:
  - With complete resection: <1% at 5 years
  - Incomplete excision: Up to 38% at 5 years
- Metastasis: 0.3-1%
- Mortality: 1% to 3%

Squamous cell carcinoma:

- Rate of recurrence: 2.4-36.9% at 5 years
- Metastasis: 2-24%
  - closer to lower number. Varies wildly
- Mortality rate: up to 40% in some series
  - Closer to 15%

Sebaceous cell carcinoma:

- Rate of recurrence: 30%
- Metastasis: reported as high as 41%
- Mortality rate: Up to 38% due to distant metastasis and delay in diagnosis

35

IN CONCLUSION

- The 3 most common eyelid malignancies:
  - Basal cell → Squamous cell → Sebaceous cell
- Must be aware of potential malignant features
- Be suspicious of unilateral blepharoconjunctivitis that is not responding to treatment
- Photographing lesions is really the only reliable way to discern change in appearance
- Most often a biopsy is required to confirm or disprove the suspicion of malignancy as these lesions are often misdiagnosed on clinical appearance alone

36

REFERENCES

Shields, Jerry A., and Carol L. Shields. *Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook.*

Erbagci, Zulal, Ibrahim Erbagci, and Suna Erkilic. "High Incidence of Demodicidosis in Eyelid Basal Cell Carcinomas." International Journal of Dermatology Int J Dermatol 42.7 (2003): 567-71. Web.)

Cook BE Jr., Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999;106:746 –50.

Riedel KG, Beyer-Machule CK. Basal cell carcinoma. In: Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology, 2nd ed. Philadelphia: Saunders, 2000; 3361–5.

Scott KR, Kronish JW. Premalignant lesions and squamous cell carcinoma. In: Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology, 2nd ed. Philadelphia: Saunders, 2000;3369–74

Wilkinson, C.P. Evidence-based analysis of prophylactic treatment of asymptomatic retinal breaks and lattice degeneration. Ophthalmology. 2000; 107: 12–15 (; discussion 15–8)

Riedel, K.G and Beyer-Machule, C.K. Basal cell carcinoma. in: D.M Albert, F.A Jakobiec (Eds.) Principles and Practices of Ophthalmology. 2nd ed. Saunders, Philadelphia; 2000: 3361–3365View

Wolf, J.E Jr and Hubler, W.R Jr. Tumor angiogenic factor and human skin tumors. Arch Dermatol. 1975; 111: 321–327

Piest, K.L. Malignant lesions of the eyelids. J Dermatol Surg Oncol. 1992; 18: 1056–1059

Hornblass, A and Stefano, J.A. Pigmented basal cell carcinomas of the eyelids. Am J Ophthalmol. 1981; 92: 193–197

Howard, G.R, Nerad, J.A, Carter, K.D, and Whitaker, D.C. Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid. Am J Ophthalmol. 1992; 113: 123–123

Gorlin, R.J and Goltz, R.W. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib(a syndrome) . ([case report])N Engl J Med. 1960; 262: 908–912

Scott, K.R and Kronish, J.W. Premalignant lesions and squamous cell carcinoma. in: D.M Albert, F.A Jakobiec (Eds.) Principles and Practices of Ophthalmology. 2nd ed. Saunders, Philadelphia; 2000: 3369–3374

Doxanas, M.T and Green, W.R. Sebaceous gland carcinoma(review of 40 cases) . Arch Ophthalmol. 1984; 102: 245–249

Boniuk, M and Zimmerman, L.E. Sebaceous carcinoma of the eyelids, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol. 1968; 72: 619–642

37

Shedding Light on Night Blindness

Heather M. French, O.D.
Primary Care/Ocular Disease Resident
VA Southern Oregon Rehabilitation Center & Clinics

Case History: 73yo CM

- CC: gradually worsening vision OU and progressive night blindness. Frequently bumps into things at night, requires flashlight to get around in the dark.
- POHx:
  - s/p CE/PCIOLs OU
  - s/p YAG capsulotomies OU

Case History: 73yo CM

- Ocular Meds: Refresh Plus NPATs prn OU
- (-)Family Hx
- Social Hx:
  - Smokes 1 pack per day
  - Hx alcohol dependence

Case History: 73yo CM

- Medical Hx:
  - HTN
  - Major depression
  - COPD
  - Chronic otitis media
  - Hx pneumonia
  - Leukocytosis
  - Hypothyroidism
  - Crohn's disease, s/p multiple small bowel resections
  - Peripheral vascular disease
  - Lumbar post-laminectomy syndrome

Case History: 73yo CM

- Meds:
  - Ondansetron
  - Methadone
  - Cyclobenzaprine
  - HCTZ
  - Multivitamin
  - Budesonide/formoter
  - Levothyroxine
- NKDA

Exam

- Entrance tests
  - PERRL, (-)RAPD OU
  - EOMs FULL OU
  - VF FTFC OD/OS
  - CT: ortho cc
- BCVA
  - OD: plano-1.25x107 **$20/50^{-1+1}$ PHNI**
  - OS: -2.25 -1.25x032 **$20/40^{-1}$ PHNI**

Exam

- Anterior Segment
  - Conjunctiva: gray-white, frothy deposits temporally OS
  - Cornea: 3-4+ diffuse, coalesced PEE OU
  - Angles: 4/4 OU
  - AC: deep & quiet OU
  - Iris: flat & even OU
  - Lens: well-centered PCIOLs, clear centrally OU

Conjunctiva OS



Conjunctiva OS



Exam

- T_a 16/14 mmHg @ 1311
- Posterior Segment
  - Vitreous: mild syneresis OU
  - Optic discs: 0.30 H/V, pink rims with distinct margins, (-)pallor
  - Vessels: mild-moderate crossing changes OU
  - And…see photos


Portland_50DX
10/9/2015
1




Portland_50DX
10/9/2015
10


Macula Thickness : Macular Cube 512x128
OD
OS
500
400
300
200
100
0 µm
Overlay: ILM - RPE Transparency: 50 %
226
249
237
253
212
265
244
268
240
ILM-RPE Thickness (µm)
Fovea: 234, 64
ILM - RPE
ILM
RPE
Diversified Distribution of Normals
99%
95%
5%
1%
Central Subfield Thickness (µm)
Cube Volume (mm³)
Cube Average Thickness (µm)
ILM - RPE
212
8.7
242


Macula Thickness : Macular Cube 512x128
OD
OS
Overlay: ILM - RPE Transparency: 50 %
ILM-RPE Thickness (µm)
Fovea: 250, 68
ILM - RPE
ILM
RPE
Diversified Distribution of Normals
99%
95%
5%
1%
Central Subfield Thickness (µm)
Cube Volume (mm³)
Cube Average Thickness (µm)
ILM - RPE
202
8.3
234


ONH and RNFL OU Analysis:Optic Disc Cube 200x200
OD
OS
RNFL Thickness Map
RNFL Deviation Map
Average RNFL Thickness
RNFL Symmetry
Rim Area
Disc Area
Average C/D Ratio
Vertical C/D Ratio
Cup Volume
Neuro-retinal Rim Thickness
RNFL Thickness
Disc Center(0.09,0.15)mm
Disc Center(-0.03,-0.09)mm
Extracted Horizontal Tomogram
Extracted Vertical Tomogram
RNFL Circular Tomogram
RNFL Quadrants
RNFL Clock Hours
TEMP
SUP
NAS
INF


Central 30-2 Threshold Test
Fixation Monitor: Gaze/Blind Spot
Fixation Target: Central
Fixation Losses: 0/13
False POS Errors: 7 %
False NEG Errors: 9 %
Test Duration: 06:29
Fovea: 25 dB
Stimulus: III, White
Background: 31.5 ASB
Strategy: SITA-Fast
Pupil Diameter: 5.0 mm
Visual Acuity:
RX: +2.50 DS DC X
Date: 08-21-2015
Time: 9:35 AM
Age: 73
GHT
Outside Normal Limits
VFI 72%
MD -8.92 dB P < 0.5%
PSD 7.08 dB P < 0.5%
Total Deviation
Pattern Deviation
< 5%
< 2%
< 1%
< 0.5%
VA WHITE CITY
8495 CRATER LAKE HWY
WHITE CITY, OR 97503


Central 30-2 Threshold Test
Fixation Monitor: Gaze/Blind Spot
Fixation Target: Central
Fixation Losses: 1/16
False POS Errors: 2 %
False NEG Errors: 0 %
Test Duration: 06:32
Fovea: 26 dB
Stimulus: III, White
Background: 31.5 ASB
Strategy: SITA-Fast
Pupil Diameter: 4.5 mm
Visual Acuity:
RX: +0.00 DS -1.50 DC X 30
Date: 08-21-2015
Time: 9:44 AM
Age: 73
GHT
Outside Normal Limits
VFI 54%
MD -14.56 dB P < 0.5%
PSD 9.32 dB P < 0.5%
Total Deviation
Pattern Deviation
< 5%
< 2%
< 1%
< 0.5%
VA WHITE CITY
8495 CRATER LAKE HWY
WHITE CITY, OR 97503

Differential Diagnosis

- Vitamin A deficiency (VAD)/Xerophthalmia
  - Xerosis & retinopathy
- Fundus albipunctatus
- Retinitis pigmentosa variant
- Choroideremia

Work-Up

- Stat labs: vitamin A serology
- Refer to Portland VAMC Retina with indication for ffERG
  - Rule out hereditary retinopathy vs acquired

Lab Results

- Serum vitamin A: **4 µg/dL**
  - Reference range: **18 - 77 µg/dL**

- Final Dx: Vitamin A deficiency xerophthalmia with xerosis, Bitot's spots, & retinopathy secondary to chronic malabsorption; retinal specialist in agreement

Vitamin A

- Fat soluble vitamin absorbed via small intestines



[2]Chae T, Foroozan R. Vitamin A deficiency in patients with a remote history of intestinal surgery. *Br J Ophthalmol* 2006;90:955-6.

Vitamin A Deficiency (VAD)

- Malnutrition
- Malabsorption
- Liver disease
- Global scale annually:[6]
  - 1-2 million deaths
  - 500,000 cases irreversible blindness
  - Millions affected by xerophthalmia

[6]Humphrey JH, West KP, Sommer A. "Vitamin A deficiency and attributable mortality in under-5-year-olds." *WHO Bulletin.* 1992;70:225-32.

Clinical Implications

- Not just a disease of the developing world!
- Consider in:
  - Crohn's disease
  - Anorexia nervosa
  - Celiac disease
  - Liver disease (hepatitis, cirrhosis)
  - s/p gastric bypass Sx
  - Hx intestinal Sx

Gastric Bypass Sx



Gastric Bypass Sx

- 2013: 179,000 bariatric surgeries in USA*
  - 34.2% Roux-en-Y gastric bypass procedure

American Society for Metabolic and Bariatric Surgery

Crohn's Disease

- Type of inflammatory bowel disease
- "Nonspecific chronic transmural inflammatory disease that most commonly affects the distal ileum and colon but may also occur in any part of the GI tract from the mouth to the anus…"[4]



[4]"Crohn's Disease." Chronic Inflammatory Diseases of the Bowel. 16(57):830-4. The Merck Manual. 1992.

Our Patient

- **Multiple, extensive small bowel resections (~10ft) & hospitalizations for small bowel obstructions**



Xerophthalmia

- Clinical findings:
  - Dry eyes (xerosis)
  - Corneal liquefaction (keratomalacia)
  - Bilateral flecked retinal lesions
  - Nonspecific visual field defects
  - Depressed ffERG
    - Disappearance of A-wave followed by loss of B-wave

Xerosis



Bitot's Spots



Keratomalacia



Uyemura's Syndrome



Phototransduction

Photoreceptor



- **Rhodopsin**: opsin and retinal complex in **rod** cells
- **Photopsin**: opsin and retinal complex in **cone** cells

Phototransduction

- Early deficiency → rod function lost first
- Chronic deficiency → cones later affected
  - S cones suffer greater impact vs L & M
    - Tritan color vision defect?



[9]McBain VA, Egan CA, Pieris SJ, Supramaniam, et al. Functional observations in vitamin A deficiency: diagnosis and time course of recovery. *Eye.* 2007;21:367-76.

Why do rods suffer earlier than cones?

- Hypotheses
  - Novel pathway for opsin photopigment regeneration involving cones & Müller cells[8]
  - Cone visual pigment more rapidly synthesized[9]
  - With decreased availability, cones may capture vitamin A at expense of rods[9]

[8]Mata NL, Radu RA, Clemmons RC, Travis GH. Isomerization and oxidation of vitamin A in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight. *Neuron.* 2002;36(1):69-80.
[9]McBain VA, Egan CA, Pieris SJ, Supramaniam, et al. Functional observations in vitamin A deficiency: diagnosis and time course of recovery. *Eye.* 2007;21:367-76.

Treatment

- IM injections Aquasol A 100,000 IU x 2 days, then 50,000 IU x 2 weeks, then 20,000 IU maintenance
- Copious ocular surface lubrication
- Partially or fully reversible, depending on chronicity

Treatment

- VA approach:
  1. Vitamin A tabs 100,000 units po x 3 days, then 50,000 units po 10 days, then 10,000 units po x 1mo.
  2. Retest serum vitamin A at 1 mo.
  3. Order FER for IM form if low levels persist

Lab Results (7 mos vitamin A po)

- Serum vitamin A: **10 µg/dL**
  - Reference range: **18 - 77 µg/dL**



Treatment

- Ordered FER for IM vitamin A injections
  - **100,000 IU x 2 days**
  - **50,000 IU x 2 weeks**
  - **20,000 IU maintenance dosing**



Patient Update as of 05/17/16

- Patient notices subjective mild improvement in night vision
- Resolution of Bitot spot OS & corneal PEE OU
- Persistent parafoveal retinal flecks OU with similar OCT findings
- Unreliable GVF OU

Patient Update as of 05/17/16

- ffERG finally performed at Casey Eye Institute, *but after beginning IM vitamin A:*
  - OU: slight decrease in b-wave amplitude on dim scotopic, mildly prolonged implicit time



[9]McBain VA, Egan CA, Pieris SJ, Supramaniam, et al. Functional observations in vitamin A deficiency: diagnosis and time course of recovery. *Eye.* 2007;21:367-76.

Considerations

- Medical/surgical Hx
- Family Hx
- Constellation of signs & symptoms
- Ordering vitamin A lab
- Liver stores **2 years** worth of vitamin A as retinyl palmitate

References

1. Bruanstein A, Trief D, Wang NK, Chang S, et al. Vitamin A deficiency in New York City. *Lancet* 2010;376(9737):267.
2. Chae T, Foroozan R. Vitamin A deficiency in patients with a remote history of intestinal surgery. *Br J Ophthalmol* 2006;90:955-6.
3. Clifford LJ, Turnbull AMJ, Denning AM. Reversible night blindness – A reminder of the increasing importance of vitamin A deficiency in the developed world. *J of Optometry* 2013;6:173-4.
4. "Crohn's Disease." Chronic Inflammatory Diseases of the Bowel. 1992;16(57):830-4. The Merck Manual.
5. "Flecked Retina Associated with Vitamin A Deficiency." Toxic Diseases Affecting the Pigment Epithelium and Retina. 2005;5(1):780. Gass' Atlas of Macular Diseases.
6. Humphrey JH, West KP, Sommer A. "Vitamin A deficiency and attributable mortality in under-5-year-olds." *WHO Bulletin.* 1992;70:225-32.
7. Main A, Mills PR, Russell RI, Bronte-Stewart J, et al. Vitamin A deficiency in Crohn's disease. *Gut* 1983;24:1169-75.
8. Mata NL, Radu RA, Clemmons RC, Travis GH. Isomerization and oxidation of vitamin a in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight. *Neuron.* 2002;36(1):69-80.
9. McBain VA, Egan CA, Pieris SJ, Supramaniam, et al. Functional observations in vitamin A deficiency: diagnosis and time course of recovery. *Eye.* 2007;21:367-76.

IN-OFFICE REMOVAL OF BENIGN EYELID LESIONS

Shelby Gross, O.D.
VA Portland Health Care System

Outline

- Before the procedure
- Chemical cautery
- Anesthesia
- Incisions
- Intralesional injection
- Incision & curettage
- Summary





Before The Procedure

- Explanation/consent form
  - What the lesion is
  - Procedure for removal
  - Course of healing and desired outcome
  - Possible complications and side effects
  - Discuss all treatment alternatives
- Minimum exam elements
  - ROS:
    - Systemic and ocular health history
      - Bleeding conditions (or family hx) or anticoagulant medications
    - Allergies: anesthetics, latex
  - Visual acuities
  - Intraocular pressures
  - Blood pressure and pulse

Chemical Cautery

- Uses **dichloroacetic acid or trichloroacetic acid**
  - Keratolytic agent that rapidly penetrates and causes protein denaturing and cell death when applied to skin
- Equipment:

Chemical Cautery

- **Procedure:**

1 gtt proparacaine OU → Swab area with alcohol → Apply acid with sharpened wooden applicator

- Patient will experience a stinging sensation that will escalate, level off, then subside
- Larger lesions may require a second application in 2 weeks

Chemical Cautery

- If patient is in extreme pain, or if excessive amount is applied, the CDC recommends the affected area be covered with **sodium bicarbonate (baking soda)**, and washed with liquid soap to neutralize and remove the acid

Lesion will turn a milky white *immediately* after application

↓

After a few hours the lesion will darken

↓

After a few days, an eschar will form and fall off in 7-10 days

↓

Underlying skin will initially be lighter than surrounding skin

Chemical Cautery

- **Cutaneous warts (verrucca vulgaris, flat warts, squamous papilloma)**
  - Human papilloma virus induces hyperplasia and hyperkeratosis
    - Overall prevalence in US: 2-20%
  - Most will eventually spontaneously resolve in months or years
  - Alternative therapy:
    - liquid nitrogen (cryotherapy), electrocautery, excision
    - immunotherapy with contact allergens or interferons via intralesional injection



2 weeks later

Chemical Cautery

- **Seborrheic keratosis**
  - Common benign epidermal tumors consisting of a benign proliferation of immature keratinocytes
  - Genetic predisposition; pathogenesis not completely understood
  - Well-demarcated round or oval lesions with a dull verrucous surface and 'stuck on' appearance



- **Molluscum contagiosum**
  - Caused by a poxvirus and spread by direct contact or formites
  - One or multiple small, pale, shiny nodules with central umbilication
  - Most pts are not immunodeficient, but 10-20% of HIV infected individuals will develop this infection on the face, neck or genital areas
  - May resolve spontaneously in one year



Chemical Cautery



- **Xanthelasma palpebrarum**
  - Yellow plaques containing lipid-rich deposits that occur most commonly near the inner canthus of the upper eyelid
  - About half of cases have been found to be associated with elevated plasma lipid levels; seldom resolve when this is lowered
  - Several studies have shown chemical cautery with dichloroacetic acid or trichloroacetic acied to be a simple, effective remedy
    - Alternative therapies: surgery, cryotherapy
  - Recurrences common. Greatest risk: young age, family history, four lid involvement, underlying hyperlipemic syndrome, past history of recurrence



Snip Incision



- **Pedunculated verucca**
- **Acrochordon (skin tag)**
  - Outgrowth of normal skin
  - Pedunculated lesions on narrow stalks
  - Common on obese patients and diabetic patients
  - Occur in sites of friction



- **Equipment:**



Anesthesia

- **Ice**- effective for superficial anesthesia <5 seconds
- Local infiltration with injection
  - **Amides** (**lidocaine**, mepivacaine, bupivacaine, etidocaine, prilocaine, ropivacaine, levobupivacaine)
  - **Esters** (procaine, tetracaine, cocaine, benzocaine)
    - Due to toxicity and allergic reactions, esters have limited indication for local infiltration
  - Direct infiltration of local anesthetic into the **subcutaneous layer** effectively blocks transmission from the free nerve endings located in the epidermal and dermal layers



Anesthesia

- **1% lidocaine (xylocaine) with epinephrine (1:100,000)**
  - Epineprine cuts down on local bleeding, prolongs the anesthetic action by keeping the solution in local tissues for longer and allows larger volumes of anesthetic to be used safely
  - Onset typically *2-5 minutes*; duration *30 min- 2 hours* (up to 3 hours with epinephrine)
  - **Toxicity rare**; only need about 1-2mL around the eyelids (recommended safe dose of lidocaine/epinephrine for healthy adult is about *0.70mL/kg*)



Injecting Anesthetics

- Place the injection between the origin of the nerve and the lesion
  - Upper eyelid is innervated from above (*lacrimal nerve, supraorbital nerve, supratrochlear nerve and infratrochlear nerve*) and the lower eyelid is innervated from below (*infraorbital nerve*)



Epidermoid Cysts

- "epidermal inclusion cysts", "sebaceous cyst"
- Typically present as dome-shaped, firm, skin-colored nodule that is freely moveable on palpation; sometimes has a small, dilated punctum





Epidermoid Cysts



Apocrine Hydrocystoma

- "cyst of molls gland", "suderiferous cyst"
- Translucent or semitransparent, round, skin-colored or bluish mass along the eyelid margin; contain a watery fluid; usually at the lateral edges of the eyelid
- Complete surgical excision of the cyst is necessary to completely remove; otherwise, recurrences are common





Chalazion- Intralesional Injection

- Direct delivery of medication into skin lesions to treat local tissues with minimal systemic effects
  - The skin serves as a reservoir, resulting in prolonged therapy
- **Kenalog (triamcinolone)**
  - Anti-inflammatory + atrophogenic
  - available in 10mg/mL and 40mg/mL



Chalazion- Intralesional Injection



1-2mL triamcinalone

Chalazion- Intralesional Injection



Intralesional Injection



- Can cause a burning sensation for up to 3-5 minutes after injection; the higher the concentration, the more discomfort
- **Atrophy or pigment changes**, usually resolve over several weeks but can last longer and become permanent
  - Darker pigmented skin most susceptible
- Use the lowest concentration and smallest quantity of drug needed
  - Better to use small amount/low concentration and have to repeat 2x than overestimating amount and suffering complication
- Not indicated when the possibility of infection is present

Chalazion- Incision & Curettage



Chalazion- Incision & Curettage



Two lidocaine injections

1. Subcutaneously between the lesion and the nerve origin
2. Deep peri-bulbar injection (aspirate)

Chalazion- Incision & Curettage



Chalazion- Incision & Curettage



Chalazion- Excision & Curettage



Lineate incision perpendicular to the lid margin



Second lineate incision parallel to the lid margin, bisecting the first incision



Excise the four 'flaps' with snip incisions

Complications



- Some patients have a tendency to form **keloids**
  - Fibroproliferative disorder of the skin caused by abnormal healing of injured or irritated skin
    - Higher risk: genetic predisposition, adolescence, pregnancy, hypertension, local mechanical forces
    - Can ask patients about past trauma and tendency to form scars
    - Treatment: surgery, radiation, corticosteroid injections; combination
- Eyelid margin notching, trichiasis, loss of lashes
- Allergic reaction:
  - Contact dermatitis: local eczematous and pruritic rash within 72 hours at the site of administration
  - Urticaria and anaphylaxis: rare

Summary



references

- Aldahan A, Mlacker S, Shah V, Alsaidan P, Samarkandy S, Nouri K. Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature. Dermatologic therapy. 15 March, 2016. 0.1111/dth.12352
- Bergmanson, Jan. Clinical Ocular Anatomy and Physiology, 19th Ed.Texas Eye Research and Technology Center, Houston: 2012.
- Ghosh, Chandak and Ghosh, Tanya. Eyelid lesions. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Goldstein, Beth, Goldstein, Adam, and Morris-Jones, Rachel. Cutaneous warts. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Goldstein, Beth and Goldstein, Adam. Dermatologic Procedures. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Goldstein, Beth and Goldstein, Adam. Overview of benign lesions of the skin. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Haygood, LJ, Bennet, JD, and Brodell, RT. Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatologic surgery, 24: 1027-1031. 1998.
- Hsu, Deborah. Infiltration of local anesthetics. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Melore, Gerald. Lessons to Remove Lid Lesions and Anomalies. Optometric Study Center: April 2005.
- Mathes, Barbara M, Alguire, Patrick C. Inralesional injection. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
- Ogawa R, Skaishi S, Kuribayashi S, MiyashitaT. Keloids and Hypertrophic Scars Can Now Be Cured Completely: Recent Progress in Our Understanding of the Pathogenesis of Keloids and Hypertrophic Scars and the Most Promising Current Therapeutic Strategy. J Nippon Med Sch. 2016;83(2):46-53. doi: 10.1272/jnms.83.46.

Thank you!

Malingering or true visual distress?

Alexandra Bavasi, OD

Pediatric | VT Resident
Pacific University College of Optometry

Course description

- Case review
- Clinical techniques to help distinguish between
  - Malingering
  - Psychogenic vision loss
  - True binocular vision anomalies
- Review of clinical management techniques

Learning objectives

- Attendees will
  - Learn about the difference between malingering, embellishment, conversion disorder, hysterical amblyopia, and Streff syndrome
  - Discover useful clinical techniques to help differentiate between malingering and true visual anomalies
  - Learn when an appropriate psychological referral may be warranted

Referral from Costco, 4/2015

- 11 year old white female
  - Ocular history: none
  - Medical history: unremarkable
  - Family history: unremarkable
  - Chief concern:
    - Recent onset of blurred vision
  - Cyclоplegic refraction not indicated

- **Assessment:**
  - Exotropia
  - Hyperopic anisometropia
  - Reduced best-corrected visual acuity
- **Plan:**
  - Referral to PUCO for VT
  - Rx spectacles for full time wear

PUCO vision therapy evaluation, 7/2015

- (Another intern/doctor)
- Chief concern: blurred vision, double vision
  - Most symptomatic when practicing Hebrew for upcoming bat mitzvah
- No blur or double vision when playing sports: tennis, soccer, gymnastics
  - Mom notes excellent hand-eye coordination, especially with tennis; no apparent depth perception issues with any sport
- Avid reader: no blur or diplopia noted while leisurely reading

PUCO vision therapy evaluation, 7/2015

- Uncorrected distance visual acuities: Snellen
  - OD: 20/100
  - OS: 20/60
- Uncorrected near visual acuities: Snellen
  - OD: 20/120
  - OS: 20/80
- Habitual Rx: None: Rx from Costco not filled
  - OD: +3.25 -0.25 x034
  - OS: +1.00 sph
- Pupils: PERRLA (-) APD OD, OS
- Confrontation visual fields: Grossly full OD, OS
  - Unsteady fixation; many reflex saccades
- Extraocular motilities: full, no restrictions OD, OS
  - Erratic, exaggerated; large saccadic intrusions
- Pursuits: jerky; lag followed by catch-up saccade
- Saccades: inaccurate: mix of hypo- and hypermetric movements
  - Normal eye movements observed during conversation

PUCO vision therapy evaluation, 7/2015

- Near point of convergence: 35 cm
- Stereo: (-) global; 140" lateral disparity
- Worth 4 dot: (+) diplopia all distances
- Uncorrected distance cover test: 16 alt X (T)
- Uncorrected near cover test: 20-30 alt X (T)
- Vertical Maddox rod: ortho
- Red lens: fusion with 14 BI
- Dry retinoscopy: OD: +3.50 -0.25 x090
  OS: +1.00 sph
- Cycloplegic ret: OD: +4.25 -0.25 x090
  OS: +1.75 sph
- Final Rx: OD: +3.25 sph 7 BI
  OS: +0.75 sph 7 BI

PUCO vision therapy evaluation, 7/2015

- **Assessment:**
  - Hyperopic anisometropia
  - Refractive amblyopia OD
  - Intermittent alternating exotropia
  - Saccadic eye movement deficiency
  - Abnormal pursuit eye movements
- **Plan:**
  - Spectacle Rx with prism full time
  - RTC to re-evaluate vision and binocularity through Rx

Follow up, 8/2015

- Habitual Rx:
  - OD: +3.25 sph 7 BI
  - OS: +0.75 sph 7 BI
- Corrected distance visual acuity: Snellen
  - OD: 20/70
  - OS: 20/60
  - OU: 20/40
- Corrected Pacific Acuity Test:
  - OU: 20/50
- Stereo:
  - (+) Lang I: (+) float, but (-) identification
  - (+) Stereo fly
- Eye movements:
  - Pursuits: jerky, inaccurate, inconsistent
  - Saccades: inaccurate; grossly off target
    - Normal eye movements observed during conversation
- NPC: 20 cm

Follow up, 8/2015

- Corrected distance cover test: 15 alt X(T)
- Corrected near cover test: 20 alt X(T)
- MEM: +1.00 to +1.50 OD, OS: variable
- Prism bar vergence ranges:
  - BI: 20/14
  - BO: 8/2
- Visuoscopy:
  - OD: central, slightly unsteady
  - OS: central steady
- Undilated fundus exam:
  - Unremarkable OD, OS: normal optic nerve and macular health

Follow up, 8/2015

- **Assessment:**
  - Hyperopic anisometropia
  - Refractive amblyopia OD
  - Intermittent alternating exotropia
  - Saccadic eye movement deficiency
  - Abnormal pursuit eye movements
  - Unexplained reduced best corrected visual acuity OS
- Possible malingering:
  - Mom notes that the complaint of blur/double vision started when the patient was reluctantly learning how to read Hebrew for her upcoming bat mitzvah
  - Otherwise, has always been an avid reader and has never complained of vision issues

Follow up, 8/2015

- **Plan:**
  - Refer to PUCO ocular motility and neuro optometry clinic for eye movement evaluation to rule out pathologic cause of eye movement abnormalities
  - Refer for electrodiagnostic evaluation to evaluate reduced BCVA OS
  - Rule out pathological reasons for reduced vision and abnormal eye movements before attributing it to malingering/embellishment
  - Develop vision therapy plan for X(T) and amblyopia OD pending results of referral evaluations

OMNO evaluation, 9/2015

- To rule out malingering, patient was evaluated under the presumed setting of a **trial vision therapy session**:
  - Completed vision therapy-like tasks while measurements were gathered simultaneously

OMNO, 9/2015

- Corrected distance visual acuity:
  - Monocular hart chart near/far rock:
    - 7 ft away from chart with 5 mm optotypes:
      - - 20/33 OD, OS
  - Snellen:
    - Single column of letters of descending size:
      - -20/30 OD, OS

OMNO, 9/2015



- Corrected near visual acuity:
  - "of Mr. Read" reduced M notation reading card:
    - 0.5M paragraph @ 50 cm:
      - -20/30 OU
- Reduced Snellen:
  - Could not "see" lower than 20/100 line @ 40 cm...
    - Called out 20/20 line OU @ 20 cm:
      - -20/40 OU

OMNO, 9/2015

- Stereo:
  - (+) global forms (250")
  - 3/3 lateral disparity animals (100")
  - 1/9 LD Wirt circles (800")
    - Either X(T) or malingering
- Normal NPC: 8 inches
- "Convergence surprise" NPC: 5 inches
- Corrected distance cover test:
  - Distance Hart chart: read down first column, then 2nd, etc.:
    - Orthophoric: no tropia, no exophoria
- Corrected near cover test:
  - Habitual reading material/reduced Snellen chart as target:
    - 8 esophoria

OMNO, 9/2015

- EOMs and pursuits:
  - Marsden ball:
    - Pursuits: smooth, accurate; able to call out individual letters on ball as it moved side to side, fore and aft, and in circular motion
      - Once the doctors remarked how smooth her eye movements were, the patient immediately started moving eyes erratically
- Saccades:
  - Pencil saccades: accurate, no errors

OMNO, 9/2015

- MEM:
  - Level 3 card and habitual reading material:
    - OD: +0.75
    - OS: +1.50
- Over-retinoscopy:
  - Circulating 20/200 letter:
    - OD: Pl sph
    - OS: +1.00 sph



- Visagraph 2 oculography software:
  - 3 trials at grade-level text: 6th grade
  - Relative grade-level efficiency: 12.4 (vs. 6.0)
  - Adjusted words per minute: 254 (vs. 185)
  - Fixations: 28% less fixations
  - Regressions: 24% less regressions
  - Raw data: more accurate with right eye
  - Comprehension: 100%

OMNO, 9/2015

- **Assessment:**
  - Hyperopic anisometropia
    - Under-plussed OS per over-ret and MEM
  - Intermittent alternating exotropia:
    - Over-corrected with prism: significantly esophoric at near
  - Eye movements normal
- **Plan:**
  - Update Rx empirically:
    - OD: +2.75 sph 4 BI
    - OS: +1.25 sph 4 BI
  - Improvement in aniso and ocular alignment
  - Vision therapy to treat X(T)

Summary of vision therapy

- 10 office-based vision therapy sessions
- Maintenance therapy: HTS
- Weaning out of prism:
  - 4 BO placed on left lens of habitual
  - New Rx without prism:
    - OD: +3.00 sph
    - OS: +1.00 -0.25 x095
- Considering contact lenses for sports

Sample exercises:	
Marsden ball	Vergence facility
Minus lens rock	Aperture rule trainer: single/double aperture
Monocular/binocular accommodative facility	Stereoscope: BO/BI
Brock string	Lifesaver card: chiastopic/orthopic fusion
Variable vectograms/tranaglyphs	VTS 4 and HTS software

Malingering vs. Embellishment vs. Non-malingering syndromes

Malingering

- The patient knowingly misleads the examiner for a desired purpose; conscious decision
- Legal cases; getting out of work/school duties; wanting glasses because friend/family member has them
- Responses are typically exaggerated and inconsistent
- Will attempt to avoid testing/assessment

Embellishment

- The patient exaggerates severity of symptoms/diagnosis
- May already have confirmed diagnosis, but clinical measures and symptomatology may not match
- No clear incentive: typically desire increased attention and care
- Subconscious reaction to symptoms or situation

Non-malingering syndromes

- Conversion disorder
- Hysterical amblyopia
- Streff syndrome
- Munchausen syndrome
  - By proxy

Conversion disorder

- Psychological stress resulting in physical problems:
  - Could affect any motor or sensory system, not just vision
  - Broader definition encompassing hysterical amblyopia



Hysterical amblyopia

- Loss of visual function primarily due to the result of emotional/psychological problems
  - Psychological stressor precedes visual problems
- **Primary psychological etiology**
- Secondary visual signs/symptoms

Hysterical amblyopia

- Primary criteria:
  - Preceding emotional/traumatic event
    - Divorce, death, bullying, abuse
  - Reduced visual acuity, significantly worse at near
  - Refractive status essentially unremarkable:
    - -0.50 to +1.00D with <0.75D cyl
  - Reduced stereoacuity
  - Abnormal accommodation: either large lag or lead

Hysterical amblyopia

- Other characteristics:
  - Usually female: age 8-14 years
  - Lowered school performance
  - Detached affect
  - Tubular/restricted visual fields
  - Reduced fusional ability
  - Visual tracking difficulties
  - Cooperative with testing
  - Responses typically consistent and predictable
  - Psychological consultation recommended
  - May or may not respond immediately to lenses and/or vision therapy
    - May work in conjunction with psychotherapy/counseling

Streff syndrome

- Loss of visual function due to the result of primary visual problems
  - Visual problems precede psychological stressor, resulting in reduced visual function
- **Primary visual inefficiencies**
  - Autonomic nervous system disorder affecting accommodative response at near: usually related to stress
- Secondary psychological signs/symptoms

Streff syndrome

- Primary criteria:
  - Reduced/variable distance and near acuities:
    - Near most likely worse
  - Refractive status essentially unremarkable:
    - -0.50 to +1.00D with <0.75D cyl
  - No change in distance acuity with corrective lenses
  - Immediate change in near acuity through low plus lenses (+0.50D)

Streff syndrome

- Other characteristics:
  - Usually female: age 6–12 years
  - Lowered school performance
  - Detached affect, but amiable
  - Accommodative lag at near
  - Reduced fusional ability
  - Visual tracking difficulties
  - Distortion in color vision
- Cooperative with testing
- Responses are typically consistent and predictable
- Respond well to lenses and vision therapy
- No significant psychosis exists, but stressors may be associated with decline in vision:
  - Underlying visual inefficiencies
  - Increased academic/athletic demands: visual symptoms manifest
  - Emotional sequelae from visual dysfunction

Differential diagnosis

Test or Characteristic	Malingering	Hysterical amblyopia	Streff syndrome
Gender	**Nonspecific (1:1)**	**Female (2:1)**	**Female (2:1)**
Age	Any	8-14 years	6-12 years
Attitude	**Hostile, nervous**	**Detached**	**Amiable, detached**
Involved eye(s)	Unilateral or bilateral	Bilateral	Bilateral
Accommodation	**Normal**	**Possible spasm**	**Unstable lag**
Visual fields	Implausible, restricted	Implausible, restricted	Implausible, restricted
Ocular health	**Normal**	**Normal**	**Normal**
Symptoms	Various complaints	Recent onset of significantly blurred vision	Difficulty in school
Stereopsis	**Normal (with surreptitious testing)**	**Reduced**	**Reduced**
Color vision	Normal	Normal	Unreliable
Mobility	**Exaggerated difficulty**	**Normal**	**Possible clumsiness**

Munchausen syndrome

- Psychological disorder where the patient simulates, worsens, or self-induces an injury or illness for the main purpose of being treated as a medical patient
  - Seeking the attention received by truly ill patients
  - May self-harm or induce injuries

Munchausen syndrome, by proxy

- A rare form of child abuse when a parent/caregiver exaggerates or falsifies symptoms of his/her child
  - May go as far as causing symptoms by poisoning, medicating, or injuring the child
  - Seeking attention and sympathy from medical professionals
  - May seek the satisfaction of deceiving medical professionals

To note:

- Organic and nonorganic/functional disease can and do coexist:
  - Possible that over 50% of patients with evidence of functional visual loss may have coexistent organic disease
  - Determining the non-physiologic nature of the patient's complaint is the optometrist's role

Clinical techniques to catch malingering

Determining visual acuity

- Start with smallest optotypes and work up
- Change charts:
  - Use multiple optotypes and optotype presentations
    - Letters, numbers, Lea symbols, broken wheel, Pacific Acuity Test
    - Whole chart vs. line vs. single optotype vs. vertical column of decreasing size
- Use "non-traditional" charts: Hart chart

Determining visual acuity

- Trial frame:
  - Put smallest power minus lens (-0.25 or -0.12D) into trial frame and tell the patient that this is his/her new glasses Rx: if improve to 20/20, positive for malingering
  - Put large (+) cyl x090 and equal (-) cyl x 180 into trial frame: will be very blurry for patient; spin axis of (-) cyl until the patient can see the chart: axis should end at x090 to counter the (+) cyl

Determining accuracy of eye movements

- Mirror test:
  - Hold mirror in front of patient and move it around: difficult for patient to not accurately track object in mirror
- Marsden ball:
  - Have patient play with MB and swing it around: watch pursuit accuracy

Determining visual fields



- Tangent screen:
  - Perform at 1 and 2 meters:
    - Visual field should increase by twice the size at twice the distance; if the same size at longer distance, positive for malingering
- Tangent screen with reverse telescope:
  - Reverse telescope will minify the image by a certain amount, so the field through the telescope should be increased by that same amount

Electrodiagnostic assessments

- Visual evoked potential (VEP) and electroretinogram (ERG)
  - Objectively measure the electrical responses of the brain/retina when presented with a stimulus
  - Does not give information about the interpretation of these electrical signals after they arrive to the areas of the brain responsible for vision

Treatment for Streff syndrome

- Low plus Rx (+0.50D) for near
  - Or full time, depending on refractive error
- In-office vision therapy
  - Accommodation
  - Vergence
  - Saccades/pursuits
  - Increase peripheral fields/awareness

Summary

- **Malingering:** knowingly misleading examiner for particular purpose
- **Embellishment:** exaggeration of symptoms
- **Hysterical amblyopia:** primary psychological problems resulting in secondary visual symptoms
- **Streff syndrome:** primary visual problems resulting in secondary psychological symptoms
- Variety of clinical techniques to catch malingering and gather accurate information: need to be creative and subtle

Summary

- **Treatment:**
  - Malingering:
    - Reassurance, education
  - Hysterical amblyopia:
    - Psych referral, possible benefit of concurrent vision therapy
  - Streff syndrome:
    - Low plus Rx for near (+0.50D), vision therapy

References

Optometric Extension Program. Juvenile Bilateral Functional Amblyopia: Streff Syndrome. Behavioral Aspects of Vision Care, 2001; 42(1)

Journal of Optometric Vision Development, 1994; 25(2)

Harris P. The non-malingering syndrome: Catching it twice. Journal of Optometric Vision Development. 1999; 30:142-151. Retrieved from http://oepf.org/sites/default/files/THE_NON_MALINGERING_SYNDROM.PDF

Caughell S. Clinical diagnosis and management of Sreff Syndrome: A case report. Indiana Journal of Optometry. 2010; 13(1-2): 8-11. Retrieved from http://www.opt.indiana.edu/indjopt/pdf/ijosum10.pdf

Bruce B, Newman N. Functional visual loss. Neurologic Clinics Journal. 2010 Aug; 28(3): 789-802. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907364/

Bealty S. Non-organic visual loss. Postgrad Medical Journal. 1999; 75:201-7. Retrieved from http://pmj.bmj.com/content/75/882/201.full

Scott JA, Egan RA. Prevalence of organic neuro-ophthalmologic disease in patients with functional visual loss. American Journal of Ophthalmology. 2003 May; 135(5):670-5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12719075

Keltner JL, May WN, Johnson CA, et al. The California syndrome. Functional visual complaints with potential economic impact. Ophthalmology. 1985 Mar; 92(3):427-35. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3991130

Lim SA, Siatkowski RM, Farris BK. Functional visual loss in adults and children. Ophthalmology. 2005 Oct; 112(10): 1821-8. Retrieved from http://www.aaojournal.org/article/S0161-6420(05)00791-8/fulltext?refuid=S1529-1839(08)00285-6&refissn=1529-1839

Websites:

http://www.paulharrisod.com/non-malingering-syndrome

AAO posters:

http://www.aaopt.org/hysterical-amblyopia-and-vision-therapy

http://www.aaopt.org/streff-syndrome-case-report

Addressing Motion Processing Asymmetry in Essential Infantile Esotropia

VISION NORTHWEST
Jacob Dufour, OD | Curtis Baxstrom, MA OD

INFANTILE STRABISMUS



Addressing Motion Processing Asymmetry in Essential Infantile Esotropia


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
ESSENTIAL INFANTILE ESOTROPIA
MOST PREVALENT
form of developmental strabismus
40% of all strabismus
ONSET < 6 MONTHS
Usually emerges at 3-4 months of age
LARGE ANGLE ~30Δ
Similar angle at distance and near
TYPCIALLY ALTERNATING
Cross fixation pattern : amblyopia rare (7%)
HYPEROPIA < +3.00
Considered non-accommodative
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
INFERIOR OBLIQUE OVERACTION
73% Adducting eye deviates upward during right and left gaze
CROSS FIXATION
78% OD used for viewing left field
OS used for viewing right field
DISSOCIATED VERTICAL DEVIATION
59% Covered-eye deviates upward during monocular occlusion
LATENT NYSTAGMUS
80% Temporal beat nystagmus under monocular conditions
NASALWARD MOTION BIAS
85% Temporalward OKN absent and temporalward pursuits jerky
ASSOCIATED FINDINGS
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
VISUAL MOTION PROCESSING
Unaligned
Normal
Window for aligning motor neuron pool
Aligned
Delayed
Visual Pathways
Strabismus
Birth 1 2 3 4 5 6
Postnatal Months
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
INFANTILE STRABISMUS
Birth
3mo
6mo
3yr
CRITICAL PERIOD 3-6mo
motor fusion
temporalward motion processing
stereopsis
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS

MONOCULAR VIEWING



Nasalward Drift

Temporal Refixation



Nasalward motion asymmetry manifests as
LATENT NYSTAGMUS

ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS

MOTION PROCESSING ASSESSMENT

OKN DRUM Tested monocular
Drum at 30 cm
Rotate 20 cycles/min

T-N present | N-T reduced or absent

Tested monocular
Sinusoidal target **PURSUITS**

Nasalward:Smooth | Temporalward:Jerky

ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
ASSESSING ASSOCIATED FINDINGS
80%
LATENT NYSTAGMUS
Temporal beat nystagmus under monocular occlusion
78%
CROSS FIXATION
Hirschberg or Worth-4-Dot in left and right gaze
73%
INFERIOR OBLIQUE OVERACTION
Adducting eye deviates upward during right and left gaze
59%
DISSOCIATED VERTICAL DEVIATION
Opaque occluder : Occluded eye deviates upward during monocular occlusion
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
ESSENTIAL INFANTILE ESOTROPIA TREATMENT
BINASAL OCCLUSION
Promotes abduction
Inhibits cross fixation
Normal Visual Field
Binasal Visual Field
Reduces demand on binocular processing
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
MOTION ASYMMETRY THERAPY
NASALWARD ROTATIONS
Patch one eye
Slowly rotate toward patched side
TEMPORAL PURSUITS
Hand things to infant from either side instead of at midline
RED-GREEN MFBF
Red-green toys/blocks on black felt
Red-green puzzles boards
VERGENCE
Swing: Peek-a-boo
Fruit Loops on a straw
GENERAL ESOTROPIA THERAPY
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
CASE 1: MILD INTERMITTENT ESOTROPIA
8mo old male
INITIAL EXAM
Complaint: Eyes cross occasionally, becoming more frequent
Dry retinoscopy: +1.00 OU
CT: 6Δ IAET at distance and near
OKN: T-N (3+) / N-T (1+)
Lang: No stereopsis response
Tx: Emphasize temporal pursuits and monocular N-T rotations. Monitor 4 months
6 MONTH FOLLOW UP
Complaint: Eyes cross very rarely, mostly when tired
CT: 6Δ EP at distance and near
OKN: T-N (3+) / N-T (3+)
Lang: (+) stereopsis response
Tx: Emphasize temporal pursuits and monocular N-T rotations. Monitor 1 year
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

CASE 2: AVERAGE ESSENTIAL INFANTILE ET

18mo old male

INITIAL EXAM		6 MO. POST INITIAL EXAM
Complaint: Eyes cross, started before 6 months	Three follow up appointments incorporating home MFBF and adjusting binasals	*Complaint*: Eye turn rarely noted
Dry retinoscopy: +0.50 OU *CT*: 30Δ CAET (OD>OS) at distance and near *OKN*: T-N (3+) / N-T (1+) *Lang*: No stereopsis response		*CT*: 10Δ EP at distance and near *OKN*: T-N (3+) / N-T (3+) *Lang*: 400"
Tx: +0.50 OU with binasals, emphasize temporal pursuits and monocular N-T rotations		*Tx*: Continue binasals. Monitor 2 months.

ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

CASE 3: EIET WITH COMPLICATIONS

5mo old female

INITIAL EXAM	6 MONTHS POST INITIAL EXAM		23 MONTHS POST INITIAL EXAM
Complaint: Eyes crossing soon after birth, constant *Hx*: Down syndrome	*Complaint*: Eyes crossing 20% of time when using SRx	Two craniosacral manipulations performed.	*Complaint*: Eye turn rare. Last craniosacral manipulation 5 months prior.
Wet retinoscopy: +2.00 OU *CT*: 20Δ CAET (OD>OS) at distance and near *EOM*: 4- bilateral abduction deficits (0°) *OKN*: T-N (3+) / N-T (0) *Lang*: No stereopsis response	*CT*: 20Δ CAET (OD>OS) at distance and near *Abduction*: OD: 10° from midline OS: 30° from midline *N-T OKN*: OD: 2+ OS: 3+	Improvement of abduction, but ET and OKN asymmetry remain.	*CT*: Dist - Ortho Near - 6Δ EP *Abduction*: OD: 40° from midline OS: 40° from midline *N-T OKN*: OD: 3+ OS: 3+
Tx: Doll's eye, binasals, emphasize temporal pursuits, and monocular N-T rotations	*Tx*: Referral for craniosacral manipulation (DO)		*Tx*: Monitor 3 months

ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
INFANTILE STRABISMUS
Birth
3mo
6mo
3yr
CRITICAL PERIOD 3-6mo
motor fusion
temporalward motion processing
stereopsis
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA


INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS
SENSORY MECHANISMS
CORTICAL
Maldevelopment of cortical binocular cells in:
Visual Cortex (V1-4b)
Middle Temporal Visual Area
Medial Superior Temporal Visual Area
Corpus Callosum
CORTICAL-SUBCORTICAL
Maldevelopment of connections from cortex to subcortical:
Pretectal Nucleus of the Optic Tract (NOT)
Accessory Optic System (Dorsal Terminal Nucleus)
NOT-DTN
LGN
SCC
MST
MT
L
R+L
R
V1
ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

PROPOSED MECHANISM

65%
CN6 biforcated by cranial ligaments

95%
Abduction deficits (often subclinical)



INFANTILE STRABISMUS | ESSENTIAL INFANTILE ESOTROPIA | VISUAL MOTION PROCESSING | ASSESSMENT AND TREATMENT | CASE SERIES | THEORIZED MECHANISMS

PROPOSED MECHANISM



ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

REFERENCE

Ansons, A. and Davis, H. (2014). Infantile Strabismus and Dissociated Strabismus Complex. Diagnosis and Management of Ocular Motility Disorders, Fourth Edition. pp.380-401

Brodsky, M. (2012) An Expanded View of Infantile Esotropia Bottoms Up! Arch Ophthalmol. 130(9):1199-1202.

Brodsky, M. (2012). The Accessory Optic System: The Fugitive Visual Control System in Infantile Strabismus. Arch Ophthalmol. 130(8):1055-1058

Brodsky, M and Klaehn, L. (2013). The Optokinetic Uncover Test: A New Insight Into Infantile Esotropia. JAMA OPHTHALMOL; 131 (6)

Bui Quoc, E. and Milleret, C. (2014). Origins of strabismus and loss of binocular vision. Frontiers in Integrative Neuroscience, 8

Calcutt, C. (1993). Infantile Esotropia: Current Concepts in Aetiology and Management. Br Orthopt J; 50: 37

Gallegos-Duarte, M. (2005). Stigma and origin of congenital esotropia. Rev Mex Oftalmol; 79 (1): 10-16

Norcia, A; Hamer, R; Jampolsky, A; Orel-Bixler, D. (1995) Plasticity of human motion processing mechanisms following surgery for infantile esotropia Vision Res; 35 (23-24), pp. 3279-3296

Tychsen, L. (2013). Why do humans develop strabismus? Pediatric Ophthalmology and Strabismus

Tychsen, L. (2007). Transactions of the American Ophthalmological Society;105: pp.564-93

Tychsen, L. (1993). Motion sensitivity and the origins of infantile strabismus. Early visual development, normal and abnormal, Oxford University Press, New York, pp. 364-390

ADDRESSING MOTION PROCESSING ASYMMETRY in ESSENTIAL INFANTILE ESOTROPIA

Vision Rehabilitation with the Cortically Blind Patient

Charlotte Forgie, OD
Pediatric and Vision Rehabilitation Resident
Bruce Wojciechowski, OD, FCOVD
Northwest Eye Care Professionals, Clackamas, OR

Learning Objectives

By the end of the presentation, attendees will be better able to:

- Understand the challenges associated with examination and visual rehabilitation of cortically blind patients.
- Recognize the potential for dramatic functional improvements regardless of permanent visual limitations.
- Recognize which values on a VEP/ERG printout are of note and distinguish what is a normal reading and what is abnormal.
- Identify useful and therapeutic activities that may be prescribed for rehabilitation of patients who have experienced a traumatic brain injury.

Introduction

- MW, a 36 year old male presents for a neuro-optometric evaluation following an anoxic brain injury. His injury occurred approximately 9 months prior.
- He suffered the anoxic brain injury when he was stabbed in the heart during a bar fight. He reports his heart was stopped for 10 minutes.

Symptoms

- Very blurred central vision. Peripheral vision has improved but is still very blurry, like "white snow on TV"
- Experiences headaches and eye strain when tired. Cannot read because print is too small.
- Headaches are on the bridge of his nose and behind it.
- Double vision
- Concurrently doing OT, PT and classes with OR Commission for the blind
- Uses a CCTV and pocket magnifier

Symptoms

- Frustration and stress
- Low self-esteem
- Disoriented in crowds
- Difficulty judging distances when reaching for objects
- Frequently bumps into things

Exam Findings (3/12/2015)

- Acuities

OD: HM at 5', able to Count fingers with peripheral viewing at about 4'

OS: HM at 5', only HM in periphery, no CF

- EOM: full, no restrictions OD/OS
- Cover Test: Ortho at Distance and Near
- NPC: 20cm
- Pursuits: full
- Saccades: unable to test
- Attempted Worth Dot: unable to see 2 lights, reports light looks white
- Anterior and Posterior Health were unremarkable

Visual Evoked Potential



Figure 2. A normal pattern reversal VEP.

What is normal?
For a 32x32 stimulus, 85%
Amp=6uV or greater
Latency=95-117ms
(Diopsys)

- **Visual Evoked Potential** is an objective way to measure the function of the visual system beyond the retinal ganglion cells

- Stimulus Variables:

-Check size or flash

-Contrast

-Orientation (bars or squares)

Check sizes

16x16 85%



32x32 15%

64x64 85%



Visual Evoked Potential

1st-VEP
March 26, 2015



Parameters	OD	OS	Difference	Remarks
Amplitude Low Contrast µV	5.6	7.0	1.5	
Amplitude High Contrast µV	20.8	10.1	10.7	
Latency Low Contrast ms	122.1	128.9	6.8	Borderline Delayed
Latency High Contrast ms	159.2	137.7	21.5	Both Delayed



15% (low contrast) –No P100 or N75
85% (high contrast)-good reading, normal amplitudes, delayed latencies



	T=15-P=16 x 16-OU-15%-C-3/26/2015 2:08:04 PM	T=15-P=16 x 16-OU-20%-C-3/26/2015 2:09:02 PM	T=15-P=16 x 16-OU-85%-C-3/26/2015 2:09:29 PM	T=15-P=32 x 32-OU-20%-C-3/26/2015 2:11:28 PM	T=15-P=64 x 64-OU-15%-C-3/26/2015 2:12:26 PM	T=15-P=64 x 64-OU-20%-C-3/26/2015 2:12:53 PM	T=15-P=64 x 64-OU-85%-C-3/26/2015 2:13:51 PM	T=15-P=32 x 32-OU-85%-C-3/26/2015 2:11:55 PM
Left Cursor Lat	70.3 ms	106.4 ms	109.4 ms	97.6 ms	111.3 ms	118.2 ms	80.1 ms	110.3 ms
Amp	-1.80 uV	-1.84 uV	-6.86 uV	-1.09 uV	-1.65 uV	-0.27 uV	0.07 uV	-4.95 uV
Right Cursor Lat	103.5 ms	143.5 ms	156.2 ms	125.0 ms	141.6 ms	145.5 ms	114.3 ms	157.2 ms
Amp	8.17 uV	6.98 uV	23.05 uV	6.43 uV	7.36 uV	4.57 uV	5.62 uV	12.17 uV
Eye	OU	OU	OU	OU	OU	OU	OU	OU
Test Duration	15 sec	15 sec	15 sec	15 sec	15 sec	15 sec	15 sec	15 sec
Pattern	Checkerboard	Checkerboard	Checkerboard	Checkerboard	Checkerboard	Checkerboard	Checkerboard	Checkerboard
CheckSize	16 x 16	16 x 16	16 x 16	32 x 32	64 x 64	64 x 64	64 x 64	32 x 32
Correction	Y	Y	Y	Y	Y	Y	Y	Y
Sensor Value	118	113	121	129	120	132	130	128
Sensor Threshold	140	140	140	140	140	140	140	140
Operator Name	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany	Ly,Tiffany
Waveform	VEP	VEP	VEP	VEP	VEP	VEP	VEP	VEP

1st-VEP
March 26, 2015



2nd VEP
April 20, 2016



Figure 2. A normal pattern reversal VEP.





2nd VEP
April 20, 2016

	T=15-P=16 x 16-OU-85%-C-4/20/2016 1:01:38 PM	T=15-P=16 x 16-OU-20%-C-4/20/2016 1:09:32 PM	T=15-P=16 x 16-OU-15%-C-4/20/2016 1:10:12 PM
Left Cursor Lat	116.2 ms	104.5 ms	58.6 ms
Amp	-5.30 uV	-0.90 uV	3.02 uV
Right Cursor Lat	**148.4 ms**	**130.9 ms**	**89.8 ms**
Amp	10.83 uV	10.58 uV	9.59 uV
Delta Lat	32.2 ms	26.4 ms	31.2 ms
Amp	**16.12 uV**	**11.48 uV**	**6.57 uV**
Artifacts	3	1	1
Eye	OU	OU	OU
Test Duration	15 sec	15 sec	15 sec
Pattern	Checkerboard	Checkerboard	Checkerboard
CheckSize	16 x 16	16 x 16	16 x 16
Correction	N	N	N
Sensor Value	128	127	127
Sensor Threshold	140	140	140
Operator Name	Forgie,Charlotte	Forgie,Charlotte	Forgie,Charlotte
Waveform	VEP	VEP	VEP



		T=15-P=16 x 16-OU-85%-C-3/26/2015 2:09:29 PM	T=15-P=16 x 16-OU-20%-C-3/26/2015 2:09:02 PM	T=15-P=16 x 16-OU-C-3/26/2015 2:00:
Left Cursor	Lat	109.4 ms	106.4 ms	78.1 ms
	Amp	-6.86 uV	-1.84 uV	-1.80 uV
Right Cursor	Lat	156.2 ms	143.5 ms	103.5 ms
	Amp	16.19 uV	5.14 uV	6.57 uV
Delta	Lat	46.9 ms	37.1 ms	33.2 ms
	Amp	23.05 uV	6.98 uV	8.17 uV

		T=15-P=16 x 16-OU-85%-C-4/20/2016 1:01:38 PM	T=15-P=16 x 16-OU-20%-C-4/20/2016 1:09:32 PM	T=15-P=16 x 16-OU-15%-C-4/20/2016 1:10:12 PM
Left Cursor	Lat	116.2 ms	104.5 ms	58.6 ms
	Amp	-5.30 uV	-0.90 uV	3.02 uV
Right Cursor	Lat	148.4 ms	130.9 ms	89.8 ms
	Amp	10.83 uV	10.58 uV	9.59 uV
Delta	Lat	32.2 ms	26.4 ms	31.2 ms
	Amp	16.12 uV	11.48 uV	6.57 uV

Vision Disk

- Right field: 95-35
- Left field: 40-95

Visual Field

Left



Right



Vision Therapy-Sensorimotor Exam

- 8/12/2015

-most standardized testing font was too small

-Pursuits: slight movement of head with significant re-fixations

-Saccades: intermittent movement of head and body with moderate undershooting

Stereo-unable to detect depth

VTS4 Ranges-unable

Sensorimotor Exam

- Near Point of Convergence (target-blue ball about the size of 2 fists)-11 feet
- MVPT <1st percentile, leans in very close to material with searching head movement, 45 minutes

Vision Therapy

- 1st session:

Pencil Pushups (large target)-able to converge today, has been practicing at home with his phone. Reports he has to work to keep his eyes converged, can converge up to 8cm.

Large Target Pursuits- jumpy, OD better than OS

Home Vision Therapy Activities

- Large target pursuits/saccades and pushups
- OKN strips app

Vision Therapy

2nd visit

- Double vision is closer together than last session
- Reports watching OKN strips for 15min per day 2 times a day. He says it seems to have made both his central and peripheral vision more clear
- Lora's card-reports everything is moving on the sides, when he points to a letter it is just a guess



Office Therapy Activities

…over the next 8 weeks….

- Sanet Vision Integrator

-Eye hand

>proactive

>reactive

-Rotator

-Tachistoscope



Saccades



Tachistoscope



Rotator



Office Therapy Activities



- Prism Pops
- "Pencil" Push-ups
- Visual Thinking and Sequential Movement
- Eye-Hand/Eye-Body Coordination Activities
  - Bean Bag Sequence (Belgau)
  - Tootie Launcher
  - Parquetry



- Tootie launcher

Home Therapy Activities-first 8

- Enlarged Lora Card
- Anti-suppression with RG Glasses
- 4 corner saccades*
- OKN Strips
- Large target pursuits/saccades/pushups

Subjective improvements

- **9/21** He feels like the static is calming down. The static area is not as large as it used to be. He has been doing 4 corner saccades everywhere and it is going well. He can make his vision more clear by focusing harder on it. He noticed it after using the OKN stripes and doing the 4 corner saccades, his vision is "way better than it was before".
- **9/28**-He is doing his homework and feels like he is getting faster visually. He is able to pull back his fusion if he is seeing double. Sometimes he sees 4 but he can bring in back to one.
- **10/26**- He is taking a woodworking class and loving it. He is trying to concentrate less on using his peripheral vision and trying to use his central vision more. He has really noticed great improvements in his vision.

Progress Exam 1 October 29, 2015

	SME 8/12/15	10/26/15
Convergence	20 cm at exam, 11feet at SME	Motor movement to nose with larger target
Pursuits	Slight movement of head, significant re-fixations	No head movement, much fewer re-fixations
Saccades	Intermittent slight movement of head and body and mild undershooting	No head movement, consistently hypometric but much more accurate
Large X's and O's (1.7 cm)		Accuracy better when not timed 2.27 min. no magnifier, 3.45 min. with magnifier.

Progress Exam 1

Doctor's Notes:

Pursuits-full in right gaze, cannot follow target smoothly into left field

Saccades-searching motion

NPC-6 cm

Assessment:

Large Improvement in Pursuits and Saccades, CI much improved with VT

Plan:

New spec rx for mild myopia-patient reported improved clarity and comfort with trial frame.

Patient and wife educated about huge improvements. Continue with VT.

Short term goal: able to complete pursuits with cardinal eccentric fixation points.

Long term goal: better aware of space and vision.

PE every 8 sessions or PRN

Office Therapy Activities-next 8

- Sanet Vision Integrator

  -same activities, smaller targets, adding balance board, cognitive loading
- Marsden Ball Pursuits/Convergence/Bunting
- Prism Pops-gradually increasing prism amount
- Belgau Bean Bag Protocol

Office Therapy Activities-next 8

- VTS4
  - Able to do flat fusion, no float
  - Not able to do RDS, even when enlarged
- Visual Thinking and Sequential Movement-trying to improve speed
- Bilateral Circles/Lazy 8's on whiteboard
- Parquetry
- Hart Chart Saccades (with projected chart)

Home Therapy Activities-next 8

Pencil pushups/pursuits/saccades - OU/OD/OS

Pursuits in all areas of gaze-focusing more on vertical and oblique

OKN Strips app

Enlarged Lora card

10^ BO BI prism to use for BO/BI to fuse

Anti-Suppression using R/B glasses

4 corner Saccades

Parquetry

Progress Exam #2 Feb. 10 2016

	SME 8/12/15	10/26/15	1/18/16
Convergence	20 cm at MU II, 11feet at SME	Motor movement to nose with larger target	Motor movement to nose with larger target
Pursuits	Slight movement of head, significant re-fixations	No head movement, much fewer re-fixations	Horizontal- mostly smooth. Vertical- some jumps ahead. Obliques- mostly smooth to start then had some jumps ahead
Saccades	Intermittent slight movement of head and body and mild undershooting	No head movement, consistently hypometric but much more accurate	Started hypometric but smoothed out as he better located target.
Large X's and O's (1.7 cm)		Accuracy better when not timed 2.27 min. no magnifier, 3.45 min. with magnifier.	Without magnifier- 3:27 min. & 9 errors With magnifier- 4:03 min. 1 error, 1 skipped line
DEM- modified			V-34sec.5substitutions H- 87 sec. 1 skipped line & 7 errors
Modified Davis Visual Scan			13/15 O's (2 min.)



Progress Exam 2

Doctor's Notes:

Saccades: fast and accurate

NPC 4 cm

Trial yoked prism

Assessment: Continued improvement in saccades/pursuits and convergence with vision therapy.

Plan:

Educated about stability in findings regarding visual field defect. Continue with habitual specs. Consider trying VF at next PE

Educated patient and wife about huge improvements. Continue with VT. Has met previous short and long term goals.

Keep going to VT with until the results are maximized and no improvement is noticed with PE.

PE every 8 sessions or PRN

Progress Exam #3 April 20, 2016

	SME 8/12/15	1/18/16	4/4/16
Convergence	20 cm at MU II, 11feet at SME	Motor movement to nose with larger target	Equal convergence to nose OU, no diplopia reported
Pursuits	Slight movement of head, significant re-fixations	Horizontal- mostly smooth. Vertical- some jumps ahead. Obliques- mostly smooth to start then had some jumps ahead	Great improvement in smooth pursuits in all directions. Does not seem to need to fixate eccentrically as much as he used to.
Saccades	Intermittent slight movement of head and body and mild undershooting	Started hypometric but smoothed out as he better located target.	Mostly accurate. Distraction caused hypometric to return but not for long
Large X's and O's (1.7 cm)		Without magnifier- 3:27 min. & 9 errors With magnifier- 4:03 min. 1 error, 1 skipped line	Without magnifier- 4min 4 sec. 4 errors. No skipped lines
DEM-modified		V-34sec.5substitutions, 12 letters H- 87 sec. 1 skipped line & 7 errors (27 letters)	On chalkboard- V- 19 sec (12 letters) H- 48 sec. 27 letters. (3 substitutions)
Modified Davis Visual Scan		13/15 O's in 2 min.	14/15 O's in 1 minute

Modified Davis





Progress Exam 3

Doctor's Notes:

Pursuits-fast with mild intrusions

Saccades-fast and accurate

Assessment: Continue to see improvements with VT

Plan:

Educated patient and wife about huge improvements. Continue with VT. New goal: work with prism (sticks) to see if we can 'learn' how to get the 'lock' he noticed with BO prism in office. Keep going to VT with until the results are maximized and no improvement is noticed with PE.

PE every 8 sessions or PRN

How Has Vision Therapy Changed Things?

- " Getting around the house and even in the world is better. I am able to see cars now a little bit and be more aware of them, before I felt like I couldn't see them. I have increased awareness of them and I feel like I can see more details. "
- "My field of vision has always been better on the right and really grainy on the left, worst in the center. Since VT I was able to realize what the center of my vision is (happens to be where it's the worst). As soon as I realized that I could fixate, I could keep focus on a ball or anything. Since that happened everything started to come back. It's a lot better. Now that I know what my central vision is I don't have to try to focus on it so much. I can pay more attention to the sides of my vision."

May 23, 2016

How Has Vision Therapy Changed Things?

- "Even just the requirement to physically get myself to vision therapy has been helpful. It has helped me to be more confident and I can go places by myself using public transit.
- Before I started vision therapy I felt like I was seeing double or even quadruple, but after a few weeks I started to see singly and that has helped a lot. I feel much more confident now."

How Has Vision Therapy Changed Things?

- "Between Oregon Commission for the Blind and Vision Therapy, you guys have given me a huge part of my life back. Parts that I never thought I would get back. "

Thank you!

Violet and Murdoch

References

- Extra-powerful on the visuo-perceptual space, but variable on the number space: Different effects of optokinetic stimulation in neglect patients
- Marco Pitteri[1], Georg Kerkhoff[2,3], Ingo Keller[4], Francesca Meneghello[1] and Konstantinos Priftis[1,5,*] Article first published online: 22 AUG 2014 Journal of Neuropsychology
- Volume 9, Issue 2, pages 299–318, September 2015
- http://onlinelibrary.wiley.com.proxy.lib.pacificu.edu:2048/doi/10.1111/jnp.12051/full
- Optokinetic nystagmus during selective retinal stimulation **Article** Experimental Brain Research August 1975, Volume 23, Issue 2, pp 129-139.
- Cortical blindness with absent visually evoked potential in non-ketotic hyperglycemia
- Indian J Ophthalmol. 2008 Jan-Feb; 56(1): 88–89. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636067/
- Visually Evoked Potentials..Creel DJ.: Kolb H, Fernandez E, Nelson R, editors. Source:Webvision: The Organization of the Retina and Visual System [Internet]. Salt Lake City (UT): University of Utah Health Sciences Center; 1995-. 2012 Mar 01
- Clinical Utility of Evoked Potentials: Author: Andrew B Evans, MD; Chief Editor: Selim R Benbadis, MD Source: http://emedicine.medscape.com/article/1137451-overview#a1
- The multi-disciplinary nature of low vision rehabilitation – A case report
- Michelle Markowitza,*, Rachel E. Markowitza and Samuel N. Markowitzb, Work 39 (2011) 63–66 63, DOI 10.3233/WOR-2011-1151
- Temporal sensitivity in a hemianopic visual field can be improved by long-term training using flicker stimulation. **A Raninen**, **S Vanni**, **L Hyvärinen**, and **R Näsänen**.J Neurol Neurosurg Psychiatry. 2007 Jan; 78(1): 66–73. Published online 2006 Sep 4. oi: **10.1136/jnnp.2006.099366** Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117780/
- The ABCs of Electrophysiology, Diopsys Manual



Retinoschisis

Clinical Pearls and Differentiation from Retinal Detachment

Karisa Etter, O.D.

Retinoschisis

- Presence of fluid filled cavity separating two retinal layers, uniform inner surface without folds
- Peripheral : degenerative, acquired, or senile
- Inferior temporal periphery, usually bilateral, reported as 50-82% [5,7]
- Low elevation of inner retina or
- Very elevated thin, transparent inner wall with blood vessels



Peripheral Retina

- Single layer of ganglion cells
- Glial cells: Muller, astrocytes, micoglia
- Outer plexiform layer: synaptic layer, photoreceptors make connections with bipolar and horizontal cells of inner nuclear layers.
- Retinal arteries are within the nerve fiber layer



Pathophysiology

- Confluence of **micro cysts** in the periphery
- Break down of neuroretinal and glial support tissue in areas of peripheral cystoid degeneration
- Flat (Typical) schisis:
  - inner layer:
    - inner limiting membrane, retinal vessels, and inner plexiform layer
  - Outer layer:
    - outer plexiform layer, outer nuclear layer, and photoreceptors
- Bullous (Reticular) schisis:
  - Thin inner wall :
    - inner limiting membrane, nerve fiber layer, attenuated blood vessels, disrupted ganglion cell layer and INL



Peripheral retinal degenerations and the risk of retinal detachment**,** Original Research Article, *American Journal of Ophthalmology*, *Volume 136, Issue 1, July 2003, Pages 155-160*, Hilel Lewis

Epidemiology

- More common in hyperopes
- 7% prevalence in people over 40
- 3.4% in another study in persons 60-80 with no gender predilection. [5]
- Peak incidence in males 50-60, females 60-70 [3]
- 44.4% in inferior temporal quadrant of retina

Associated Findings

- **Beaten metal** appearance of inner layer [7]
- **Snowflake** degeneration, flecks that are more opaque, remnants of glial pillars, present in 70% of schisis [7]
- **Micro cystic** degenerations
- **Absolute vision defect** in the area of the schisis
- **Sclerosed** or attenuated inner layer blood vessels





Retinal Detachment

- Separation of sensory retina from RPE by fluid
- **Rhegmatogenous**-caused by retinal break
  - Peripheral retinal degeneration, PVD
    - Lattice, snailtracking, white without pressure
  - 1:10,000 annual incidence
  - Complication of cataract surgery
    - Predisposition to multiple breaks in the far periphery
  - Increasing floaters or photopsias, visual field defect
  - Longstanding will develop pigmentation* lines and changes to RPE

- Non-rhegmatogenous-tractional or exudative
  - Retinal neovascularization; Diabetic tractional RD
  - Exudative: choroidal lesions, inflammation, Iatrogenic, central serous
  - **Retinoschisis causes <2.5% of retinal detachments**

Cases One and Two

- 48 year old Caucasian male
- BCVA 20/20 OU
- Posterior Pole & Periphery:
  - OD: superior temporal bullous retinoschisis , superior temporal linear intra-retinal heme
  - OS: inferior temporal, flatter retinoschisis without breaks or holes OU
- 69 year old Caucasian male
- BCVA 20/20 OU
- Posterior Pole and Periphery:
  - OD: bullous retinoschisis superior temporally and inferotemporally
  - OS: bullous retinoschisis, flatter retinoschisis superior temporal periphery

Case One





Case Two



Case Two



Additional Tests

Scleral Depression

- Retinal detachment will flatten as fluid will be forced into the vitreous space though the retinal break, this may or may not be apparent dependent on extent of detachment
- Schisis will not flatten with scleral depression, unless significant inner layer holes are present

Visual Field

- Retinoschisis will have an **absolute visual field** defect secondary to splitting of neurosensory retina
- Detachment keeps the integrity of the neurosensory retina even when separated from the RPE so a **relative field defect** is common
- Longstanding detachments may show absolute defects making diagnosis based on the visual field alone very difficult. [6]

Schisis Complications

Posterior Progression

Retinal breaks; inner and outer layers

Schisis detachment

Retinal detachment

Posterior Progression

- Retinoschisis may **enlarge** over time, either in height, width laterally, or move posteriorly, towards the posterior pole
- This only occurs in a very small number of cases, 3-6% [4]
- Very few documented cases of enlargement reaching or involving the macula
- Risks vs. benefits of treating a posteriorly enlarging schisis need to be weighed carefully

Inner and Outer Layer Breaks

- Inner layer breaks: little significance, fluid can move freely from inside schisis to vitreous
- **Outer layer breaks are more consequential**, possibly leading to detachment
- Prevalence of outer layer breaks : 11-24% [1,4]
- Of the eyes with outer layer breaks, ~60% develop a detachment. [4]
- Detachment: schisis area only, or become a retinal detachment

Inner and Outer Layer Holes



Fig. 3.—Schematic cross section of a senile retinoschisis—(*a*) sclera; (*b*) choroid; (*c*) retina. On the left, the inner layer of the retinoschisis shows white flecks (*d*), sheathed peripheral retinal vessels (*e*), and round retinal holes (*f*). The outer layer shows a retinal tear with rolled edge (*g*). On the right, the retinoschisis is complicated by retinal detachment.

Schisis Detachment

- Movement of intracystic fluid from the schisis to underneath the retina via an outer retina break
- Low risk of progression beyond the area of the schisis
- Finite amount of cystic fluid to occupy the space beneath the retina, with small breaks, **very low risk of extension beyond the schisis border.**
- 178:1, non progressive to progressive retinal detachment requiring treatment [1,4]
- To identify a detachment underlying a schisis:
  - **Outer retinal break must exist**
  - Uneven elevation or texture of the schisis. Transparency may be variable across the area.
  - Pigmentation line**. This occurs when there is detachment of the outer layer chronically.

Retinal Detachment

Occurs in 0.05% of cases, 1:2000 [4]

2.2% in another study, although cases had cataract extraction [5]

Both inner and outer layer breaks, or just outer layer breaks (schisis detachment progression)

Treatment has been shown to be very successful. May include scleral buckle or cryo.

73.7% of schisis remained unchanged in 14 year follow up [5]

Resolution can occur spontaneously in 2-9% of schisis [5]

Recommendations

- **Only treat progressive, symptomatic retinal detachments**
- Prophylactic treatment is not recommended,
  - 1.2-13% of cases where prophylactic treatments (barrier laser) was given developed a retinal detachment.
  - New retinal breaks or vitreous hemes
  - Posterior progression commonly stops spontaneously.
  - Macular involvement is exceedingly rare
- Follow schisis(+/- outer retinal holes or limited retinal detachment) periodically with instructions to RTC should they become symptomatic.

Peripheral retinal degenerations and the risk of retinal detachment**,** Original Research Article, *American Journal of Ophthalmology, Volume 136, Issue 1, July 2003, Pages 155-160,* Hilel Lewis

Case Three

- 70 year old Caucasian male
- Ocular history includes cataract extraction with IOL OU in 2012, second IOL implant OD few months later for refractive purposes.
- BCVA: 20/20-1 OD, 20/25-2 OS
- Periphery:
  - OD: pigmented lattice superior/inferior; **shallow peripheral retina elevation superior nasal with light line of pigmentation at border, no retinal holes or tears apparent with scleral depression**
  - OS: lattice degeneration infer/temp; No retinal holes, tears or detachment

Case Three

- Detachment
  - Faint pigment demarcation line*
  - Superior nasal location (13%) [5]
  - Not present in other eye
  - Lattice present elsewhere
  - h/o cataract surgery
- Schisis
  - Mild taut elevation
  - ? Beaten metal appearance
  - Asymptomatic for photopsias
  - **No breaks, holes, or tears**



Retina Consult:
No breaks, holes, or tears found with scleral depression 360
Diagnosis: **Focal retinoschisis OD**

Further Testing

- Laser Photocoagulation
- Indirect ophthalmoscope perimetry
- B-scan Ultrasonography
- Peripheral OCT

Laser Photocoagulation

Detachment: blanching on the inner layer of detached retina or the underlying RPE.

Retinoschisis: blanching of the outer layer (still in contact with the RPE)

Later (1977) shown to not be definitive because blanching could be reproduced in retinal detachment patients, and directly on the retinal pigment epithelium.

Indirect ophthalmoscope perimetry

Scleral depressor, or similarly sized/shaped object while performing indirect ophthalmoscopy on the area of the elevation

The patient is asked if they can see a shadow of the object and subjectively responds 'yes' or 'no'

This exploits the visual field defect differences between a schisis and a detachment in that the patient should see the shadow with a detachment, and should not with a schisis

Very subjective test

Ultrasound

Ultrasound biomicroscopy

- can recognize bi-layered hyper-reflective echoes

Dynamic scleral depression with B-scan ultrasonography

- to observe for re-apposition of the retina in a detachment.[12]

High resolution B-scan ultrasonography

- conclusively distinguish RS from RD.
- Situations : interference or light scatter from media opacities, far peripheral lesions
- Three distinct retinal interfaces as brighter lines, RNFL, outer plexiform layer, and RPE.

High Resolution B-Scan



Fig. 1 Imaging of a normal subject using high-resolution ultrasound B-scan (with eyelids open) allows identification of three distinct hyper-reflective lines from the vitreous to the scleral side. The first line (starting from the vitreous aspect) represents the retinal nerve fiber layer (RNFL) interface (blue arrowheads), followed by the outer plexiform layer (OPL) (white arrowheads) and the retinal pigment epithelium (RPE) (yellow arrowheads). The black stars denote the sclera. The optic nerve is labeled as ON



Fig. 4 High-resolution ultrasound (USG) B-scan of eyes with (A) RS and (B) RD. Panel A shows that eyes with RS demonstrate a thin single hyper-reflective line representing the RNFL interface (blue arrowhead) in the split inner retina. The schisis cavity is marked by a blue asterisk. The OPL and RPE interfaces are shown with a white and yellow arrowhead, respectively. Panel B shows that eyes with RD demonstrate the presence of two hyper-reflective lines representing the RNFL and OPL interfaces (blue and white arrowheads) in the detached portion of the retina. The red asterisk marks the subretinal space overlying the RPE interface, which is attached (yellow arrowhead)

Characterization of retinal structure and diagnosis of peripheral acquired retinoschisis using high-resolution ultrasound B-scan, A. Agarwal, S. Fan, A. Invernizzi, *Graefes Arch Clin Exp Ophthalmol* (2016) 254:69–75, DOI 10.1007/s00417-015-3013-3

OCT

- Spectral Domain Optical Coherence Tomographer
  - Study with 11 patients with uncertain diagnosis of RD vs RS
  - Definitively diagnose 4 with schisis and 7 with a detachment
  - 18 patients with a diagnosis of schisis based on ophthlamoscopy alone, 15 were confirmed, 3 showed subretinal fluid not limited to the area of the schisis
  - **Detachment; full thickness detached retina and smooth RPE**
  - **Schisis shows a thin inner layer, bridging fibers connecting the retinal layers, and an irregular outer retinal layer** [6]





Take Home Points

Senile retinoschisis has a low likelihood of progression or detachment

Generally safe to monitor periodically for changes or symptoms

Can usually distinguish between schisis and detachment with ophthalmoscopy alone based on clinical appearance

Smooth, transparent, bullous elevation of inner retina

Retinal pigment changes and pigment demarcation lines, tears/breaks, folds in bullous tissue

OCT is the Gold Standard for differentiating a retinoschisis from a retinal detachment. A high-resolution B scan (if available) can also provide conclusive diagnosis.

References

1. Peripheral retinal degenerations and the risk of retinal detachment, Original Research Article, *American Journal of Ophthalmology, Volume 136, Issue 1, July 2003, Pages 155-160*, Hilel Lewis
2. The Pathologic Anatomy of Retinoschisis, With a Report of Two Cases Diagnosed Clinically as Malignant Melanoma, L. E. ZIMMERMAN, M.D., and W. H. SPENCER, M.D., Washington, D.C., *AMA Arch Ophthalmol.* 1960;63(1):10-19. doi:10.1001/archopht.1960.00950020012002.
3. Retinoschisis I. Senile Type: A Clinical Report of One Hundred Seven Cases, M. SHEA, M.D.; C. L. SCHEPENS, M.D., and S. R. VON PIRQUET, M.D., Boston, *AMA Arch Ophthalmol.* 1960;63(1):1-9. doi:10.1001/archopht.1960.00950020003001
4. Perspectives on the management of the complications of senile retinoschisis, N E Byer, *Eye* (2002) **16**, 359–364. doi: 10.1038/sj.eye.6700191
5. Prevalence and Long-term Natural Course of Retinoschisis among Elderly Individuals: The Copenhagen City Eye Study, H. Buch, T. Vinding, N. Nielson, *Ophthalmology, Volume 114, Issue 4, April 2007, Pages 751-755,* doi:10.1016/j.ophtha.2006.08.039
6. Stehouwer, M., Tan, S. H., van Leeuwen, T. G. and Verbraak, F. D. (2014), Senile retinoschisis versus retinal detachment, the additional value of peripheral retinal OCT scans (SL SCAN-1, Topcon). Acta Ophthalmologica, 92: 221–227. doi: 10.1111/aos.12121
7. Byer NE. Clinical Study of Senile Retinoschisis. *Arch Ophthalmol.* 1968;79(1):36-44. doi:10.1001/archopht.1968.03850040038012.
8. Anatomy and Physiology of the Retina, G.D. Hildebrand, A. R. Fielder, J. Reynolds and S. Olitsky (eds.), Pediatric Retina, 39, DOI: 10.1007/978-3-642-12041-1_2, © Springer-Verlag Berlin Heidelberg 2011
9. Retinal Detachment, Dr. Seemant Raizada, MBBS, MS, DNB, FRCEd, vitreo retinal surgeon, http://slidegur.com/doc/1187711/retinal-detachment-lecture
10. D'Amico DJ. Clinical practice primary retinal detachment. N Engl J Med 2008; 359(22): 2346–2354.
11. Michael Ip, Carlos Garza-Karren, Jay S Duker, Elias Reichel, Joseph C Swartz, Arezo Amirikia, Carmen A Puliafito, Differentiation of degenerative retinoschisis from retinal detachment using optical coherence tomography, Ophthalmology, Volume 106, Issue 3, 1 March 1999, Pages 600-605, ISSN 0161-6420, http://dx.doi.org/10.1016/S0161-6420(99)90123-9.
12. Imaging in Retinoschisis; Modalities including OCT and widefield photography can help distinguish retinoschisis from other entities., Aleksandra V. Rachitskaya, MD, Retina Today, November/December, 2015 , http://retinatoday.com/2015/12/imaging-in-retinoschisis/
13. Characterization of retinal structure and diagnosis of peripheral acquired retinoschisis using high-resolution ultrasound B-scan, A. Agarwal, S. Fan, A. Invernizzi, *Graefes Arch Clin Exp Ophthalmol* (2016) 254:69–75, DOI 10.1007/s00417-015-3013-3

INJECTING KNOWLEDGE INTO YOUR OPTOMETRIC PRACTICE

SEVERAL CASES WITH INTRAVENOUS FLUORESCEIN ANGIOGRAPHY

Rachel Kurohara, O.D.
Resident
Jonathan M. Wainwright Memorial VA Medical Center 2015-2016
Walla Walla, WA

DISCLOSURE

There are no financial interests, arrangements, or affiliations with either organizations mentioned later in this presentation.

OBJECTIVES

- Be able to discriminate several fluorescein patterns on IFVA
- Brief understanding of how new IV-less optometric equipment obtain an angiogram
- Gain the appreciation on how interpretation of angiograms can better aid in diagnosis of several retinal conditions

INTRODUCTION TO FLUORESCEIN ANGIOGRAPHY

- **What is it?**
  - Sequence of serial photographs that are taken after the administration of intravenous fluorescein to visualize and document choroidal and retinal blood flow. [1,2]
- **Why use fluorescein?**
- **First started**: 1960s[1,2]
- **What is it used for?**
  - extent of damage of the RPE[1]
  - Choroid, Optic nerve head[20]
  - Treatment response[20]



http://www.opsweb.org/?page=FA

WHAT OPHTHALMIC INSTRUMENTATION IS NEEDED?

- Needs time & ability to take rapid imaging
- Fundus camera (50°)
- Scanning Laser Ophthalmoscopy (30°)
- DICOM

http://www.opsweb.org/?page=FAequipment

http://www.opsweb.org/?page=FAequipment

SUPPLIES NEEDED

- 5mL 10% or 2mL 25% fluorescein dye[20]
- Needles:
  - 17-19ga
  - 21-23ga butterfly needle
- Tourniquet, gloves, alcohol pad, gauze, sterile swab, tape, bandage
- Informed consent document
- Site of injection

https://www.reviewofoptometry.com/article/injection-the-third-method-of-drug-administration



Safesurgery.org

STATES THAT ALLOW INJECTABLE DRUGS FOR DIAGNOSTIC AND TREATMENT PURPOSES[5,10]



WHAT FACTORS CAN EFFECT MY IMAGE QUALITY?

- Skill of angiographer
- Optical/mechanical quality of instrumentation
- Media opacities
- Absorption of blue excitation light by cataracts
- Residual topical fluorescein staining of cornea
- Inadequate pupil dilation
- Poor fixation/cooperation
- Extravasation of dye

WHAT CAN GO WRONG?

- **Contraindications**
  - History of asthma, hay fever, or prior reaction to fluorescein
    - pre-medicate: diphenhydramine[8,11]
  - Pregnancy/ nursing[1,8,11]
- **Side-effects** - one of safest invasive diagnostic procedures[1,20]

Mild <5%
- Nausea*
- vomiting

Moderate <2%
- Pruritus/uticaria (<1.5 hr)
- vasovagal symptoms
- colored fluids up to 24-36 hr
- skin discoloration for few hr
- Extravasation

Severe <1%
- MI
- anaphylaxis (<1%)[23]
- Cardiac arrest (<0.01%)[23]

CONDITIONS THAT WARRANT IV-FLUORESCEIN ANGIOGRAPHY

VASCULAR
Diabetic retinopathy
Retinal Vein Occlusions
Hypertensive retinopathy
Retinal Artery Occlusions
Retinal Arterial macroaneurysms
Macular Telangiectasia

OTHER
Central Serous Chorioretinopathy
Choroidal tumors

DEGENERATIVE
Age-related macular degeneration
Subretinal neovascular membrane from other causes (myopia, histo)
Pattern Dystrophies of RPE
Chorioretinal Inflammatory conditions
Hereditary retinal dystrophies (Stargarts, Best's)

PHASES OF IVFA WITH NORMAL TRANSIENT TIMES[1,4]

Phases	Timing
Choroidal flush	8-11 seconds after injection
Retinal arterial	~12-15 seconds
Arteriovenous	~15-25 seconds
Venous	~20--30 seconds
Recirculation (mid-phase)	3.5-5 minutes
Late phase	7-10 minutes

ANGIOGRAPHIC INTERPRETATION

- **Hypofluorescence**[4]:
  - **Blockage**
    - pre-retinal hemorrhage
    - sub-retinal hemorrhage
    - pigment clumping in AMD
    - center of Cyro scars
    - CHRPE
  - **Filling**
    - Diabetic retinopathy



https://sites.google.com/site/ophthalmologynot/common-investigations/fluorescein-angiography/ro-causes-of-hypofluorescence



https://sites.google.com/site/ophthalmologynot/common-investigations/fluorescein-angiography/ro-causes-of-hypofluorescence

ANGIOGRAPHIC INTERPRETATION CONTINUED

- **Hyperfluorescence**[4]:
  - **Pooling**[4,23] – increase in intensity over time; stay well defined
    - CSR, PED,CME
    - mid-late phase
  - **Staining**[4,23] – minimal leakage
    - regressed neovascular tissue
    - peripapillary atrophy
    - fenestrated vascular anomalies,
    - disciform scar
    - Early - late phase

Hurley, Benard R. , et al. Fluorescein Angiograph: General Principles and Interpretation. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 27-42. Print



Clark, Thomas M. Retinal Photography and Angiography via Film and Digital Imaging Techniques. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 43-59. Print

ANGIOGRAPHIC INTERPRETATION CONTINUED

- **Leakage**[4,23] – leaky blood vessel
  - SRNV, DM, sickle cell, talc
  - Increases with time (intensity + size of lesion)
- **Window defect**[4,23] – transmission though break in RPE
  - atrophy, drusen, rip/tear in RPE, macular hole
  - early phase, fades in late



http://www.oculist.net/others/ebook/generalophthal/server-java/arknoid/amed/vaughan/co_chapters/ch010/ch010_print_04.html

https://sites.google.com/site/ophthalmology101/common-investigations/fluorescein-angiography/10-causes-of-hypofluorescence

ANGIOGRAPHIC INTERPRETATION CONTINUED

- **Autofluorescence**[4]:
  - Vitamin A, calcium salts, lipofuscin
    - ONH drusen
    - Flecks associated w/ fundus flavimaculatus
    - Best's disease
    - Choroidal nevus



https://sites
n-investiga

http://www.optometricmanagement.com/articleview
er.aspx?articleID=106126

LETS APPLY THAT KNOWLEDGE…

https://www.linkedin.com/pulse/technology-leadership-influences-from-cio-adam-mikesell

CASE 1: CENTRAL RETINAL VEIN OCCLUSION SPARING INFERIOR TEMPORAL QUADRANT

- 50 yo male diagnosed with likely CRVO OD with sparing of infratemporal quadrant
  - (+)HTN, Hyperlipidemia, Type 2 DM (2012)- HbA1c: 6.6
  - Incoming visual acuities: OD: 20/15-2, OS: 20/15

02/19/15



08/03/15

1 MONTH FUNDUS PHOTOS/MACULAR OCT



IVFA: NVD VS COLLATERALS?

Arteriovenous phase | Mid-phase | Late Phase



Retinal Specialist

-Non-ischemic CRVO sparing of Infratemporal arcade

-Collaterals at disc, (-)NVE/NVD

-likely low risk for Neovascularization

-Monitor every 1-2 months for first 6 months.



http://www.ejournalofophthalmology.com/ejo/ejo21a.html



CASE 2: NON-EXUDATIVE VERSES EXUDATIVE ARMD

- 83 yo white male – rare scattered drusen + atypical PED with adjacent subretinal fluid OS
  - Incoming visual acuities: OD: 20/25+, OS: 20/30+ PH: 20/25



2 MONTH IVFA



LEAKAGE VERSES STAINING?

11/23/15

01/28/16



CASE 3: IDIOPATHIC BILATERAL PRESUMED CENTRAL SEROUS VS EXUDATIVE AMD OU

- 71 yo male present with decreased vision OU for past several weeks. Reports having images of "blue or green balls" lasting for few seconds
  - NIDDM, Non-exudative AMD OU

OD: 20/50 PH: 20/40 OS: 20/50 PHNI



FLUORESCEIN ANGIOGRAPHY



PRESUMED BILATERAL CSCR 2 MONTH FOLLOW-UP



MOVING FROM THE PRESENT TO THE FUTURE…

Angioplex- Ziess

Angiovue - Optovue

http://www.ebc-europe.com/wp-content/uploads/2012/galeries/angiovue/%5BANGIOVUE%5DFULL_01.jpg

IV-less Angiography

ANGIOPLEX OCT ANGIOGRAPHY (ZEISS)[6]

- *1st FDA-approved IV-less procedure - 09/2015*
  - *Takes 1.5 seconds to get an image*
  - *Detects capillary flow rather than the presence of injected dye*



ANGIOVUE OCT ANGIOGRAPHY (OPTOVUE)[19]

- Became available 08/2015, but not FDA approved
  - Image acquisition <3 seconds[13]
  - Rapidly take multiple cross-sectional images from single location on retina[15]

http://www.fiercemedicaldevices.com/story/optical-imaging-startup-gets-jom-advance-wet-amd-diabetic-retinopathy-ds-to/2015-11-12



Optovue. "Introducing the Angiovue Imaging System." Angiovue Physician Presentation. Lecture

ANGIOPLEX OCT ANGIOGRAPHY (ZEISS)





Visualization of blood flow in superficial retina.

Visualization of blood flow in deep retina.

Avascular region of the retina in healthy eyes. Allows for detection of abnormal vascular growth.

https://c.ymcdn.com/sites/www.opsweb.org/resource/dynamic/forums/20151013_112610_28233.pdf

ANGIOVUE OCT ANGIOGRAPHY (OPTOVUE)



Optovue. "Introducing the Angiovue Imaging System." Angiovue Physician Presentation. Lecture

EXAMPLE WET AMD



Optovue. "Introducing the Angiovue Imaging System." Angiovue Physician Presentation. Lecture

SO WHAT DOES THIS MEAN FOR YOU?

- **Where are we now, and what can we learn from it?**
  - IVFA:
    - Areas of non-perfusion
    - leakage via late phase
  - Understanding pathophysiology and why certain findings occur with certain conditions
  - Rural area/retinal practices
- **How can we apply what is known to what is now coming available?**
  - Understanding pathophysiology and applying it to where it occurs in various retinal conditions
- **Scope of practice**

REFERENCES

1. Hurley, Benard R. , et al. Fluorescein Angiograph: General Principles and Interpretation. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 27-42. Print.
2. Wu, Lehteh, et al. Angiography of Macular disease. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 61-103.Print
3. Wu, Lehteh, et al. Angiography of Retinal Vascular Diseases. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 105-132.Print
4. Clark, Thomas M. Retinal Photography and Angiography via Film and Digital Imaging Techniques. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer, 2009. 43-59. Print
5. "State Board Requirements | NBEO."
6. "Angioplex OCT Angiography by ZEISS." *Angioplex*
7. Hwang, T. S., Jia, Y., Gao, S. S., Bailey, S. T., Lauer, A. K., Flaxel, C. J., . . . Huang, D. (2015). Optical Coherence Tomography Angiography Features Of Diabetic Retinopathy. Retina, 35(11), 2371-2376. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623938/pdf/nihms727415.pdf
8. Witmer, M. T., P., P., & Kiss, S. (2013). Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis® noncontact ultra-widefield module versus the Optos® Optomap®. OPTH Clinical Ophthalmology, 389. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623938/pdf/nihms727415.pdf
9. Barteselli, G., Chhablani, J., Lee, S. N., Wang, H., Emam, S. E., Kozak, I., . . . Freeman, W. R. (2013). Safety And Efficacy Of Oral Fluorescein Angiography In Detecting Macular Edema In Comparison With Spectral-Domain Optical Coherence Tomography. Retina, 33(8), 1574-1583.
10. Fanelli, James L., O.D. "Injection: The Third Method of Drug Administration." Injection: The Third Method of Drug Administration. Review of Optometry, 15 Jan. 2012. Web.
11. Ehlers JP, Chirag PS, Gregory LF, et al. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008
12. Yannuzzi, Lawrence A., MD. "Retinal Vascular Disease." *The Retinal Atlas*: Elsevier Limited, 2010. 382-512. Print.
13. http://www.optovue.com/products/angiovue
14. Huang, David, Yali Jia, and Simon Gao. "Chapter-01 Principles of Optical Coherence Tomography Angiography." *Clinical OCT Angiography Atlas* (2015): 1-7. Web.
15. Optovue. "Introducing the Angiovue Imaging System." Angiovue Physician Presentation. Lecture
16. Filho, Marco, Talisa Carlo, Eric Moult, and Woojhon Choi. "OCT Angiography Findings in Central Serous Chorioretinopathy." *JAMA Ophthalmol.* (2015): 89-97. Web.
17. Spaide, Richard F., James M. Klancnik, Michael J. Cooney, Lawrence A. Yannuzzi, Chandrakumar Balaratnasingam, et al. "Volume-Rendering Optical Coherence Tomography Angiography of Macular Telangiectasia Type 2." *JAMA Opthalmology*122.11 (2015): 2261-269. Web.
18. Schwartz, Daniel M., et al. "Phase-variance Optical Coherence Tomography: A New Technique for Non-Invasive Angiography." *NIH Ophthalmology*. American Academy of Ophthalmology, (Jan 2014). Web.
19. Giovanni Staurenghi, ed. "Optical Coherence Tomography Angiography of Retinal Microvasculature using the ZEISS Angioplex." (2015): 147-56. *European Ophthalmic Review* 2015. 23 Dec. 2015. Web
20. Bennett, Timothy J., CRA. "Fluorescein Fundamentals – Ophthalmic Photographers' Society." *Fluorescein Angiography Fundamentals – Ophthalmic Photographers' Society*. Penn State Hershey Eye Center, 2013. Web.
21. Bennett, Timothy, J, CRA. "Fluorescein Fundamentals – Ophthalmic Photographers; Society." *Equipment & Technique*/ Penn State Hershey Eye Center, 2013. Web.
22. Dithmar, Stefean, and Frank G. Holz. *Fluorescence Angiography in Ophthalmology*. Berlin: Springer, 2008. Print
23. Al-Abed, Shihab, MD. "What are Fluorescein Angiography Side Effects? – Ophthalmology 101." Web.
24. Al-Abed, Shihab, MD. "What is hyperfluorescence and Hypofluorescence.- Ophthalmology 101. Web.
25. Sowka, Joseph W., OD, and Alan G. Kabat, OD. "Collateral Damage." Review of Optometry, 18 Feb. 2014. Web

Choroidal Complications After Glaucoma Surgery

By: Victoria Kung, OD

Optometry Resident at American Lake VA

Outline

- **Case History**
- Risk factors for choroidal complications
  - Hypotony and Bleb Leak
  - Topiramate induced angle closure glaucoma
- Choroidal detachment and differential diagnoses
  - Retinal detachment
  - Choroidal neovascularization
  - Hypotony retinopathy
  - Suprachoroidal hemorrhages

79 year old Caucasian Male PH

- **CC:** Film over OD w/ black spots x 1 month. Longstanding flashes worsened x 1 month. No pain.
- **Ocular history:** POAG s/p trabeculectomy OU w/ complications OS
- **Ocular meds:** Latanoprost qhs OS and Cosopt bid OS
- **Systemic history:** emphysema

Exam Findings

- **Distance VA:**
  - OD 20/40-
  - OS 20/40
- **Pupils:** irregular surgical pupil OD and RRL OS, (+) APD OS
- **IOP:** NCT 5/14 mmHg
- **Anterior Chamber:** fully formed OU

Exam Findings

- **Conjunctiva:** superior temporal trab w/ mildly elevated bleb OU, (+)Seidel's sign OD
- **Discs:**
  - OD: 0.55, (-)pallor
  - OS: 0.90, diffuse pallor
- **Fundus:**
  - OD: hazy view, choroidal folds, elevation of fundus in a multi-lobed pattern
  - OS: no breaks 360





Assessment

- Bleb leak OD
- Hypotony Retinopathy OD
- Choroidal detachment/effusion OD

Timeline of Events

- 11/20/15 American Lake VA: Presented with exam findings listed above. Same day consult to Sound Retina.
- 11/20/15 Sound Retina: Started on topical ciprofloxacin qid OD and referral placed for bleb leak repair.
- 11/25/15 American Lake VA, pertinent exam findings:
  - Distance VA: OD 20/70+
  - (+)Seidel's sign OD
  - Fully formed anterior chamber OU
  - IOP: NCT 3/11 mmHg
  - Choroidal detachment 360 OD: worsened from last visit

Timeline of Events

- 12/02/2015 PCLI Chehalis: Uncomplicated bleb leak revision OD
- 1/20/16 American Lake VA, pertinent exam findings:
  - Distance VA: OD 20/25
  - (-)Seidel's sign OU
  - IOP: Goldmann 10/12 mmHg
  - Resolution of subretinal fluid and choroidal detachment OD

Outline

- Case History
- **Risk factors for choroidal complications**
  - **Hypotony and Bleb Leak**
  - **Topiramate Induced Angle Closure Glaucoma**
- Choroidal detachment and differential diagnoses
  - Retinal detachment
  - Choroidal neovascularization
  - Hypotony retinopathy
  - Suprachoroidal hemorrhages

Risk factors for development of choroidal complications

- Hypotony or lower postoperative IOP
- Overfiltration of bleb or bleb leak
- Topiramate
- Advanced age: connective tissue is more fragile→ enhances movement across the choroid→ increased risk of choroidal complications

Hypotony

- Defined as IOP of 5 mmHg or less
- Causes of hypotony
  - Increased aqueous outflow: overfiltration of bleb or bleb leak
  - Decreased aqueous production: uveitis
- Complications of hypotony
  - Shallowed anterior chamber
  - Hypotony retinopathy
  - Choroidal detachment
  - Suprachoroidal hemorrhage

Bleb Leak

- Confirmed with positive Seidel's sign



Bleb Leak

- Use of antifibrosis agents during trabeculectomy, particularly mitomycin C→ thin bleb wall→ increased risk of bleb leak
- Combined cataract and trabeculectomy surgery→ thicker bleb wall→ decreased risk of bleb leak

Bleb Wall Thickness



Thick Wall Bleb

Thin Wall Bleb

Nonfunctioning Bleb

Treatment for Bleb Leaks

- Conservative treatment includes
  - aqueous suppressants: beta blocker or carbonic anhydrase inhibitor
  - broad-spectrum antibiotics: prevent blebitis and/or endophthalmitis
  - patching or bandage contact lens application: pressure at the leak site will slow or stop aqueous flow and reduce mechanical irritation

Bleb Leak Repair



Topiramate Induced Angle Closure Glaucoma

- Topiramate is a sulfonamide derivative used in the treatment of epilepsy and migraine
- Clinical presentation: elevated IOP, shallow anterior chambers, myopic shift, choroidal effusions
- Mechanism: anterior shifting of the lens iris diaphragm → shallowing of the anterior chamber in the periphery → acute angle closure without pupillary block

Topiramate Induced Angle Closure Glaucoma

- 85% of cases occurred within the first 2 weeks of treatment
- 50% of cases occur with doses of 50 mg or less
- Treatment: discontinue topiramate, lowering the intraocular pressure, cycloplegics can help deepen the anterior chamber
- Peripheral iridotomies and miotics are not useful in these cases because there is no pupillary block present
- Suspect topiramate induced angle closure glaucoma in bilateral cases with myopic shift and choroidal effusion

Outline

- Case History
- Risk factors for choroidal complications
  - Hypotony and Bleb Leak
  - Topiramate Induced Angle Closure Glaucoma
- **Choroidal detachment and differential diagnoses**
  - **Retinal detachment**
  - **Choroidal neovascularization**
  - **Hypotony retinopathy**
  - **Suprachoroidal hemorrhages**

Choroidal Detachment/effusion

- Accumulation of serous fluid within the suprachoroidal space
- Usually asymptomatic and painless
- Classic clinical appearance: elevation of fundus in a multi-lobed presentation



Choroidal Detachment/effusion

- Clinical features: hypotony, overfiltration of a bleb or bleb leak, shallow to flat anterior chamber
- Resolution usually with conservative therapy and no significant reduction of best corrected visual acuity



Pathophysiology

- Imbalance of hydrostatic (IOP in interstitial spaces) and osmotic pressure (choroidal fluid)
- As IOP decreases → Choroidal fluid accumulates in these interstitial spaces



Differential Diagnosis: Retinal Detachment

Differential Diagnosis: Choroidal Neovascularization



Differential Diagnosis: Hypotony Retinopathy

Clinical signs: choroidal folds, retinal edema, optic disc edema, retinal vascular tortuosity

Management: identifying and correcting the source of the hypotony



Differential Diagnosis: Suprachoroidal Hemorrhage

- Clinical presentation: Elevation of fundus in a multi-lobed pattern
- Lobes are brown in color due to the presence of blood



Differential Diagnosis: Suprachoroidal Hemorrhage



Suprachoroidal Hemorrhage

- Sudden, often very painful accumulation of blood in the suprachoroidal space
- Marked reduction in visual acuity and worse visual prognosis compared to choroidal detachments
- Pathogenesis: mechanical stress on the posterior ciliary arteries due to hypotony
- Risk factors: age, postoperative hypotony, choroidal detachment

Suprachoroidal Hemorrhage



Differentiation

- Fundus exam
- **B Scan**




Choroidal
Detachment
Suprachoroidal
Hemorrhage



Management and Treatment for Choroidal Detachment

- Observation
- Medical therapy: topical steroids, cycloplegic agents
- Surgical drainage: usually only indicated after failure of conservative therapy
  - Indications for surgical drainage include:
    - Persistent corneal edema with shallow anterior chamber
    - Prolonged duration of choroidal detachment
    - Severe eye pain
    - Concern for visual loss
    - Appositional choroidal detachment aka “kissing choroidals”



Choroidal detachment vs Suprachoroidal hemorrhage

Choroidal Detachment	**Suprachoroidal hemorrhage**
Usually asymptomatic and painless	Sudden and painful
Minimal reduction in visual acuity	Marked reduction in visual acuity
Serous fluid- clear, whitish fundus appearance	Blood- brown fundus appearance
Usually no significant reduction in visual acuity	Poor visual prognosis





Prevalence of Complications

- Tube vs Trab





Prevalence of Complications

- Tube versus Trabeculectomy Study
  - Compared Baerveldt implant with trabeculectomy with similar results of serous choroidal effusions and suprachoroidal hemorrhages
- Tube shunt
  - Ahmed implant: serous choroidal effusion in 13-15%, no suprachoroidal hemorrhages
  - Baerveldt implant: serous choroidal effusion in 11.7-14%, suprachoroidal hemorrhage in 2%

Key Points

- Recognize the differences between choroidal detachment and suprachoroidal hemorrhage
- Management and prognosis of choroidal detachment
- Consider choroidal detachment in atypical presentations of "retinal detachment"
- Check for Seidel's sign in patients with history of ocular surgery

References

- Dugel, P, et al. (1997). Annular peripheral choroidal detachment simulating aqueous misdirection after glaucoma surgery. *Ophthalmology.* 104 (3): 439-444.
- Eha, J, et al. (2008). Flap suture- a simple technique for the revision of hypotony maculopathy following trabeculectomy with mitomycin C. *Graefes Archive for Clinical and Experimental Ophthalmology.* 246: 869-874.
- Greenfield, D, et al. (1998). Late-onset bleb leaks after glaucoma filtering surgery. *Archives of Ophthalmology.* 116: 443-447.
- Haga, A, et al. (2013). Risk factors for choroidal detachment after trabeculectomy with mitomycin C. *Clinical Ophthalmology.* 7: 1417-1421.
- Nguyen, Q, et al. (1998). Complications of Baerveldt glaucoma drainage implants. *Archives of Ophthalmology.* 116: 571-575.
- Paciuc-Beja, M, et al. (2011). Secondary bilateral angle closure glaucoma due to topiramate. *Case Reports in Ophthalmological Medicine.*
- Schrieber, C, et al. (2015) . Choroidal effusions after glaucoma surgery. *Current Opinion Ophthalmology.* 26(2): 135-142.
- Tan, Y, et al. (2011). Postoperative complications after glaucoma surgery for primary angle-closure glaucoma vs primary open-angle glaucoma. *Archives of Ophthalmology.* 129 (8): 987-992.
- Vijaya, L, et al. (2011). Management of complications in glaucoma surgery. *Indian Journal of Ophthalmology. 59 (1): S131-S140.*
- Willet, M, et al. (2011). Refractory topiramate- induced angle-closure glaucoma in a man: a case report. *Journal of Medical Case Reports*. 5: 33.

Photo Credits

- http://www.retinalphysician.com/content/archive/2010/October/images/RP-1010_A09_Fig01.JPG
- http://www.retinareference.com/diseases/3d88a2552988052a/images/c0b575d508/image.jpg
- http://scielo.isciii.es/img/aseo/v78n4/img/f07-01.jpg
- http://www.timothyjackson.net/retinal%20detachment.JPG
- http://www.ijo.in/viewimage.asp?img=IndianJOphthalmol_2011_59_7_131_73689_u7.jpg
- http://www.omicsonline.org/articles-images/2155-9570-S4-005-g010.gifhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765186/
- http://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/choroidal-detachments/SAK.htm
- http://soroudivision.com/glaucoma-surgery-with-tube-shunt-implantation
- https://www.researchgate.net/publication/6724942_Imaging_of_Trabeculectomy_Blebs_Using_Anterior_Segment_Optical_Coherence_Tomography
- http://www.ricktl.com/unique-10-design-diagram-basic-view-part-anatomy-of-the-eye/vein-center-anatomy-of-the-eyes-sciera-ciliary-iris-pupil-aqueous-humor-lens-vitreous-humor-choroid-retina/
- http://emedicine.medscape.com/article/1207755-overview
- http://tradomed-invest.ru/Clinique/clin12-2/?template=26
- http://m4.wyanokecdn.com/c7d062d32478aced6ebdb563d5b8b2d5.jpg
- https://classconnection.s3.amazonaws.com/938/flashcards/1106938/jpg/choroid1336075091844.jpg
- http://www.timothyjackson.net/disciform.JPG
- https://www.reviewofoptometry.com/CMSImagesContent/2015/6/F4.3.jpg
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396511/figure/f1-opth-9-579/
- http://cms.galenos.com.tr/FileIssue/6/828/article/132-137-ing.pdf
- http://www.ekjo.org/ArticleImage/0065KJO/kjo-27-294-g002-l.jpg

Thank you